Note: Descriptions are shown in the official language in which they were submitted.
CA 03149497 2022-02-01
WO 2021/030271
PCT/US2020/045625
METHODS AND APPARATUSES FOR MANUFACTURING FOR REMOVING
MATERIAL FROM A THERAPEUTIC COMPOSITION
CROSS REFERENCE TO RELATED APPLICATIONS
[0001] This patent application claims priority to U.S. Provisional Patent
Application No.
62/885,159, filed on August 9, 2019, and titled "MICROFLUIDIC APPARATUS AND
METHODS OF USE THEREOF," as well as U.S. Provisional Patent Application No.
62/885,170, filed August 9, 2019, and titled "METHODS AND APPARATUSES FOR
MANUFACTURING THERAPEUTIC COMPOSITIONS," and U.S. Provisional Patent
Application No. 62/914,374, filed on October 11, 2019, titled "METHODS AND
APPARATUSES FOR MANUFACTURING FOR REMOVING MATERIAL FROM A
THERAPEUTIC COMPOSITION," each of which is herein incorporated by reference in
its
entirety.
INCORPORATION BY REFERENCE
[0002] All publications and patent applications mentioned in this
specification are herein
incorporated by reference in their entirety to the same extent as if each
individual publication or
patent application was specifically and individually indicated to be
incorporated by reference.
FIELD
[0003] This disclosure is related generally to methods and systems for
rapid, high-yield
manufacturing of polynucleotide-based therapeutics. This disclosure may relate
specifically to
automated manufacture of therapeutic mRNAs, including vaccines, which may be
performed
rapidly and efficiently. Such therapeutics may take into account patient
specific information, and
may be produced on-demand and completely or partially at the point-of-care
(e.g., hospital,
clinic, etc.).
BACKGROUND
[0004] Currently available technologies for manufacturing and
formulating polynucleotide
therapeutics, particularly mRNA therapeutics, often expose the products to
contamination and
degradation. Currently available centralized production can be too costly, too
slow, and
susceptible to contamination for use in therapeutic formulations possibly
including multiple
polynucleotide species. Development of scalable polynucleotide manufacturing,
production of
single patient dosages, elimination of touchpoints to limit contamination,
input and process
tracking for meeting clinical manufacturing requirements, and use in Point-of-
Care operations
- 1 -
CA 03149497 2022-02-01
WO 2021/030271
PCT/US2020/045625
can advance the use of these promising therapeutic modalities. Microfluidic
instrumentation and
processes can provide major advantages against these goals.
[0005] Described herein are methods and apparatuses (e.g., systems) that
for making a
variety of therapeutics that may address the needs mentioned above.
SUMMARY OF THE DISCLOSURE
[0006] Described herein are apparatuses and methods useful for making a
wide variety of
vaccines and therapeutics. For example, described herein are methods and
apparatuses (e.g.,
systems, devices, etc.) for making personalized therapeutics, including
vaccines. In one, non-
limiting example, the methods and apparatuses described herein may be used to
produce a
therapeutic mRNA vaccine against a cancer-specific antigen active in Cutaneous
T-Cell
Lymphoma.
[0007] Thus, in general, described herein are automated, high-yield
manufacturing methods
for mRNA therapeutics, optionally deployed at point-of-care.
[0008] For example, described herein are methods of forming (e.g.,
manufacturing, making,
synthesizing, etc.) a therapeutic polynucleotide using a system comprising a
plurality of fluid
depots configured to be secured in sealed fluid communication with one or more
microfluidic
path devices, the method comprising: transporting reagents between one or more
fluid depots of
the plurality of fluid depots and a plurality of reactors on the one or more
microfluidic path
devices in a sealed and closed fluidic path that is protected from atmospheric
contact to perform
the steps of: forming a synthetic template, performing in vitro transcription
from the template to
produce a therapeutic polynucleotide, and purifying the therapeutic
polynucleotide.
[0009] A method of manufacturing a therapeutic mRNA using a system
comprising a
plurality of fluid depots configured to be secured in sealed fluid
communication with one or
more microfluidic path plate devices, wherein the one or more microfluidic
path plate devices
comprise a plurality of reactors, may include: delivering a template precursor
material from one
or more fluid depots to a first one or more reactor regions of the plurality
of reactors and
processing the template precursor material to prepare a template from the
template precursor
material; transferring the template to a second one or more reactor regions of
the plurality of
reactors and processing the template by in vitro transcription to form a
therapeutic mRNA; and
transferring the therapeutic mRNA to a third one or more reactor regions of
the plurality of
reactors and purifying the therapeutic mRNA by two-dimensional (2D)
purification within the
third one or more reactor regions; wherein all of the method steps are
performed without
exposing the template and therapeutic mRNA to atmospheric contact.
- 2 -
CA 03149497 2022-02-01
WO 2021/030271
PCT/US2020/045625
[0010] A method of manufacturing a therapeutic mRNA using a system
comprising a
plurality of fluid depots in sealed fluid communication with one or more
microfluidic path plate
devices, wherein the one or more microfluidic path plate devices comprise a
plurality of reactors,
may include: delivering, using fluid power, a template precursor material from
one or more fluid
depots to a first one or more reactor regions of the plurality of reactors and
processing the
template precursor material to prepare a template from the template precursor
material;
transferring, using fluid power, the template to a second one or more reactor
regions of the
plurality of reactors and processing the template by in vitro transcription to
form a therapeutic
mRNA; transferring, using fluid power, the therapeutic mRNA to a third one or
more reactor
__ regions of the plurality of reactors and purifying the therapeutic mRNA by
two-dimensional (2D)
purification within the third one or more reactor regions; transferring, using
fluid power, the
therapeutic mRNA to a fourth one or more reactor regions of the plurality of
reactors and
encapsulating the therapeutic mRNA with a delivery vehicle to form a
therapeutic mRNA
composition; and concentrating, using fluid power, the therapeutic mRNA
composition in a fifth
one or more fluid depots, wherein all of the method steps are performed
without exposing the
template and the therapeutic mRNA to atmospheric contact.
[0011] Purifying the therapeutic polynucleotide typically comprises two-
dimensional (2D)
purification of the therapeutic polynucleotide within one or more of the
plurality of reactors. 2D
purification may be performed within the substantially flat microfluidic path
devices (e.g.,
microfluidic path plate devices) described herein, and may include using a
material to remove
material (e.g., double-stranded RNA, etc.) from the therapeutic
polynucleotide. 2D purification
of the polynucleotides in the microfluidic path device may be particularly
advantageous
compared to prior art techniques, which may require the use of columns and may
involve steps
that are difficult or impossible to perform in a closed path environment
and/or in small volumes
__ as described herein. In some variations purifying the therapeutic
polynucleotide comprises
removing double-stranded mRNA using a cellulose material within the one or
more reactors.
[0012] Any of these methods may include formulating the therapeutic
polynucleotide with a
delivery vehicle in one or more reactors on the one or more microfluidic path
devices to form a
therapeutic polynucleotide composition. The therapeutic polynucleotide (e.g.,
mRNA) may be
encapsulated with the delivery vehicle as described herein, and in some
variations may include
additional mRNAs in addition to the therapeutic mRNA, including adjuvant mRNAs
(e.g.,
mRNA enclosing proteins that enhance the immune response). The delivery
vehicle may
comprise an amphipathic nanoparticle, e.g., an amino-lipidated peptoid.
[0013] In some variations the therapeutic composition may be stored for
later combining
with a delivery vehicle (e.g., stored at 4 degrees C, in a sealed enclosure,
container or vial). The
- 3 -
CA 03149497 2022-02-01
WO 2021/030271
PCT/US2020/045625
therapeutic composition may be moved off of the microfluidic path device into
a fluid depot in
the microfluidic control apparatus and used in the same microfluidic control
apparatus or
provided to another (e.g., geographically separated, including proximate to
the hospital or clinic
in which it is to be used) microfluidic control apparatus for combining with
delivery vehicle.
Combining the therapeutic polynucleotide (e.g., therapeutic mRNA) with a
delivery vehicle
forms the therapeutic composition. The therapeutic composition may be further
modified prior to
use (e.g., injection into a patient).
[0014] For example, any of these methods may include dialyzing and/or
concentrating the
therapeutic polynucleotide composition in the one or more microfluidic path
devices. As used
herein dialyzing may refer to the separation of particles in a liquid based on
differences in the
ability of the particles to pass through a membrane (dialysis membrane). In
some variation
dialysis includes countercurrent exchange.
[0015] The system may automatically and continuously perform the steps
of forming the
synthetic template, performing in vitro transcription from the template, and
purifying the
therapeutic polynucleotide with optical feedback from one or more sensors of
system.
[0016] In general, the therapeutic polynucleotide may be an mRNA. For
example, the
therapeutic polynucleotide may be an mRNA, a circular RNA or a self-
replicating RNA, etc.
[0017] In general, the system may transport the reagents between the one
or more fluid
depots and the plurality of reactors by fluid power, e.g., using one or more
fluid circuits. Fluid
power refers generally to both pneumatic and hydraulic. A fluid power circuit
may include
multiple elements (e.g., fluid lines, valves, etc.) and components of
different fluid power circuits
(also referred to herein as fluid circuits) may be shared by more than one
fluid power circuit,
which may switch, under control of the controller, via one or more valves. For
example, the
system may pneumatically transport the reagents between the one or more fluid
depots and the
plurality of reactors. The use of fluid power, controlled by the controller,
may advantageously
permit non-contact control of the processing used to form the template,
therapeutic mRNA
and/or therapeutic composition. For example, the system may transport the
reagents between the
one or more fluid depots and the plurality of reactors by deflecting one or
more elastic layers
within the one or more microfluidic path devices.
[0018] The methods described herein may be performed locally (e.g., at a
site of care)
completely or in part, as mentioned above. Advantageously, the methods
described herein may
permit on-demand manufacture of therapeutic mRNAs without the use of
preservatives or
additives into the therapeutic mRNA that may decrease efficacy and/or risk
complications. It
may be particularly beneficial to formulate the delivery vehicles with the
therapeutic
polynucleotide (e.g., therapeutic mRNA) locally, as the therapeutic
composition including the
- 4 -
CA 03149497 2022-02-01
WO 2021/030271
PCT/US2020/045625
therapeutic mRNA and delivery vehicle may aggregate and cluster over time.
Further, these
methods may be performed quickly, compared to existing methods. For example,
the systems
described herein may automatically and continuously perform the steps of
forming a synthetic
template, performing in vitro transcription from the template to produce a
therapeutic
polynucleotide, and purifying the therapeutic polynucleotide in less than 5
days (e.g., less than 4
days, less than 3 days, etc.).
[0019] Any of these methods may include sealing the fluid depots to the
one or more
microfluidic path devices and pressurizing the fluid depots before
transporting the reagents
between the fluid depots and the plurality of reactors on the one or more
microfluidic path
devices. The controller may control pressurizing the fluid depots.
[0020] In general, these methods and apparatuses may record the
manufacture in part or
entirely, and this recording may be optical (e.g., showing the movement of
fluid within the
microfluidic path device, including movies, video, etc.) and/or non-optical
sensor data (pressure
readings, temperature readings, etc.). This manufacturing data may be saved,
stored and/or
transmitted for later review, including for quality control and testing. Thus,
any of these methods
may include recording movement of fluid within the one or more microfluidic
path devices
during the performance of the steps in a file associated with the therapeutic
polynucleotide that is
manufactured.
[0021] Any of the methods described herein may be performed
automatically or semi-
automatically by a system including a computer (e.g. processor) executing
software configure to
perform all or some of these methods (e.g., a non-transitory, computer
readable media encoding
these instructions). For example, a non-transitory computer readable medium
embodying
instructions for manufacturing a therapeutic polynucleotide, that when
executed by a controller
of a system comprising a plurality of fluid depots configured to be secured in
sealed fluid
communication with one or more microfluidic path devices, cause the controller
to perform the
method of: pressurize the plurality of fluid depots in fluid communication
with one or more
microfluidic path devices; transporting reagents between one or more fluid
depots of the plurality
of fluid depots and a plurality of reactors on the one or more microfluidic
path devices in a
sealed and closed fluidic path that is protected from atmospheric contact to
perform the steps of:
forming a synthetic template, performing in vitro transcription from the
template to produce a
therapeutic polynucleotide, and purifying the therapeutic polynucleotide
(e.g., all in one or more
microfluidic path devices).
[0022] The instructions may further cause the controller to
automatically and continuously
perform the steps of forming the synthetic template, performing in vitro
transcription from the
template, and purifying the therapeutic polynucleotide based on optical
feedback from one or
- 5 -
CA 03149497 2022-02-01
WO 2021/030271
PCT/US2020/045625
more optical sensors of the system. The instructions may further cause the
controller to control
purifying of the therapeutic polynucleotide by two-dimensional (2D)
purification within one or
more of the plurality of reactors, and/or formulate the therapeutic
polynucleotide with a delivery
vehicle in one or more reactors on the one or more microfluidic path devices
to form a
therapeutic polynucleotide composition, and/or dialyze and/or concentrate the
therapeutic
polynucleotide composition in the one or more microfluidic path devices, etc.
[0023] Also described herein are automated methods of making a synthetic
double-stranded
DNA template for an mRNA synthesis using any of the closed-path systems
described herein.
For example, a method of making a synthetic double-stranded DNA template for
an mRNA
synthesis using a closed-path system comprising a plurality of fluid depots
configured to be
secured in sealed fluid communication with one or more microfluidic path
devices may include:
transporting reagents between one or more fluid depots of the plurality of
fluid depots and a
plurality of reactors on the one or more microfluidic path devices in a closed
fluidic path that is
protected from atmospheric contact to combine the reagents; and forming the
synthetic double-
stranded DNA template for in vitro transcription of a therapeutic mRNA.
[0024] The synthetic template formed (synthetic double-stranded DNA
template) may be
free of bacterial DNA and free of endotoxin.
[0025] These methods may include receiving, in a controller for the
closed-path system,
optical sensor data from one or more sensors of the closed-path system,
wherein the controller
controls the operation of the closed-path system based on the optical sensor
data.
[0026] The methods may include pressurizing the fluid depots, and/or
transporting reagents
comprises transporting a synthetic gene of interest and a synthetic in vitro
transcription facilitator
cassette from one or more fluid depots of the plurality of fluid depots to a
first one or more
reactors in the microfluidic path device, joining the synthetic gene of
interest with the synthetic
in vitro transcription facilitator cassette to create a synthetic product,
removing unreacted
material away from the synthetic product, and amplifying the synthetic product
to generate the
synthetic double-stranded DNA template. The one or more microfluidic path
devices comprises a
microfluidic path plate device seated in the closed-path system.
[0027] Advantageously, these methods may include making significant
amounts of templates
(mM amounts) compared to other systems (which typically produce only
femtomolar amounts).
The methods and apparatuses described herein may be produce large amounts of
template.
[0028] An automated method of making a synthetic double-stranded DNA
template for in
vitro transcription using a closed-path system comprising a plurality of fluid
depots in sealed
fluid communication with a microfluidic path device may include: transporting
reagents,
including a synthetic gene of interest and a synthetic in vitro transcription
facilitator cassette,
- 6 -
CA 03149497 2022-02-01
WO 2021/030271
PCT/US2020/045625
from one or more fluid depots of the plurality of fluid depots to a first one
or more reactors in the
microfluidic path device in a closed fluidic path that is protected from
atmospheric contact;
joining the synthetic gene of interest with the synthetic in vitro
transcription facilitator cassette to
create a synthetic product; transporting the synthetic product in the
microfluidic path device to
remove unreacted synthetic gene of interest and unreacted synthetic in vitro
transcription
facilitator cassette away from the synthetic product; and transporting the
synthetic product in the
microfluidic path device and amplifying the synthetic product to generate the
double-stranded
DNA template. As mentioned, amplifying the synthetic product may include
generating greater
than 1 mM of an amplified DNA template.
[0029] Also described herein are automated methods of making a synthetic
double-stranded
DNA template for in vitro transcription using a closed-path system comprising
a plurality of
fluid depots in sealed fluid communication with a microfluidic path device,
the method
comprising: transporting reagents, including a synthetic gene of interest and
a synthetic in vitro
transcription (IVT) facilitator cassette, from one or more fluid depots of the
plurality of fluid
depots to a first one or more reactors in the microfluidic path device in a
closed fluidic path that
is protected from atmospheric contact; joining the synthetic gene of interest
with the synthetic
IVT facilitator cassette in the first one or more reactors to create a
synthetic product; transporting
the synthetic product to a second one or more reactors in the microfluidic
path device to remove
unreacted synthetic gene of interest and unreacted synthetic IVT facilitator
cassette away from
the synthetic product; and transporting the synthetic product to a third one
or more reactors in the
microfluidic path device and amplifying the synthetic product to generate
greater than 1 mM of
an amplified DNA template; and receiving, in a controller for the closed-path
system, optical
sensor data from one or more sensors of the closed-path system, wherein the
controller controls
the operation of the closed-path system based on the optical sensor data.
[0030] For example, an automated method of making a synthetic double-
stranded DNA
template for in vitro transcription using a closed-path system comprising a
plurality of fluid
depots in sealed fluid communication with a microfluidic path device may
include: transporting,
using a first fluid power circuit, a synthetic gene of interest and a
synthetic in vitro transcription
(IVT) facilitator cassette from one or more fluid depots of the plurality of
fluid depots into one or
more joining reactors of the microfluidic path plate device in a closed
fluidic path that is
protected from atmospheric contact and joining the synthetic gene of interest
to the IVT
facilitator cassette to create a synthetic product; removing, using a second
fluid power circuit,
unreacted synthetic gene of interest and unreacted synthetic in vitro
transcription facilitator
cassette away from the synthetic product in the microfluidic path plate
device; transferring, using
a third fluid power circuit, the synthetic product into one or more
amplification reactors of the
- 7 -
CA 03149497 2022-02-01
WO 2021/030271
PCT/US2020/045625
microfluidic path device and amplifying the synthetic product to generate
greater than 1 mM of
an amplified DNA template; and receiving, in a controller for the closed-path
system, optical
sensor data from one or more optical sensors of the closed-path system,
wherein the controller
controls the first, second and third fluid power circuits based on the optical
sensor data and
maintains plurality of fluid depots and the microfluidic path devices in a
closed-path and sealed
environment.
[0031] In any of these methods, the synthetic double-stranded DNA
template is free of
bacterial DNA and free of endotoxin.
[0032] Any of these methods may include receiving, in a controller for
the closed-path
system, optical sensor data from one or more sensors of the closed-path
system, wherein the
controller controls the operation of the closed-path system based on the
optical sensor data. The
optical sensor data may be data from a camera or other imaging sensor. The
methods described
herein may use one or more fluid power circuits to move material between the
plurality of fluid
depots and the microfluidic path device or within the microfluidic path
device. The controller
may coordinate the operation of the fluid power circuits, including using the
optical information
to coordinate. For example, the controller may determine that fluid is within
one or more parts of
the closed-path system (e.g., the depot, fluid lines, and/or region(s) of the
microfluidic path
sensor).
[0033] Any of these methods may include transferring the amplified DNA
template to one or
more digestion reactors of the microfluidic path device and enzymatically
modifying the
amplified synthetic product to generate the double-stranded DNA template.
[0034] As used herein, joining the synthetic gene of interest with the
synthetic in vitro
transcription facilitator cassette to create a synthetic product may include
creating a synthetic
linear or circular ligated product. Joining may be via ligation and/or by
hybridization and/or
annealing and/or primer extension. In some variations amplifying the synthetic
product includes
generating a linear, branched or circular amplified DNA product, further
comprising linearizing
the amplified DNA product to generate the double-stranded DNA template.
Ligating may
include ligating with a DNA ligase or by primer extension. In some variations
amplifying
comprises multiple displacement amplification (MDA). Alternatively, amplifying
may comprise
polymerase chain reaction (PCR) amplification.
[0035] In some variations, the synthetic in vitro transcription
facilitator cassette may
comprise a double-stranded DNA template comprising a promoter; a 5' UTR; a
cleavable linker;
a 3' UTR; and a portion encoding a polyA region comprising at least 200
adenine residues or
200 thymidine residues in a row. The double-stranded DNA template may include
a polyA
region is at least 300 bps long at the 3' end of the synthetic gene of
interest. In general, the in
- 8 -
CA 03149497 2022-02-01
WO 2021/030271
PCT/US2020/045625
vitro transcription facilitator cassette may be less than 1 kb in length. In
some variations, the
synthetic in vitro transcription facilitator cassette does not encode an
antibiotic resistance gene,
and/or does not have an origin of replication (ORI).
[0036] Also described herein are automated methods and apparatuses for
performing in vitro
transcription (IVT) using a template material (including, but not limited to
the template material
described above), to form a therapeutic mRNA. For example, described herein
are methods and
apparatuses for automatically performing an in vitro transcription (IVT)
reaction using a system
comprising a plurality of fluid depots configured to be secured in sealed
fluid communication
with one or more microfluidic path devices, the method comprising:
transporting reagents
between one or more fluid depots of the plurality of fluid depots and a
plurality of reactors on the
one or more microfluidic devices in a closed fluidic path that is protected
from atmospheric
contact to perform in vitro transcription of a therapeutic mRNA from a
template in the one or
more microfluidic path devices and to purify the therapeutic polynucleotide.
[0037] For example, an automated method of performing an in vitro
transcription (IVT)
reaction using a system comprising a plurality of fluid depots configured to
be secured in sealed
fluid communication with a microfluidic path device, the method comprising:
delivering a DNA
template, a polymerase, and nucleotides into one or more IVT reactors of the
microfluidic path
device from one or more of: a fluid depot of the plurality of fluid depots and
a site on the
microfluidic path device; processing, in the one or more IVT reactors, the DNA
template and
nucleotides to form a therapeutic mRNA; and transferring the therapeutic mRNA
into a one or
more purification reactor regions of the microfluidic path device and
purifying the therapeutic
mRNA by two-dimensional (2D) purification within the one or more purification
reactor regions,
wherein the microfluidic path device and the plurality of fluid depots form a
closed-path and
sealed environment preventing atmospheric exposure.
[0038] In general, the system may include a controller to perform these
methods, including,
e.g., performing the steps of transporting reagents by deflecting one or more
elastic layers within
the microfluidic path device. These methods may include receiving, in a
controller for the
system, optical sensor data from one or more sensors of the system, wherein
the controller
controls the operation of the system based on the optical sensor data. The
controller may also
control pressurizing of the fluid depots. In any of the methods described
herein the system may
include a microfluidic path device that is seated in the system.
[0039] In general, the DNA template may comprise a double-stranded DNA
template of a
synthetic gene of interest and a synthetic in vitro transcription facilitator
cassette.
[0040] Any of these methods may include delivering and transporting
using one or more
fluid power circuits, controlled by a controller, to move the DNA template,
polymerase,
- 9 -
CA 03149497 2022-02-01
WO 2021/030271
PCT/US2020/045625
nucleotides, and therapeutic mRNA material between the plurality of fluid
depots and the
microfluidic path device or within the microfluidic path device. For example,
the delivering and
transporting steps may be performed, under the control of a controller, by
deflecting one or more
elastic layers within the microfluidic path device to avoid atmospheric
contact during the
method.
[0041] In some variations an IVT reactor is used; this IVT reactor may
comprise a pair of
connected chambers, each having a liquid-receiving portion and a pressure-
receiving portion,
wherein the liquid-receiving portion is separated from the pressure-receiving
portion by an
elastic layer that may be deflected by the pressure-receiving portion to
adjust the volume of the
liquid receiving portion. The DNA template may comprise a double-stranded DNA
template of a
synthetic gene of interest and a synthetic in vitro transcription facilitator
cassette.
[0042] Any of these methods may include sealing the plurality of fluid
depots in fluid
communication with a plurality of receiving ports on the microfluidic path
device.
[0043] For example, an automated method of performing an in vitro
transcription (IVT)
reaction using a system comprising a plurality of fluid depots configured to
be secured in sealed
fluid communication with a microfluidic path device, may include: pressurizing
the plurality of
fluid depots; delivering, using one or more first fluid power circuits, a DNA
template, a
polymerase, and nucleotides into one or more IVT reactors of the microfluidic
path device in
amounts metered with sub-microliter precision from one or more of: a fluid
depot of the plurality
of fluid depots and a site on the microfluidic path device; processing, in the
one or more IVT
reactors, the template material and nucleotides to form a therapeutic mRNA;
and transferring,
using a second fluid power circuit, the therapeutic mRNA into a one or more
purification reactor
regions of the microfluidic path device and purifying the therapeutic mRNA by
two-dimensional
(2D) purification within the one or more purification reactor regions, wherein
the microfluidic
path device and the plurality of fluid depots form a closed-path and sealed
environment
preventing atmospheric exposure.
[0044] As mentioned, also described herein are software and/or firmware
configured to
perform any of these methods described herein. For example described herein
are non-transitory
computer readable medium embodying instructions for performing an in vitro
transcription
(IVT) reaction, that when executed by a controller of a system comprising a
plurality of fluid
depots configured to be secured in sealed fluid communication with one or more
microfluidic
path devices, cause the controller to perform the method of: pneumatically
delivering a template
material, a polymerase, and nucleotides into a first reactor of a microfluidic
path device from a
plurality of fluid depots in amounts metered with sub-microliter precision at
any time during the
reaction; processing the template material and nucleotides in the first
reactor to form a
- 10 -
CA 03149497 2022-02-01
WO 2021/030271
PCT/US2020/045625
therapeutic mRNA; and pneumatically transferring the therapeutic mRNA through
the
microfluidic path device away from the first reactor, wherein the first
microfluidic path device
and the plurality of fluid depots form a closed-path and sealed environment to
prevent
atmospheric exposure.
[0045] As mentioned above, in some variations the methods and apparatuses
described
herein may be used to formulate (e.g., compound) the therapeutic composition
by automatically
combining the therapeutic polynucleotide (e.g., therapeutic mRNA) with the
delivery vehicle,
e.g., to encapsulate the therapeutic mRNA with the delivery vehicle. This may
be done within an
apparatus as described herein and in some variations may include forming the
template, and/or
therapeutic polynucleotide. For example, a method of manufacturing a
therapeutic mRNA
composition using a system comprising a plurality of fluid depots in sealed
fluid communication
with one or more microfluidic path plate devices, wherein the one or more
microfluidic path
plate devices comprise a plurality of reactors, may include: delivering a
template precursor
material from one or more fluid depots of the plurality of fluid depots to a
first reactor of the
plurality of reactors and processing the template precursor material to form a
DNA template
from the template precursor material; transferring the DNA template to a
second reactor of the
plurality of reactors and processing the DNA template by in vitro
transcription to form a
therapeutic mRNA; transferring the therapeutic mRNA to a third reactor of the
plurality of
reactors and processing the therapeutic mRNA to combine it with a delivery
vehicle to form the
therapeutic mRNA composition; and transferring the therapeutic mRNA
composition to a
concentrator in fluid communication with the third reactor. Transferring the
therapeutic mRNA
to a third reactor may include transferring multiple different therapeutic
mRNAs with the
delivery vehicle to form the mRNA composition. The delivering and transferring
steps may be
performed by one or more fluid power circuits in the system, controlled by a
controller. For
example, the controller may control the fluid power circuits by deflecting one
or more elastic
layers within the one or more microfluidic path plate devices. The method may
be performed at a
site of care.
[0046] Any of these methods (and systems performing them) may be
configured to
automatically and in the same microfluidic path device, dialyze the
therapeutic composition (e.g.,
of the mRNA encapsulated with the delivery vehicles) to remove material and/or
to concentrate
the therapeutic composition. For example, any of these methods may include
dialyzing the
mRNA therapeutic composition in the one or more microfluidic path plate
devices to purify the
mRNA therapeutic composition. Any appropriate nanoparticle may be used (e.g.,
an amphipathic
nanoparticle such as an amino-lipidated peptoid).
- 11 -
CA 03149497 2022-02-01
WO 2021/030271
PCT/US2020/045625
[0047] In addition, any of these methods may include two-dimensional
(2D) purification
within one or more of the plurality of reactors in fluid communication with
the second reactor.
[0048] The method of manufacturing the therapeutic mRNA composition may
be fast,
particularly as compared to known techniques and technologies. For example,
the methods
described herein may takes 5 days or less (e.g., 4 days or less, 72 hours or
less, etc.) to form the
therapeutic composition (therapeutic mRNA and delivery vehicle), including
forming the
synthetic template (e.g., de novo synthesis, without using bacterial
precursors).
[0049] For example, a method of manufacturing a therapeutic mRNA
composition using a
system comprising a plurality of fluid depots in sealed fluid communication
with one or more
microfluidic path plate devices, wherein the one or more microfluidic path
plate devices
comprise a plurality of reactors, may include: pressurizing the plurality of
fluid depots;
controlling a first fluid power circuit to deliver a template precursor
material from one or more
fluid depots of the plurality of fluid depots to a first reactor of the
plurality of reactors with sub-
microliter precision and without atmospheric contact; processing the template
precursor material
to form a DNA template from the template precursor material; controlling a
second fluid power
circuit to transfer the DNA template to a second reactor of the plurality of
reactors with sub-
microliter precision and without atmospheric contact; processing the DNA
template by in vitro
transcription to form a therapeutic mRNA; controlling a third fluid power
circuit to transfer the
therapeutic mRNA to a third reactor of the plurality of reactors with sub-
microliter precision and
without atmospheric contact; processing the therapeutic mRNA to combine it
with a delivery
vehicle to form the therapeutic mRNA composition; controlling a third fluid
power circuit to
transfer the therapeutic mRNA composition to a concentrator in fluid
communication with the
third reactor; and concentrating the therapeutic mRNA composition.
[0050] The methods and apparatuses described herein may be used to
provide on-demand
synthesis of therapeutic polynucleotide compositions. In some variations these
methods may
include remotely synthesizing some of the components and using the apparatuses
to locally
synthesize the therapeutic polynucleotide composition that may then be
delivered to the patient.
For example, a method of producing a therapeutic polynucleotide composition on-
demand, the
method comprising: receiving, at a local facility, a therapeutic
polynucleotide that has been
synthesized at a remote facility; formulating the therapeutic polynucleotide
composition at the
local facility by performing, in an automated system that is protected from
atmospheric contact,
the steps of: combining the therapeutic polynucleotide with a delivery vehicle
in a microfluidic
path device held in the system to form the therapeutic polynucleotide
composition, dialyzing the
therapeutic polynucleotide composition in the microfluidic path device; an
providing the
therapeutic polynucleotide composition.
- 12 -
CA 03149497 2022-02-01
WO 2021/030271
PCT/US2020/045625
[0051] Synthesizing the therapeutic polynucleotide may comprise
synthesizing the
therapeutic polynucleotide using a microfluidic system at the remote facility
by performing, in a
closed fluidic path apparatus that is protected from atmospheric contact, the
steps of: forming a
synthetic template, performing in vitro transcription from the synthetic
template to form the
therapeutic polynucleotide; and purifying the therapeutic polynucleotide.
[0052] For example, a method of producing a therapeutic mRNA composition
on-demand,
the method comprising: synthesizing a therapeutic mRNA at a remote facility;
transporting the
therapeutic mRNA to a local facility; formulating the therapeutic mRNA
composition at the local
facility by performing, in an automated closed fluidic path apparatus that is
protected from
atmospheric contact, the steps of: combining the therapeutic mRNA with
delivery vehicle in a
microfluidic path device to form the therapeutic mRNA composition, dialyzing
the therapeutic
mRNA composition in the microfluidic path device; and providing the
therapeutic mRNA
composition. The local facility is a hospital or clinic, and typically
includes one or more
microfluidic control systems, as described herein. In some variations the
remote facility may be a
manufacturing facility include one or more (e.g., multiple microfluidic
control systems as
described herein).
[0053] The methods described herein may further include concentrating
the therapeutic
polynucleotide composition.
[0054] Any of these methods may include synthesizing the therapeutic
polynucleotide using
a system as described herein, then storing (e.g., cold and/or frozen) the
transferring them (e.g.,
shipping them) while stored cold, from the remote facility to the local
facility and receiving the
therapeutic polynucleotide (e.g., mRNA) at the local facility. For example,
the therapeutic
polynucleotide composition may comprise an mRNA vaccine. Any of these methods
may
include formulating the therapeutic polynucleotide using the system, wherein
the system
comprises a plurality of fluid depots configured to be secured in sealed fluid
communication with
the microfluidic path device.
[0055] A first fluid power circuit may be used to deliver the
therapeutic polynucleotide and
the delivery vehicle from the plurality of fluid depots to one or more
reactors of the microfluidic
path device with sub-microliter precision and without atmospheric contact, in
order to combine
the therapeutic polynucleotide with the delivery vehicle.
[0056] As mentioned, any of these therapeutic compositions may include
multiple mRNAs
(including but not limited to multiple therapeutic mRNAs) encapsulated with
the same (or
different) delivery vehicles. For example, forming the therapeutic
polynucleotide composition at
- 13 -
CA 03149497 2022-02-01
WO 2021/030271
PCT/US2020/045625
the local facility may further comprise combining one or more additional
therapeutic
polynucleotides with the therapeutic polynucleotide and the delivery vehicle.
Any appropriate
delivery vehicle may be used, including those described herein. The
therapeutic polynucleotide
may be an mRNA, such as a linear mRNA, a circular RNA or a self-replicating
RNA, etc.
[0057] The therapeutic polynucleotide may be stable at cold (e.g., 4
degrees, 0 degrees, -10
degrees, etc.) temperatures for method months (e.g., 1 month or more, 2 months
or more, 3
months or more 6 months or more 8 months or more, 9 months are more, 1 year or
more, etc.)
and may be stored remotely or locally. For example, these methods may include
storing the
therapeutic polynucleotide at the local facility prior to formulating the
therapeutic composition.
[0058] For example, a method of manufacturing an mRNA therapeutic
composition using a
closed-path system comprising a plurality of storage depots configured to be
secured in sealed
fluid communication with one or more microfluidic path devices, the method
comprising:
transporting reagents between one or more storage depots of the plurality of
storage depots and a
plurality of reactors on the one or more microfluidic devices in a closed
fluidic path that is
protected from atmospheric contact to perform, in the one or more microfluidic
path devices,
each of the steps of: forming a DNA template, performing in vitro
transcription of therapeutic
mRNA from the template, purifying the therapeutic mRNA, and combining the mRNA
with a
delivery vehicle.
[0059] A method of manufacturing an mRNA therapeutic composition using a
closed-path
system comprising a plurality of storage depots configured to be secured in
sealed fluid
communication with one or more microfluidic path devices (wherein the one or
more
microfluidic path devices comprise a plurality of reactors) may include:
delivering a template
precursor material from one or more storage depots to a first reactor region
of the plurality of
reactors and processing the template precursor material to prepare a template
from the template
precursor material; transferring the template to a second reactor region of
the plurality of reactors
and processing the template by in vitro transcription to form a therapeutic
mRNA; and
transferring the therapeutic mRNA to a third reactor region of the plurality
of reactors and
processing the therapeutic mRNA to combine it with a delivery vehicle to form
the mRNA
therapeutic composition, wherein materials including the template precursor
material and
delivery vehicle are delivered from the storage depots into the plurality of
reactors without
atmospheric contact.
[0060] A method of manufacturing an mRNA therapeutic composition using a
closed-path
system comprising a plurality of storage depots in sealed fluid communication
with one or more
microfluidic path devices (e.g., wherein the one or more microfluidic path
devices comprise a
- 14 -
CA 03149497 2022-02-01
WO 2021/030271
PCT/US2020/045625
plurality of reactors), may include: inducing fluidic flow to deliver a
template precursor material
from one or more storage depots to a first reactor region of the plurality of
reactors and
processing the template precursor material to prepare a template from the
template precursor
material; transferring the template to a second reactor region of the
plurality of reactors and
processing the template by in vitro transcription to form mRNA; transferring
the mRNA to a
third reactor region of the plurality of reactors and processing the mRNA to
combine it with
delivery vehicle to form the mRNA therapeutic composition; and transferring
the mRNA product
depot of the one or more storage depots, wherein the materials are delivered
from the storage
depots into the reactors of the microfluidic path device with sub-microliter
precision and without
atmospheric contact. In any of the methods described herein, any of the steps
may be performed
pneumatically, e.g., the fluidic flow may be induced pneumatically, the fluid
may be transferred
pneumatically, etc. Alternatively or additionally, fluid may be driven by
mechanically,
hydraulically, etc.
[0061] In any of these methods (and apparatuses for performing them) the
closed-path
system may automatically and continuously perform the steps of forming a
template, performing
in vitro transcription of therapeutic mRNA from the template, purifying the
therapeutic mRNA,
and combining the mRNA with a delivery vehicle. The closed-path system may
pneumatically
control the performance of the steps of forming a template, performing in
vitro transcription of
therapeutic mRNA from the template, purifying the therapeutic mRNA, and
combining the
mRNA with a delivery vehicle. In some variations, the closed-path system
pneumatically
controls the performance of the steps of forming a template, performing in
vitro transcription of
therapeutic mRNA from the template, purifying the therapeutic mRNA, and
combining the
mRNA with a delivery vehicle by deflecting one or more membranes within the
one or more
microfluidic path devices.
[0062] Any of the methods and apparatuses described herein may be
configured to be set up
and operate at a site of care, such as a hospital, clinic, etc. This may allow
immediate/on-
demand, patient-specific therapeutics to be custom manufactured to a
particular patient.
Alternatively or additionally, therapeutic molecules that are not specific to
a particular patient
may be formulated with delivery vehicles in a "patient-individualized" way.
Because of the
methods and apparatuses described herein, any of these methods may be
performed very quickly.
For example, the closed-path system may automatically and continuously perform
the steps of
forming a template, performing in vitro transcription of therapeutic mRNA from
the template,
purifying the therapeutic mRNA, and combining the mRNA with a delivery vehicle
in less than 5
days. Alternatively, the system may use a pre-made template as an input, and
perform the
remaining steps in shorter time.
- 15 -
CA 03149497 2022-02-01
WO 2021/030271
PCT/US2020/045625
[0063] Combining the mRNA with a delivery vehicle (formulating the
therapeutic) may
further comprise dialyzing the mRNA therapeutic composition in the one or more
microfluidic
path devices to purify the mRNA therapeutic composition.
[0064] Any of these methods may further comprise concentrating the mRNA
therapeutic
composition on the one or more microfluidic path devices, and/or dialyzing the
therapeutic.
[0065] Any appropriate delivery vehicle may be used, including, e.g., an
amphipathic
nanoparticle. For example, the amphipathic nanoparticle may comprise an amino-
lipidated
peptoid.
[0066] Alternatively or additionally in any of the methods and
apparatuses described herein,
mRNAs may be pre-made and stored (e.g., at 10 degrees C, 4 degrees C, 0
degrees C, -10
degrees C, etc.) for some time. For example, any of these methods and
apparatuses for
performing them may include a library of therapeutic mRNAs that may be
individually or
collectively (e.g., 2, 3, 4, 5, 6, etc. or more individual therapeutic mRNAs
may be combined and)
compounded to form an mRNA therapeutic composition. As described herein, an
mRNA
therapeutic composition may therefore be manufactured on demand, and may be
formulated just-
in-time in a single or multiple mRNA therapeutic composition "cocktails".
[0067] Also described herein are methods for forming the template (e.g.,
the DNA template).
For example, a method of making a synthetic double stranded DNA template for
in vitro
transcription using a closed-path system comprising a plurality of storage
depots in sealed fluid
communication with a microfluidic path device, may include: joining a
synthetic gene of interest
with a synthetic in vitro transcription facilitator cassette to create a
synthetic linear or circular
ligated product; removing unreacted synthetic gene of interest and unreacted
synthetic in vitro
transcription facilitator cassette away from the synthetic linear or circular
ligated product;
amplifying the circular ligated product to generate linear, branched or
circular amplified DNA;
and linearizing the amplified DNA ligated product to generate double stranded
DNA template,
wherein each of the joining, removing, amplifying and linearizing steps are
performed in the
microfluidic path device by the closed-path system.
[0068] For example, a high-efficiency, automated method of making a
synthetic double
stranded DNA template for in vitro transcription, may include: pneumatically
delivering each of:
a synthetic gene of interest and a synthetic in vitro transcription
facilitator cassette from one or
more storage depots of a plurality of storage depots in fluid communication
with a microfluidic
path device into a ligation reactor of the microfluidic path device to create
a synthetic linear or
circular ligated product by joining the synthetic gene of interest with the
synthetic in vitro
transcription facilitator cassette; pneumatically introducing one or more
exonuclease agents from
one or more storage depots of the plurality of storage depots into the
ligation reactor to remove
- 16 -
CA 03149497 2022-02-01
WO 2021/030271
PCT/US2020/045625
unreacted material by removing unreacted synthetic gene of interest and
unreacted synthetic in
vitro transcription facilitator cassette away from the synthetic linear or
circular ligated product;
pneumatically delivering the synthetic linear or circular ligated product into
an amplification
reactor of the microfluidic path device to combine with one or more
amplification agents for
amplifying the linear or circular ligated product to generate linear, branched
or circular amplified
DNA; and pneumatically transferring the amplified DNA ligated product to a
digestion reactor of
the microfluidic path device to generate fully synthetic, double stranded DNA
template free of
any unreacted input material by linearizing the amplified DNA ligated product,
wherein the
ligation reactor, amplification reactor and digestion reactor and plurality of
storage depots form a
closed-path and sealed environment.
[0069] A method of making a synthetic double stranded DNA template for
an mRNA
therapeutic composition (using a closed-path system comprising a plurality of
storage depots
configured to be secured in sealed fluid communication with one or more
microfluidic path
devices) may include: transporting reagents between one or more storage depots
of the plurality
of storage depots and a plurality of reactors on the one or more microfluidic
devices in a closed
fluidic path that is protected from atmospheric contact to, in the one or more
microfluidic path
devices: form a template for in vitro transcription of a therapeutic mRNA.
[0070] In general, the methods and apparatuses described herein may
produce double
stranded DNA template that may be free of bacterial DNA and/or free of
endotoxin. The
template generation methods and apparatuses described herein may not involve
bacterial culture.
In addition, the therapeutic mRNA manufactured as described herein may be
synthesized from
the template without the use of bacterial polynucleotides. Thus, any of the
methods described
herein may be methods for producing therapeutic mRNA without the use of
bacterial DNA,
and/or isolated from endotoxin. In particular, described herein are methods of
manufacturing
double stranded DNA template that is free of bacterial DNA and/or endotoxin.
Any of the
methods described herein may be aseptic manufacturing methods.
[0071] Any of these methods may include digesting the synthetic in vitro
transcription
template with a type IIS restriction enzyme and or methylation sensitive
restriction enzymes.
Joining may include ligating with a DNA ligase, or ligation by DNA synthesis
or ligation by
primer extension. Removing may comprise digesting linear DNA with an
exonuclease or by a
methylation sensitive restriction enzyme. The exonuclease may comprise
exonuclease V.
Amplifying may comprise multiple displacement amplification (MDA). Amplifying
may
comprise amplifying with (1)29 DNA polymerase. Amplifying may comprise
generating
branched amplified DNA. Amplifying may comprise polymerase chain amplification
(PCR).
Amplifying may comprise amplifying with thermostable DNA polymerase.
- 17 -
CA 03149497 2022-02-01
WO 2021/030271
PCT/US2020/045625
[0072] Linearizing may comprise digesting with a type IIs restriction
enzyme. Linearizing
may comprise digesting with a BsaI restriction enzyme. Digestion of the
synthetic in vitro
transcription template may comprise digesting with a methylation sensitive
restriction enzyme
such as DpnI. The synthetic gene of interest may be linear. In some
variations, the synthetic in
vitro transcription facilitator cassette comprises double stranded DNA
template comprising a
promoter; a 5' UTR; a cleavable linker; a 3' UTR; and a portion encoding a
polyA region
comprising at least 200 adenine residues or 200 thymidine residues in a row.
The synthetic in
vitro transcription facilitator cassette may be delivered as a single unit or
as two or more units.
The portion encoding the polyA region may be at least 300 bps long. In some
variations, the
portion encoding polyA region may be at least 350 bps long.
[0073] The synthetic gene of interest may comprise at least part of a T-
cell receptor. The
synthetic gene of interest may comprise a Complementary Determining Region
(CDR).
[0074] The in vitro transcription facilitator cassette may be less than
2 kb in length. The in
vitro transcription facilitator cassette maybe less than 1 kb in length. The
in vitro transcription
facilitator cassette may be less than 700 basepairs in length. The synthetic
in vitro transcription
facilitator cassette may not encode an antibiotic resistance gene.
[0075] The synthetic linear or circular ligated product may not have an
origin of replication
(ORI). The in vitro transcription facilitator cassette may not have an origin
of replication (ORI).
[0076] As mentioned, the steps of any of the methods described herein
may be performed in
a closed microfluidic path device. The steps may be performed in a closed
microfluidic path
device and the joining step may be performed in a different module (e.g., a
different microfluidic
path device) from the amplifying step and the amplifying step is performed in
a different module
from the linearizing step.
[0077] Any of these methods may include purifying, in the closed path of
the one or more
microfluidic path devices, the template.
[0078] Also described herein are methods of performing in vitro
transcription using the
closed-path method and apparatuses described herein. For example, a method of
performing an
in vitro transcription (IVT) reaction using a closed-path system (e.g.,
comprising a plurality of
storage depots configured to be secured in sealed fluid communication with one
or more
microfluidic path devices) may include: transporting reagents between one or
more storage
depots of the plurality of storage depots and a plurality of reactors on the
one or more
microfluidic devices in a closed fluidic path that is protected from
atmospheric contact to
perform in vitro transcription of a therapeutic mRNA from a template in the
one or more
microfluidic path devices.
- 18 -
CA 03149497 2022-02-01
WO 2021/030271
PCT/US2020/045625
[0079] A method of performing an in vitro transcription (IVT) reaction
may include:
automatically delivering a DNA template through directed fluid flow, a
polymerase, and
nucleotides into a first reactor of a microfluidic path device from a
plurality of storage depots in
amounts metered with sub-microliter precision; processing the template
material and nucleotides
in the first reactor to form a therapeutic mRNA; and pneumatically
transferring the therapeutic
mRNA through the microfluidic path device away from the first reactor, wherein
the first
microfluidic path device and the plurality of storage depots form a closed-
path and sealed
environment to prevent atmospheric exposure.
[0080] The closed-path system may operate automatically and
continuously. The closed-path
system may pneumatically control the performance of the in vitro transcription
of the therapeutic
mRNA from the template.
[0081] Any of these methods may also include purifying the therapeutic
mRNA in the one or
more microfluidic devices. Transporting reagents may comprise transporting the
reagents to a
first reactor of the microfluidic path device from the plurality of storage
depots.
[0082] Also described herein are methods of formulating (e.g., combining
with delivery
vehicle) a therapeutic mRNA. For example, a method of manufacturing an mRNA
therapeutic
composition (e.g., using a closed-path system comprising a plurality of
storage depots configured
to be secured in sealed fluid communication with one or more microfluidic path
devices) may
include: transporting reagents between one or more storage depots of the
plurality of storage
depots and a plurality of reactors on the one or more microfluidic devices in
a closed fluidic path
that is protected from atmospheric contact to formulate the mRNA therapeutic
composition by
combining a therapeutic mRNA with a delivery vehicle in the one or more
microfluidic path
devices. The closed-path system may automatically and continuously combine the
mRNA with a
delivery vehicle. The closed-path system may pneumatically control combining
the mRNA with
a delivery vehicle. For example, the closed-path system may pneumatically
control combining
the mRNA with a delivery vehicle by deflecting one or more membranes within
the one or more
microfluidic path devices.
[0083] Combining the mRNA with a delivery vehicle may further comprise
dialyzing the
mRNA therapeutic composition in the one or more microfluidic path devices to
purify the
mRNA therapeutic composition, and/or concentrating the mRNA therapeutic
composition on the
one or more microfluidic path devices.
[0084] For example, described herein are methods of manufacturing an
mRNA using a
system comprising a plurality of storage depots configured to be secured in
sealed fluid
communication with one or more microfluidic path devices. Any of these methods
may include:
transporting reagents between one or more storage depots of the plurality of
storage depots and a
- 19 -
CA 03149497 2022-02-01
WO 2021/030271
PCT/US2020/045625
plurality of reactors on the one or more microfluidic devices in a closed
fluidic path that is
protected from atmospheric contact to perform, in the one or more microfluidic
path devices, one
or more of the steps of: forming a template, performing in vitro transcription
of mRNA from the
template, and purifying the mRNA.
[0085] A method of manufacturing an therapeutic mRNA composition using a
system
comprising a plurality of storage depots configured to be secured in sealed
fluid communication
with one or more microfluidic path devices may include: transporting reagents
between one or
more storage depots of the plurality of storage depots and a plurality of
reactors on the one or
more microfluidic devices in a closed fluidic path that is protected from
atmospheric contact to
perform, in the one or more microfluidic path devices, one or more of the
steps of: forming a
template, performing in vitro transcription of therapeutic mRNA from the
template, purifying the
therapeutic mRNA, and formulating the mRNA with a delivery vehicle.
[0086] A method of manufacturing an therapeutic mRNA composition using a
system
comprising a plurality of storage depots configured to be secured in sealed
fluid communication
with one or more microfluidic path devices may include: transporting reagents
between one or
more storage depots of the plurality of storage depots and a plurality of
reactors on the one or
more microfluidic devices in a closed fluidic path that is protected from
atmospheric contact to
perform, in the one or more microfluidic path devices, one or more of the
steps of: forming a
template, performing in vitro transcription of therapeutic mRNA from the
template, purifying the
therapeutic mRNA, formulating the mRNA with a delivery vehicle, and performing
dialysis and
concentration of the formulated therapeutic mRNA.
[0087] A method of manufacturing an therapeutic mRNA composition using a
system
comprising a plurality of storage depots configured to be secured in sealed
fluid communication
with one or more microfluidic path devices may include: following a sequence
of steps for
forming the therapeutic mRNA composition that are encoded in a non-transitory,
computer-
readable medium, wherein the steps include: transporting reagents between one
or more storage
depots of the plurality of storage depots and a plurality of reactors on the
one or more
microfluidic devices in a closed fluidic path that is protected from
atmospheric contact to
perform, in the one or more microfluidic path devices, one or more of the
steps of: forming a
template, performing in vitro transcription of therapeutic mRNA from the
template, purifying the
therapeutic mRNA, and combining the mRNA with a delivery vehicle.
[0088] Also described herein are methods of manufacturing an therapeutic
mRNA
composition using a system comprising a plurality of storage depots configured
to be secured in
sealed fluid communication with a microfluidic path device, the method
comprising performing
in vitro transcription of therapeutic mRNA from a template on the microfluidic
path device, and
- 20 -
CA 03149497 2022-02-01
WO 2021/030271
PCT/US2020/045625
purifying the therapeutic mRNA in one or more fluidically connected reactors
on the
microfluidic path device.
[0089] Also described herein are therapeutics made by any of these
methods, including in
particular, mRNA therapeutics. For example, described herein are therapeutic
mRNAs made
using a system comprising a plurality of storage depots configured to be
secured in sealed fluid
communication with one or more microfluidic path devices, the mRNA made by:
transporting
reagents between one or more storage depots of the plurality of storage depots
and a plurality of
reactors on the one or more microfluidic devices in a closed fluidic path that
is protected from
atmospheric contact to perform, in the one or more microfluidic path devices,
one or more of the
steps of: forming a template, performing in vitro transcription of mRNA from
the template, and
purifying the mRNA.
[0090] For example, described herein are therapeutic mRNAs made using a
system
comprising a plurality of storage depots configured to be secured in sealed
fluid communication
with one or more microfluidic path devices, the mRNA made by: transporting
reagents between
one or more storage depots of the plurality of storage depots and a plurality
of reactors on the
one or more microfluidic devices in a closed fluidic path that is protected
from atmospheric
contact to perform, in the one or more microfluidic path devices, one or more
of the steps of:
forming a template, performing in vitro transcription of therapeutic mRNA from
the template,
purifying the therapeutic mRNA, and formulating the mRNA with a delivery
vehicle.
[0091] For example, described herein are therapeutic mRNAs made using a
system
comprising a plurality of storage depots configured to be secured in sealed
fluid communication
with one or more microfluidic path devices, the mRNA made by transporting
reagents between
one or more storage depots of the plurality of storage depots and a plurality
of reactors on the
one or more microfluidic devices in a closed fluidic path that is protected
from atmospheric
contact to perform, in the one or more microfluidic path devices, one or more
of the steps of:
forming a template, performing in vitro transcription of therapeutic mRNA from
the template,
purifying the therapeutic mRNA, formulating the mRNA with a delivery vehicle,
and performing
dialysis and concentration of the formulated therapeutic mRNA.
[0092] Described herein are therapeutic mRNA compositions formed using a
system
comprising a plurality of storage depots configured to be secured in sealed
fluid communication
with one or more microfluidic path devices, by: following a sequence of steps
for forming the
therapeutic mRNA composition that are encoded in a non-transitory, computer-
readable medium,
wherein the steps include: transporting reagents between one or more storage
depots of the
plurality of storage depots and a plurality of reactors on the one or more
microfluidic devices in a
closed fluidic path that is protected from atmospheric contact to perform, in
the one or more
- 21 -
CA 03149497 2022-02-01
WO 2021/030271
PCT/US2020/045625
microfluidic path devices, one or more of the steps of: forming a template,
performing in vitro
transcription of therapeutic mRNA from the template, purifying the therapeutic
mRNA, and
combining the mRNA with a delivery vehicle. For example, a therapeutic mRNA
may be a
therapeutic mRNA composition formed using a system comprising a plurality of
storage depots
configured to be secured in sealed fluid communication with a microfluidic
path device, the
method comprising performing in vitro transcription of therapeutic mRNA from a
template on
the microfluidic path device, and purifying the therapeutic mRNA in one or
more fluidically
connected reactors on the microfluidic path device.
[0093] Any of the systems described herein may include controller
configured to perform
any of these methods. Thus, also described herein is software, firmware or
hardware configured
to perform any of the methods described herein. For example, described herein
are non-transitory
computer readable medium embodying instructions for manufacturing an mRNA,
that when
executed by a controller of a system comprising a plurality of storage depots
configured to be
secured in sealed fluid communication with one or more microfluidic path
devices, cause the
.. controller to perform the method of: transporting reagents between one or
more storage depots of
the plurality of storage depots and a plurality of reactors on the one or more
microfluidic devices
in a closed fluidic path that is protected from atmospheric contact to
perform, in the one or more
microfluidic path devices, one or more of the steps of: forming a template,
performing in vitro
transcription of mRNA from the template, and purifying the mRNA.
[0094] For example, described herein are non-transitory computer readable
medium
embodying instructions for manufacturing an mRNA, including a therapeutic mRNA
composition, that when executed by a controller of a system comprising a
plurality of storage
depots configured to be secured in sealed fluid communication with one or more
microfluidic
path devices, cause the controller to perform any of the methods described
herein.
[0095] Also described herein are methods of making a synthetic double
stranded DNA
template for an mRNA using a closed-path system comprising a plurality of
storage depots
configured to be secured in sealed fluid communication with one or more
microfluidic path
devices, that may include: transporting reagents between one or more storage
depots of the
plurality of storage depots and a plurality of reactors on the one or more
microfluidic devices in a
closed fluidic path that is protected from atmospheric contact to combine the
reagents; and
forming a template for in vitro transcription of a therapeutic mRNA.
[0096] For example, a method of making a synthetic double stranded DNA
template for use
as the input into an mRNA in vitro transcription reaction using a closed-path
system may include
a plurality of storage depots configured to be secured in sealed fluid
communication with one or
more microfluidic path devices, the method comprising: transporting reagents
between one or
- 22 -
CA 03149497 2022-02-01
WO 2021/030271
PCT/US2020/045625
more storage depots of the plurality of storage depots and a plurality of
reactors on the one or
more microfluidic devices in a closed fluidic path that is protected from
atmospheric contact; and
forming a template for in vitro transcription of a therapeutic mRNA.
[0097] A method of manufacturing an mRNA composition using a system
comprising a
plurality of storage depots configured to be secured in sealed fluid
communication with one or
more microfluidic path devices, wherein the one or more microfluidic path
devices comprise a
plurality of reactors, may include: delivering a template precursor material
from one or more
storage depots to a first reactor region of the plurality of reactors and
processing the template
precursor material to prepare a template from the template precursor material;
transferring the
template to a second reactor region of the plurality of reactors and
processing the template by in
vitro transcription to form an mRNA; and transferring the mRNA to a third
reactor region of the
plurality of reactors and processing the mRNA to combine it with a delivery
vehicle to form the
mRNA composition, wherein materials including the template material and
delivery vehicle are
delivered from the storage depots into the plurality of reactors without
atmospheric contact.
[0098] A method of manufacturing an mRNA composition using a system
comprising a
plurality of storage depots in sealed fluid communication with one or more
microfluidic path
devices, wherein the one or more microfluidic path devices comprise a
plurality of reactors, may
include: pneumatically delivering a template precursor material from one or
more storage depots
to a first reactor region of the plurality of reactors and processing the
template precursor material
.. to prepare a template from the template precursor material; pneumatically
transferring the
template to a second reactor region of the plurality of reactors and
processing the template by in
vitro transcription to form mRNA; pneumatically transferring the mRNA to a
third reactor region
of the plurality of reactors and processing the mRNA to combine it with
delivery vehicle to form
the therapeutic mRNA composition; and transferring the mRNA product to one or
more storage
depots, wherein the materials are delivered from the storage depots into the
reactors of the
microfluidic path device with sub-microliter precision and without atmospheric
contact.
[0099] A method of making a synthetic double stranded DNA template for
in vitro
transcription using a closed-path system comprising a plurality of storage
depots in sealed fluid
communication with a microfluidic path device, may include: joining a
synthetic gene of interest
.. with a synthetic in vitro transcription facilitator cassette to create a
synthetic linear or circular
ligated product; removing unreacted synthetic gene of interest and unreacted
synthetic in vitro
transcription facilitator cassette away from the synthetic linear or circular
ligated product;
amplifying the linear or circular ligated product to generate linear, branched
or circular amplified
DNA; and linearizing the amplified DNA ligated product to generate double
stranded DNA
- 23 -
CA 03149497 2022-02-01
WO 2021/030271
PCT/US2020/045625
template, wherein each of the joining, removing, amplifying and linearizing
steps are performed
in the microfluidic path device by the closed-path system.
[0100] Any of these methods may be high-efficiency, automated methods,
including high-
efficiency, automated methods of making a synthetic double stranded DNA
template for in vitro
transcription. For example, a method may include: pneumatically delivering
each of: a synthetic
gene of interest and a synthetic in vitro transcription facilitator cassette
from one or more storage
depots of a plurality of storage depots in fluid communication with a
microfluidic path device
into a ligation reactor of the microfluidic path device to create a synthetic
linear or circular
ligated product by joining the synthetic gene of interest with the synthetic
in vitro transcription
facilitator cassette; pneumatically introducing one or more exonuclease agents
from one or more
storage depots of the plurality of storage depots into the ligation reactor to
remove unreacted
material by removing unreacted synthetic gene of interest and unreacted
synthetic in vitro
transcription facilitator cassette away from the synthetic linear or circular
ligated product;
pneumatically delivering the synthetic linear or circular ligated product into
a multiple
displacement amplification (MDA) or polymerase chain reaction (PCR) reactor of
the
microfluidic path device to combine with one or more amplification agents for
amplifying the
linear or circular ligated product to generate linear, branched or circular
amplified DNA; and
pneumatically transferring the amplified DNA ligated product to a digestion
reactor of the
microfluidic path device to generate double stranded DNA template by
linearizing amplified
DNA ligated product, wherein the ligation reactor, MDA or PCR reactor and
digestion reactor
and plurality of storage depots form a closed-path and sealed environment.
[0101] A method of making a synthetic double stranded DNA template for
in vitro
transcription, the method comprising following a sequence of steps that are
encoded in a non-
transitory, computer-readable medium, may include: delivering each of: a
synthetic gene of
interest and a synthetic in vitro transcription facilitator cassette from one
or more storage depots
of a plurality of storage depots in fluid communication with a microfluidic
path device into a
ligation reactor of the microfluidic path device to create a synthetic linear
or circular ligated
product by joining the synthetic gene of interest with the synthetic in vitro
transcription
facilitator cassette; introducing one or more exonuclease agents from one or
more storage depots
of the plurality of storage depots into the ligation reactor to remove
unreacted material by
removing unreacted synthetic gene of interest and unreacted synthetic in vitro
transcription
facilitator cassette away from the synthetic linear or circular ligated
product; delivering the
synthetic linear or circular ligated product into a multiple displacement
amplification (MDA) or
polymerase chain reaction (PCR) reactor of the microfluidic path device to
combine with one or
more amplification agents for amplifying the linear or circular ligated
product to generate linear,
- 24 -
CA 03149497 2022-02-01
WO 2021/030271
PCT/US2020/045625
branched or circular amplified DNA; and transferring the amplified DNA ligated
product to a
digestion reactor of the microfluidic path device to generate double stranded
DNA template by
linearizing amplified DNA ligated product, wherein the ligation reactor, MDA
reactor and
digestion reactor and plurality of storage depots form a closed-path and
sealed environment.
[0102] A method of performing an in vitro transcription (IVT) reaction
using a system
comprising a plurality of storage depots configured to be secured in sealed
fluid communication
with one or more microfluidic path devices, may include: transporting reagents
between one or
more storage depots of the plurality of storage depots and a plurality of
reactors on the one or
more microfluidic devices in a closed fluidic path that is protected from
atmospheric contact to
perform in vitro transcription of a therapeutic mRNA from a template in the
one or more
microfluidic path devices.
[0103] Also described herein are methods of performing an in vitro
transcription (IVT)
reaction, the method comprising following a sequence of steps that are encoded
in a non-
transitory, computer-readable medium, wherein the steps include: pneumatically
delivering a
template material, a polymerase, and nucleotides into a first reactor of a
microfluidic path device
from a plurality of storage depots in amounts metered with sub-microliter
precision at any time
during the reaction; processing the template material and nucleotides in the
first reactor to form a
therapeutic mRNA; and pneumatically transferring the therapeutic mRNA through
the
microfluidic path device away from the first reactor, wherein the first
microfluidic path device
and the plurality of storage depots form a closed-path and sealed environment
to prevent
atmospheric exposure.
[0104] Also described herein are methods of performing an in vitro
transcription (IVT)
reaction, the method comprising following a sequence of steps that are encoded
in a non-
transitory, computer-readable medium, wherein the steps include: delivering,
by induced fluidic
flow, a template material, a polymerase, and nucleotides into a microfluidic
path device from a
plurality of storage depots in amounts controlled by a controller following
the sequence of steps;
processing the template material and nucleotides in one or more reactors to
form a therapeutic
mRNA; and transferring the therapeutic mRNA through the microfluidic path
device away from
the one or more reactors, wherein the first microfluidic path device and the
plurality of storage
depots form a closed-path and sealed environment to prevent atmospheric
exposure.
[0105] Also described herein are methods of performing an in vitro
transcription (IVT)
reaction, the method comprising: delivering, by induced fluidic flow, a
template material, a
polymerase, and nucleotides into a microfluidic path device from a plurality
of storage depots in
amounts controlled by pre-programmed software commands; processing the
template material
and nucleotides in a first one or more reactors in the microfluidic path
device to form a
- 25 -
CA 03149497 2022-02-01
WO 2021/030271
PCT/US2020/045625
therapeutic mRNA; and transferring the therapeutic mRNA through the
microfluidic path device
away from the first one or more reactor, into a second one or more reactors
adapted for
purification of mRNA, wherein the microfluidic path device and the plurality
of storage depots
form a closed-path and sealed environment to prevent atmospheric exposure.
[0106] Also described herein are methods of performing an in vitro
transcription (IVT)
reaction, the method comprising following a sequence of steps that are encoded
in a non-
transitory, computer-readable medium, wherein the steps include: delivering,
by induced fluidic
flow, a template material, a polymerase, and nucleotides into a first one or
more reactors of a
first microfluidic path device from a plurality of storage depots, in amounts
controlled by the
sequence of steps; processing the template material and nucleotides in the
first one or more
reactors to form a therapeutic mRNA; and transferring the therapeutic mRNA
through the first
microfluidic path device away from the first one or more reactors, into a
second one or more
reactor adapted for purification of mRNA; and transferring thus purified mRNA
for completion
of the formulation of the mRNA therapeutic, wherein the first microfluidic
path device and the
plurality of storage depots form a closed-path and sealed environment to
prevent atmospheric
exposure.
[0107] Also described herein are methods of performing an in vitro
transcription (IVT)
reaction, the method comprising following a sequence of steps that are encoded
in a non-
transitory, computer-readable medium, wherein the steps include: pneumatically
delivering a
template material, a polymerase, and nucleotides into a first one or more
reactors of a first
microfluidic path device from a plurality of storage depots; processing the
template material and
nucleotides in the first one or more reactors to form a therapeutic mRNA; and
transferring the
therapeutic mRNA through the first microfluidic path device away from the
first one or more
reactors, into a second one or more reactors adapted for purification of mRNA;
and transferring
purified mRNA to a third one or more reactors to combine the purified mRNA
with one or more
delivery vehicles to form an mRNA therapeutic, wherein the first microfluidic
path device and
the plurality of storage depots form a closed-path and sealed environment to
prevent atmospheric
exposure.
[0108] For example, also described herein are methods of performing an
in vitro
transcription (IVT) reaction, the method comprising following a sequence of
steps that are
encoded in a non-transitory, computer-readable medium, wherein the steps
include:
pneumatically delivering a template material, a polymerase, and nucleotides
into a first one or
more reactors of a first microfluidic path device from a plurality of storage
depots; processing
the template material and nucleotides in the first one or more reactors to
form a therapeutic
mRNA; and transferring the therapeutic mRNA through the first microfluidic
path device away
- 26 -
CA 03149497 2022-02-01
WO 2021/030271
PCT/US2020/045625
from the first one or more reactors, into a second one or more reactors
comprising cellulose and
adapted for purification of mRNA; and transferring purified mRNA to a third
one or more
reactors to combine the purified mRNA with one or more delivery vehicles to
form an mRNA
therapeutic, wherein the first microfluidic path device and the plurality of
storage depots form a
closed-path and sealed environment to prevent atmospheric exposure.
[0109] Also described herein are methods of manufacturing an therapeutic
mRNA
composition using a system comprising a plurality of storage depots configured
to be secured in
sealed fluid communication with one or more microfluidic path devices, the
method comprising:
transporting reagents between one or more storage depots of the plurality of
storage depots and a
plurality of reactors on the one or more microfluidic devices in a closed
fluidic path that is
protected from atmospheric contact to formulate the therapeutic mRNA
composition by
combining one or more therapeutic mRNAs with a delivery vehicle in the one or
more
microfluidic path devices.
[0110] A method of manufacturing an therapeutic mRNA composition on
demand using a
system comprising a plurality of storage depots configured to be secured in
sealed fluid
communication with one or more microfluidic path devices, may include:
transporting reagents
between one or more storage depots of the plurality of storage depots and a
plurality of reactors
on the one or more microfluidic devices in a closed fluidic path that is
protected from
atmospheric contact to perform, in the one or more microfluidic path devices,
one or more of the
steps of: forming a template, performing in vitro transcription of therapeutic
mRNA from the
template, purifying the therapeutic mRNA, and formulating the mRNA with a
delivery vehicle.
[0111] Any of these methods and apparatuses may be operated (e.g., the
therapeutic mRNA
is manufactured) at the site of care. Any of these methods and apparatuses may
be performed
rapidly and continuously, e.g., the therapeutic is manufactured in less than
72 hours.
[0112] As mentioned, in any of these methods and apparatuses the
polynucleotide formed
(e.g., by IVT) may be purified before and after being combined with a delivery
vehicle, within
the microfluidic path device, under automated control of the microfluidic
control apparatus.
[0113] In particular, described herein are method and apparatuses that
may include one or
more microfluidic path devices adapted for use with a permeable insert
material that may remove
one or more target materials (e.g., double-stranded RNA, etc.) and/or may add
one or more
additional materials (e.g., lyophilized materials) to the therapeutic material
as part of the
fabrication process. The permeable insert material may be configured to be
retained within one
or more fluid-contacting chambers of the microfluidic path device, and may be
adapted so that
the developing therapeutic solution passes through the permeable insert
material. The permeable
insert material may be compressible, and/or deformable, and/or elastic, so
that it may be
- 27 -
CA 03149497 2022-02-01
WO 2021/030271
PCT/US2020/045625
manipulated by an elastic membrane within the chamber. The permeable insert
may include a
cover (e.g., an outer cover) that is permeable and contains a modifying
material that is solid,
granular, gel, etc. In some variations the permeable insert material is a
cellulose material that is
configured to selectively remove dsRNA from the solution.
[0114] A permeable material may be porous (e.g., may include pores). In
some variations,
the permeable material may be fibrous, or layered. For example, the permeable
material may be
fibrous, and may include channels through which fluid can move. In some
variations channels
may be formed through the permeable material to allow it to be permeable to
fluid. For example,
the permeable material may have channels formed by a laser, or any other means
by which the
interior volume may be made accessible to the fluid. In some variations the
permeable material
may be formed from a plurality of layers that are arranged to allow fluid to
pass between or
among the layers. Multiple thin layers of material with only surface
accessibility, may be stacked
together. For example, functionalized graphene may be layered (e.g., in the
extreme, to single
atomic layers). As another example, slices of aerogels may be treated or
otherwise made
absorptive and stacked to form the permeable material of the insert.
[0115] In any of the permeable materials described herein the material
may be a preformed
material that is configured to allow the passage of a fluid, in some cases at
a predefined flow rate
and/or flow resistance. The permeability of the material may be selected to
allow flow through
the permeable insert when held within the apparatus chamber or channel at the
processing flow
rates and fluid pressures described herein. As mentioned above, a preformed
permeable material
may be porous, fibrous, could be stacks of layers; any of these materials may
be functionalized to
bind a material. As used herein, a functionalized material may include any
material for which a
surface of the material has been modified by the addition of a compound,
agent, or functional
group that specifically binds a target material. Materials may also or
alternatively be
functionalized by surface treatments by which specific atomic molecular groups
may be attached
to alter specific properties of the material. Functionalization can be
performed by various surface
modification techniques such as wet chemistry, or vapor, gas, and/or plasma
chemistry, and/or
microwave assisted chemical techniques, etc. including techniques that utilize
surface chemistry
to bond desirable materials to surfaces. Similar techniques may be used to
modify the material,
e.g., to "activate" the material.
[0116] The permeable material may be configured to maximize the total
surface area for the
insert within the apparatus, allowing selective binding of unwanted
impurities, and/or target
products. Any of these permeable materials may be configured to provide for
sufficient
penetration of the solution into the interior of the preformed material for
effective binding to the
substances in the solution. In some variations the permeable material may
comprises more than
- 28 -
CA 03149497 2022-02-01
WO 2021/030271
PCT/US2020/045625
one preform, each preform larger than the channels or cambers within the
microfluidic path
device, and each of these preforms may still allow for penetration of a
solution inside for
maximizing of the exposure of solution to the functionally active materials.
[0117] As mentioned above, the permeable implants inserts described
herein may be
configured to remove an impurity (e.g., an unwanted material) from a solution;
alternatively or
additionally the permeable implant may be configured to bind releasably to a
wanted materials,
so that it may be eluted (e.g., after washing, etc.).
[0118] As mentioned above, the methods and apparatuses described herein
may include the
use of a microfluidic path device that includes one or more permeable inserts
configured to
modify the solution forming the therapeutic. The permeable insert may be
adapted for use within
the microfluidic path devices described herein.
[0119] For example, described herein are permeable inserts that are
configured to fit within
the fluid-contacting side of a chamber. Thus, the permeable insert may be
sized and/or shaped to
conform substantially to the volume within all or a portion (e.g., a cross-
sectional region) of the
fluid-contacting side of the chamber. As mentioned above, the permeable
material may be a
single preformed implant, or it may be a combination of a number of preformed
materials
forming the permeable implant. The permeable implant may generally permit a
flow of solution
into and through the material. In some variations the permeable implant may
also be
compressible (e.g., "squeezable") to allow removal of fluid from within the
permeable implant
when the microfluidic path device compresses the chamber in which the
permeable implant is
inserted. In some variations the permeable implant is sufficiently elastic to
return an expanded
shape after being compressed.
[0120] The permeable insert and microfluidic path device may be
configured so that the
fluid, and particularly the material being used to generate the therapeutic
composition,
necessarily passes through the permeable insert during processing. In some
variations the
permeable insert is a compressible material and/or an elastically deformable
material (e.g.,
elastic) that may be deformed as the volume of the fluid-contacting chamber is
changed by
deflecting an elastic material (e.g., elastic layer) separating the fluid-
contacting side of the
chamber from a pressure-receiving side of the chamber. In some variations the
permeable insert
is compressible but not necessarily elastically deformable. In some variations
the permeable
insert is swellable material that, when activated (e.g., by the addition of
fluid, such as a buffer,
water, etc.) may swell within the fluid-contacting side of the chamber. The
permeable insert may
be compressed by deflecting the elastic material (layer) between the pressure-
receiving side of
the chamber and the fluid-contacting side of the chamber. In some variations,
processing the
therapeutic may include transmitting the solution used to formulate the
therapeutic material
- 29 -
CA 03149497 2022-02-01
WO 2021/030271
PCT/US2020/045625
between multiple (e.g., 2, 3, 4, etc.) chambers including a permeable insert
material. In some
variations, the method may include driving the solution in and out of a
chamber including a
permeable insert material.
[0121] In any of the methods and apparatuses described herein the
therapeutic insert material
may be compressed to drive the solution including the therapeutic material (or
in which the
therapeutic material is being formed) out of the fluid-contacting side of the
chamber, e.g., by
adjusting the pressure in the pressure-receiving side of the chamber to
deflect the elastic
membrane separating the chamber into a fluid-contacting side and a pressure-
receiving side.
[0122] The permeable insert may be any appropriate material that may be
used to modify and
further process and/or modify the therapeutic material. For example, in some
variations the
permeable insert may include a cellulose material that is configured to retain
dsRNA, in order to
remove the dsRNA from the solution as it passes through the permeable
material. Alternatively
or additionally, the permeable insert may include one or more materials that
may be added to the
solution from the permeable insert.
[0123] For example, any of the permeable inserts described herein may
include one or more
additional materials adsorbed into or on the permeable insert. In any of these
variations, the
permeable insert may include a material for release. In some variations, e.g.,
a permeable insert
may include a cellulose insert that may be pre-treated with DNAse to entrap
the DNAse in the
cellulose. This may allow the insert to simultaneously remove dsRNA (as
described herein) and
digest a DNA material, such as the DNA template from an in vitro transcription
step.
[0124] Any of the permeable inserts described herein may be configured
as surface-
functionalized inserts that include one or more additional agents attached,
adsorbed or otherwise
included on or in the permeable insert. For example, in some variation an
additional material
such included in or on the permeable inserts may include covalently-tethered
materials (e.g.,
antibodies or aptamers), electrostatically tethered materials, adsorbed
enzymes (e.g., in some
examples, that may selectively degrade an impurity, such as a DNAse as
mentioned above),
covalently or non-covalently attached sensors (e.g., to detect a material to
be removed, such as
double stranded RNA, impurities, etc.). In some variations an additional
material or materials
may include a poly(dT) sequence to capture the polyadenylated RNA molecules,
e.g., bound to
the surface(s) of/in the permeable implant (for example, poly(dT) sequences
may be used within
the permeable implant to isolate mRNA). In some variations an additional
material or materials
may include small molecules to enhance binding properties (e.g., a dsRNA
intercalator such as
ethidium bromide may selectively bind dsRNA material without binding ssRNA).
In some
variations, the permeable insert may be at least partially coated with a
material. For example, in
some variations the coating may be a carboxylate coating.
- 30 -
CA 03149497 2022-02-01
WO 2021/030271
PCT/US2020/045625
[0125] In some variations the permeable insert may include a lyophilized
material that may
be released into the solution immediately or in a timed-release manner. For
example, in some
variations, as the solution contacts the permeable insert, it may dissolve the
lyophilized material
into the solution. Examples of lyophilized materials may include one or more
buffer materials
.. (e.g., salts, chelators, detergents, polynucleotides, enzymes, proteins,
etc.). In some variations the
permeable insert may include agents, such as binding agents, for binding to
one or more
materials in the solution. For example, the permeable insert may include bound
immunoagents,
e.g., antibodies, or portions thereof, including FAB fragments, etc., that may
selectively remove
material from the solution.
[0126] In general, the permeable insert may be configured to span the fluid-
contacting side
of the chamber so that fluid passes over and/or through the permeable insert.
Permeable insert
may be a paper, e.g., sheet of material. The permeable insert may be folded so
as to span and/or
at least partially fill the fluid-contacting side of the chamber. Folded
shapes may therefore span
the fluid-contacting portion of the chamber, while being configured for
deflecting (including
elastically deflecting). The folds may include simple folds (e.g., fan-shaped
folds) or more
complex folds; in general the folds may include one or more bent, regions that
may operate as a
hinged (e.g., living hinge) region and//or may be biased to return to an
expanded shape after
being compressed or otherwise deflected by the movement of the elastic
membrane dividing the
chamber into the fluid-contacting chamber and the pressure-receiving chamber.
In some
.. variations the permeable insert may form a sponge. The permeable insert may
be formed as a
foamed or puffed material.
[0127] In any of the variations of permeable inserts described herein,
the size of the passages
(e.g., pores, channels, chambers, etc.) within the permeable insert may be
configured to pass or
exclude a material based on the size. Thus, the permeable inserts descried
herein may be
configured to perform size-exclusion (e.g., size-exclusion chromatography).
For example, a large
mRNA molecule that has unreacted mononucleotides may be passed into a chamber
containing a
nano-porous insert, and unreacted dNTPs may diffuse into the insert and become
physically
entrapped therein, while the size of the passages (e.g., pores) can exclude
the large molecules.
[0128] For example, in variations in which the permeable insert includes
cellulose (e.g., for
removing dsRNA), the cellulose may be in the form of a paper (e.g., filter
paper), which may be
folded or layered, including folds that are configured to be retained within
the fluid-contacting
portion of the chamber. In some variations the cellulose may be puffed, or
foamed. In some
variations the cellulose may be in the form of a sponge.
[0129] The permeable insert may generally have pores that are of any
appropriate size. Pore
size may be uniform or non-uniform; in some variations, the pore size may be
distributed within
- 31 -
CA 03149497 2022-02-01
WO 2021/030271
PCT/US2020/045625
a size range. For example, the pore size may be between about 1 p.m and about
200 p.m (e.g.,
from 1 p.m to 3 p.m, from 1 p.m to 5 p.m, from 2 p.m to 4 p.m, from 2 p.m to 5
p.m, from 3 p.m to 6
p.m , from 5 p.m to 10 p.m, from 6 p.m to 8 p.m, from 6 p.m to 10 p.m, from 7
p.m to 10 p.m, from
8 p.m to 10 p.m from 9 p.m to 11 p.m, from 9 p.m to 12 p.m, from 10 p.m to 12
p.m, from 10 p.m to
15 p.m, from 12 p.m to 15 p.m, from 14 p.m to 16 p.m, from 15 p.m to 18 p.m,
from 17 p.m to 19
p.m, from a lower size of 1 p.m, 2 p.m, 3 p.m, 4 p.m, 5 p.m, 6 p.m, 7 p.m, 8
p.m, 9 p.m, 10 p.m, 11
p.m, 12 p.m, 13 p.m, 14 p.m, 15 p.m, 16 p.m, 17 p.m, 18 p.m, 19 p.m, 20 p.m,
22 p.m, 25 p.m, 27 p.m,
30 p.m, 40 p.m, 50 p.m, 60 p.m, 70 p.m, 80 p.m, 90 p.m, 100 p.m, 110 p.m, 120
p.m, etc. to an upper
size of 2 p.m, 3 p.m, 4 p.m, 5 p.m, 6 p.m, 7 p.m, 8 p.m, 9 p.m, 10 p.m, 11
p.m, 12 p.m, 13 p.m, 14 p.m,
15 p.m, 16 p.m, 17 p.m, 18 p.m, 19 p.m, 20 p.m, 22 p.m, 25 p.m, 27 p.m, 30
p.m, 40 p.m, 50 p.m, 60
p.m, 70 p.m, 80 p.m, 90 p.m, 100 p.m, 110 p.m, 120 p.m, etc., where the lower
pore size is smaller
than the upper pore size. The size range may be a distribution, e.g., in which
>90% of the pores
are within the size distribution (e.g., >90%, >92%, >93%, >94%, >95%, >96%,
>97%, >98%,
>99%, >99.5%, > 99.9%, etc.).
[0130] In any of the methods and apparatuses described herein, the
temperature of the
microfluidic path device may be controlled, as described herein. In
particular, the temperature of
the chamber containing the permeable insert may be controlled. For example,
the chamber
containing the permeable insert in the microfluidic path device may be
maintained at a target
temperature when the solution including the therapeutic material (or in which
the therapeutic
.. material is being formed) contacts the permeable insert. The temperature
may be maintained,
e.g., at between 2 degrees C and 20 degrees, between 2 C and 5 C, between 2 C
and 10 C,
between 2 C and 15 C, between 5 C and 10 C, between 5 C and 15 C, between 5 C
and 20 C,
between 10 C and 15 C, between 10 C and 20 C, between 10 C and 30 C, between
10 C and
C, between 15 C and 20 C, between 15 C and 25 C, between 15 C and 30 C,
between 20 C
25 __ and 25 C, between 20 C and 30 C, between 25 C and 30 C, between 25 C and
40 C, between
25 C and 35 C, between 30 C and 35 C, between 30 C and 40 C, between 35 C and
40 C,
between 30 C and 50 C, between 30 C and 45 C, between 35 C and 40 C, between
35 C and
45 C, between 35 C and 50 C, between 40 C and 45 C, between 40 C and 50 C,
between 45 C
and 50 C, between 40 C and 60 C, between 40 C and 55 C, between 45 C and 55 C,
between
.. 45 C and 60 C, between 50 C and 55 C, between 50 C and 60 C, between 55 C
and 60 C,
between 50 C and 70 C, between 50 C and 65 C, between 55 C and 65 C, between
55 C and
70 C, between 60 C and 70 C, between 60 C and 75 C, between 65 C and 70 C,
between 65 C
and 75 C, between 65 C and 80 C, between 70 C and 80 C, between 75 C and 80 C,
between
60 C and 80 C, between 65 C and 75 C, between 65 C and 80 C , between 75 C and
80 C,
between 70 C and 90 C, between 75 C and 90 C , between 80 C and 90 C ,
between 85 C and
- 32 -
CA 03149497 2022-02-01
WO 2021/030271
PCT/US2020/045625
85 C, between 85 C and 90 C, etc. The temperature may be constant, or it may
be varied (e.g.,
increased, decreased, etc.) before, during and/or after exposure to the
permeable insert.
[0131] In some variations the permeable insert may be referred to as a
solid permeable insert;
the permeable (e.g., solid permeable) insert may be configured so that it
remains entirely
contained within the fluid-contacting side of the chamber. In some variations,
as mentioned
above, in some variations the permeable insert may be configured as a
permeable package that is
enclosed by an outer contained, e.g., a permeable cover, that encloses a
material and confines the
material within the permeable cover. For example, the permeable cover may
enclose a granular
material, or a gel (e.g., a hydrogel), or the like. The permeable cover may be
formed of a material
.. such as a membrane material that is sufficiently permeable to allow fluid
to pass through the
cover and into the volume contained by the cover. The permeable insert may
therefore form a
pillow-like shape that may be compressible and/or elastically deformable.
[0132] In general, the permeable insert may be inserted into the fluid-
contacting chamber of
the microfluidic path device and may be configured to fit within the fluid-
contacting chamber as
mentioned above. In some variations the permeable insert is configured to fit
snuggly in the
fluid-contacting side of the chamber; for example, the permeable insert may
have a shape that is
complementary to the shape of the fluid-contacting side of the chamber (e.g.,
oval, round, square,
rounded square, etc.). As mentioned, the permeable insert may be configured to
span and/or fill
the volume, and in particular, span the volume in a direction perpendicular to
the direction of
flow through the volume of the fluid-contacting side, so that fluid passes
through the permeable
insert.
[0133] For example, described herein are microfluidic path devices that
may include: a
means for inducing fluid flow of a solution within the microfluidics path
device; a plurality of
chambers; and a permeable insert within a first chamber of the plurality of
chambers, wherein the
insert is configured to be compressed. The means for inducing fluid flow of a
solution may
include any appropriate means, in particular, a plurality of pressure ports on
the microfluidics
path device configured to receive positive or negative pressure to deflect a
membrane within the
microfluidics path device. For example, described herein are microfluidic path
devices
comprising: an elastic material sandwiched between a first plate and a second
plate; and a
plurality of chambers formed between the first plate and the second plate,
wherein a portion of
the elastic material divides each chamber into a fluid-contacting side and a
pressure-receiving
side. Any of these microfluidic path devices may include a solid and permeable
insert within the
fluid-contacting side of a first chamber.
[0134] For example, described herein are microfluidic path devices
comprising: an elastic
material sandwiched between a first plate and a second plate; a plurality of
chambers formed
- 33 -
CA 03149497 2022-02-01
WO 2021/030271
PCT/US2020/045625
between the first plate and the second plate, wherein a portion of the elastic
material divides each
chamber into a fluid-contacting side and a pressure-receiving side; and a
solid and permeable
insert within the fluid-contacting side of a first chamber of the plurality of
chambers, wherein the
insert is configured to be compressed by deflection of the elastic material
when pressure is
applied to the pressure-receiving side of the first chamber.
[0135] In some variations, the microfluidic path device comprises: an
elastic material
sandwiched between a first plate and a second plate; a plurality of chambers
formed between the
first plate and the second plate, wherein a portion of the elastic material
divides each chamber
into a fluid-contacting side and a pressure-receiving side; and a solid and
permeable insert within
the fluid-contacting side of a first chamber of the plurality of chambers,
wherein the insert
comprises a cellulose material configured to purify RNA, wherein the elastic
material diving the
first chamber is configured to be deflected by the application of pressure to
the pressure-
receiving side to move fluid into or out of the first chamber.
[0136] A microfluidic path device may comprise: an elastic material
sandwiched between a
first plate and a second plate; a plurality of chambers formed between the
first plate and the
second plate, wherein a portion of the elastic material divides each chamber
into a fluid-
contacting side and a pressure-receiving side; a plurality of fluid ports
configured to be in fluid
communication with the fluid-contacting sides of the plurality of chambers; a
plurality of
pressure ports in fluid communication with the pressure-receiving sides of the
plurality of
chambers; and a solid and permeable insert within the fluid-contacting side of
a first chamber of
the plurality of chambers, wherein the insert is configured to be compressed
by deflection of the
elastic material when pressure is applied to the pressure-receiving side of
the first chamber from
one or more of the pressure ports.
[0137] In some variations, and in particular, variations in which the
permeable insert is
configured to remove an undesired material (e.g., dsRNA) from the solution,
such as variations
including cellulose, the chamber may be referred to as a separation chamber.
[0138] As mentioned, in any of these apparatuses (e.g., systems,
devices, etc.) the solid and
permeable insert may include a cellulose material configured to purify RNA.
For example, the
solid and permeable insert may comprise a sheet of cellulose material.
Alternatively or
additionally, the solid and permeable insert may comprise a lyophilized
material.
[0139] The solid and permeable insert may have a profile that matches
the profile of the first
chamber. As mentioned, the solid and permeable insert may be elastic.
[0140] The solid and permeable insert may comprise a permeable outer
covering containing
a granular material. In some variations, the solid and permeable insert
comprises a folded
structure.
- 34 -
CA 03149497 2022-02-01
WO 2021/030271
PCT/US2020/045625
[0141] In some variations, the microfluidic path device may include a
second chamber that is
fluidly connected to the first chamber. The device may be configured to
transfer fluid between
the first chamber and second chamber by deflecting the elastic material. In
some variations the
fluid may be reciprocated between the first chamber and the second chamber.
[0142] The microfluidic path device may include a plurality of individually
addressable
pressure ports extending through the first plate and configured to deliver
pressure to the pressure-
receiving sides of the plurality of chambers to move fluid in the fluid-
receiving side.
[0143] Also described herein are methods of using any of the devices
described herein. For
example, a method of processing a therapeutic material in a fluid (e.g., an
RNA sample) may
include: coupling a microfluidic path device to a pressure source; applying
pressure to transport
the sample to a fluid-contacting side of a separation chamber of the
microfluidic path device;
passing the sample into a solid and permeable insert within the fluid-
contacting side of the
separation chamber, wherein the sample is modified by the solid and permeable
insert; and
applying pressure to transport the sample out of the fluid-contacting side of
the separation
chamber.
[0144] For example, a method of removing double-stranded RNA (dsRNA)
from an RNA
sample containing both dsRNA and single-stranded RNA (ssRNA), may include:
coupling a
microfluidic path device to a pressure source; applying pressure to transport
the RNA sample to
a fluid-contacting side of a separation chamber of the microfluidic path
device; passing the RNA
sample into a solid and permeable insert within the fluid-contacting side of
the separation
chamber, wherein the solid and permeable insert comprises cellulose, so that
dsRNA is retained
by the insert; and applying pressure to transport the RNA sample out of the
fluid-contacting side
of the separation chamber.
[0145] A method of removing double-stranded RNA (dsRNA) from an RNA
sample
containing both dsRNA and single-stranded RNA (ssRNA) may include: coupling a
microfluidic
path device to a pressure source; applying pressure to transport the RNA
sample to a fluid-
contacting side of a separation chamber of the microfluidic path device so
that the RNA sample
passes through a solid and permeable insert comprising cellulose within the
fluid-contacting side
of the separation chamber, so that the dsRNA is retained by the insert; and
applying pressure to a
pressure-receiving side of the separation chamber to transport the RNA sample
out of the fluid-
contacting side of the separation chamber.
[0146] The method may include synthesizing the RNA sample by in vitro
transcription in the
microfluidic path device. In some variations the method may include coupling
the microfluidic
path device to a source of the RNA sample.
- 35 -
CA 03149497 2022-02-01
WO 2021/030271
PCT/US2020/045625
[0147] Applying pressure to transport the RNA sample out of the fluid-
contacting side may
include applying pressure to a pressure-receiving side of the separation
chamber to deflect an
elastic material separating the pressure-receiving side of the separation
chamber from the fluid-
contacting side of the separation chamber. Applying pressure to the pressure-
receiving side of
the separation chamber may include transporting the RNA sample out of the
fluid-contacting
side of the separation chamber and into a fluid-contacting side of a mixing
chamber, further
comprising applying pressure to a pressure-receiving side of the mixing
chamber to transport the
RNA sample back into the fluid-contacting side of the separation chamber.
Applying pressure to
transport the RNA sample out of the fluid-contacting side of the separation
chamber may include
compressing the solid and permeable insert by an elastic material separating
the pressure-
receiving side of the separation chamber from the fluid-contacting side of the
separation
chamber.
[0148] Any of these methods may include pre-wetting the solid and
permeable inset.
BRIEF DESCRIPTION OF THE DRAWINGS
[0149] The patent or application file contains at least one drawing
executed in color. Copies
of this patent or patent application publication with color drawings will be
provided by the
Office upon request and payment of the necessary fee.
[0150] The novel features of the invention are set forth with
particularity in the claims that
follow. A better understanding of the features and advantages of the present
invention will be
obtained by reference to the following detailed description that sets forth
illustrative
embodiments, in which the principles of the invention are utilized, and the
accompanying
drawings of which:
[0151] FIG. 1A schematically illustrates one variation of a method of
manufacturing an
mRNA therapeutic.
[0152] FIG. 1B schematically illustrates one variation of an exemplary
process for
manufacturing a patient-specific T-cell lymphoma vaccine drug product.
[0153] FIG. 2A illustrates one example of a microfluidic path device
control system as
described herein.
[0154] FIG. 2B schematically illustrates one variation of a microfluidic
path device control
system that may be used as described herein.
[0155] FIGS. 3A-3C illustrate variation of microfluidic path devices as
described herein.
[0156] FIG. 4 is a section through a portion of one variation of a
microfluidic path device as
described herein.
- 36 -
CA 03149497 2022-02-01
WO 2021/030271
PCT/US2020/045625
[0157] FIG. 5 is one example of a peptoid delivery vehicle that may be
used in any of the
methods as described herein.
[0158] FIG. 6 shows an example of an in vitro transcription facilitator
cassette useful for
making a double-stranded DNA template.
[0159] FIG. 7 shows an example of a double-stranded DNA template generated
as described
herein.
[0160] FIG. 8 shows one region of an example of a T-cell receptor useful
for making a
double-stranded DNA for use in a vaccine or therapeutic.
[0161] FIG. 9 shows an overview of one variation of an architecture of a
microfluidic path
device reactor for generating double-stranded DNA.
[0162] FIG. 10 schematically illustrates one example of a codon
optimization process that
may be used in any of the methods and apparatuses described herein.
[0163] FIG. 11 schematically illustrates one example of a functional
diagram for a
microfluidic path device configured to perform IVT as described herein.
[0164] FIG. 12 schematically illustrates one example of a functional
diagram for a
microfluidic path device configured as a formulation microfluidic path device
as described
herein.
[0165] FIG. 13 schematically illustrates another example of a functional
diagram for a
microfluidic path device configured as a formulation microfluidic path device
as described
herein.
[0166] FIG. 14 schematically illustrates another example of a functional
diagram for a
formulation microfluidic path device as described herein
[0167] FIG. 15 describes one example of an experiment examining in vivo
mRNA
expression and biodistribution using an exemplary model of an mRNA therapeutic
as described
herein.
[0168] FIGS. 16A-16D are graphs illustrating the therapeutic efficacy of
an exemplary
therapeutic mRNA vaccine as described herein.
[0169] FIG. 17A illustrates the whole-body luciferase expression
following injection with
stored model mRNA therapeutics manufactured as described herein.
[0170] FIG. 17B shows a quantitative example of the expression of the model
mRNA
therapeutic from FIG. 17A.
[0171] FIG. 18 schematically illustrates various times at which
filtration may be applied in
the methods and apparatuses described herein.
[0172] FIG. 19A is a top view of an example of a microfluidics path
device including a
permeable insert within a fluid-contacting side of a chamber.
- 37 -
CA 03149497 2022-02-01
WO 2021/030271
PCT/US2020/045625
[0173] FIG. 19B is an example of a section through one region of an
example of a
microfluidics path device including a permeable insert in one side of a
chamber.
[0174] FIG. 19C illustrates one example of a portion of a microfluidic
path device
schematically showing a vacuum cap for bubble removal.
[0175] FIG. 20A schematically illustrates one method of processing a
therapeutic material in
a fluid (e.g., an RNA sample) using a microfluidics path device including a
permeable insert as
described herein
[0176] FIG. 20B schematically illustrates a method of a method of
removing dsRNA from a
therapeutic material using a microfluidics path device including a permeable
insert as described
herein.
[0177] FIG. 21A shows one example of a system including a microfluidic
apparatus in a
class 5 isolation cabinet within a class 7 space. The system may be configured
as a mini-factory.
[0178] FIG. 21B illustrates the microfluidic apparatus within the class
5 cabinet.
DETAILED DESCRIPTION
[0179] Described herein are methods and apparatuses for manufacturing
therapeutics that
may include the use of fully-automated, software-controlled microfluidic
apparatuses. These
methods and apparatuses may be used for personalized or individualized
therapies. Also
described herein are apparatuses (e.g., systems, devices, etc.) and methods
that include software
control of any of the manufacturing steps described herein, including forming
the template, in
vitro transcription, purification of the therapeutic mRNA, concentration of
the mRNA, and
compounding of the mRNA(s) with one or more delivery vehicle. The software
control may
allow these methods to be automated so that any, some or all of these steps
for manufacturing
one or more therapeutic mRNA may be performed rapidly with accuracy and
precision. Software
control and micro-fluidic precise delivery and transfer of reaction
constituents offer the
opportunity to increase process control, efficiency and reproducibility whilst
substantially
reducing or eliminating manual manipulations, reducing facility needs and
shortening production
cycle times, ultimately leading to lower cost therapies produced just-in-time,
if required.
[0180] In some of the apparatuses (e.g., systems, devices, etc.)
described herein, each batch
.. of therapeutic material may be produced in dedicated, single-use,
disposable microfluidic path
devices (also referred to herein as biochips), that may be housed inside a
microfluidic path
device control system (also referred to herein as a control system). The
entire production may
proceed as a sterile-by-design, closed-path process without contact with the
atmosphere. All the
production steps may be automated, controlled by the control system to achieve
a copy-exact
process, regardless of the attributes of the facility housing the system. The
production
- 38 -
CA 03149497 2022-02-01
WO 2021/030271
PCT/US2020/045625
parameters, raw materials and environment data (including a full visual
record) may become a
part of an extensive, encrypted electronic file secured in the cloud and
associated with each
production run. In addition, purification steps, as well as a number of QC
assays may be
performed in-line during the production process in a single fluid flow,
allowing anomalies to be
detected at an early stage, through process control concepts developed in the
semi-conductor
industry. By harnessing a fully automated, software controlled approach to
manufacturing,
personalized and individualized mRNA therapeutics may be manufactured in a
cost-effective
manner for the benefit of the patients.
[0181] In particular these methods and apparatuses may produce mRNA
therapeutics
synthetically outside of the human body through a synthesis technology known
as in vitro
transcription (IVT). Typically, naked mRNA molecules are large, polyanionic
molecules that do
not cross the cell membrane, and are rapidly degraded by extracellular
nucleases in vivo. The
methods and apparatuses described herein may produce formulations of mRNA
molecules with
one or more delivery vehicles, designed to transport the mRNA to a target
(tissue, body, region
of tissue, etc.). For example, in some variations the delivery vehicle may be
a lipid-containing
amphipathic delivery vehicle that provides packaging and protection of mRNA
cargos during
circulation, avoid immune recognition, and may facilitate cellular uptake and
release.
[0182] In general, as will be described in greater detail herein, in
some variations all or some
of the production steps, including template synthesis, IVT, purification, and
formulation with
delivery vehicles, may be performed in the highly controlled environment of
one or more
microfluidic path devices, allowing for the optimization of a robust, high-
quality and highly
reproducible manufacturing process.
Definitions
[0183] As used herein a delivery vehicle may refer to any appropriate
nanoparticle.
Examples of such nanoparticles may include, but are not limited to amphipathic
nanoparticle
such as amino-lipidated peptoids.
[0184] As used herein "amplification" may refer to polynucleotide (e.g.,
DNA)
amplification. For example, amplification may be performed entirely within the
microfluidic
path plate devices described herein. Amplification may include, but is not
limited to, multiple
displacement amplification (MDA), polymerase chain reaction (PCR)
amplification, Loop
Mediated Isothermal Amplification. LAMP, Nucleic Acid Sequence Based
Amplification, Strand
Displacement Amplification, Rolling Circle Amplification, Ligase Chain
Reaction, etc.
- 39 -
CA 03149497 2022-02-01
WO 2021/030271
PCT/US2020/045625
[0185] As used herein, automated and semi-automated may refer to methods
and processes
that are performed largely without human intervention, and may be under the
control of one or
more computer processes. Automated methods may be supervised and/or guided by
human input.
[0186] As used herein, the terms "nucleic acid," "polynucleotide," and
"oligonucleotide"
may be used interchangeably and refer to deoxyribonuclotides (DNA),
ribonucleotides (RNA),
and functional analogues thereof, such as complementary DNA (cDNA) in linear
or circular
conformation. Nucleic acid molecules provided herein can be single stranded or
double stranded.
Nucleic acid molecules comprise the nucleotide bases adenine (A), guanine (G),
thymine (T),
cytosine (C). Uracil (U) replaces thymine in RNA molecules. Analogues of the
natural
nucleotide bases, as well as nucleotide bases that are modified in the base,
sugar, and/or
phosphate moieties are also provided herein. The symbol "N" can be used to
represent any
nucleotide base (e.g., A, G, C, T, or U).
[0187] As used herein a "cassette" (e.g., a synthetic in vitro
transcription facilitator cassette)
refers to a polynucleotide sequence which may include or be operably linked to
one or more
expression elements such as an enhancer, a promoter, a leader, an intron, a 5'
untranslated region
(UTR), a 3' UTR, or a transcription termination sequence. In some embodiments,
a cassette
comprises at least a first polynucleotide sequence capable of initiating
transcription of an
operably linked second polynucleotide sequence and optionally a transcription
termination
sequence operably linked to the second polynucleotide sequence. The cassette
might be provided
as a single element or as two or more unlinked elements.
[0188] As used herein, "polynucleotide" refers to a nucleic acid
molecule containing
multiple nucleotides and generally refers both to "oligonucleotides" (a
polynucleotide molecule
of 18-25 nucleotides in length) and polynucleotides of 26 or more nucleotides.
Aspects of this
disclosure include compositions including oligonucleotides having a length of
18-25 nucleotides
(e. g., 18-mers, 19-mers, 20-mers, 21-mers, 22-mers, 23-mers, 24-mers, or 25-
mers), or medium-
length polynucleotides having a length of 26 or more nucleotides (e. g.,
polynucleotides of 26,
27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45,
46, 47, 48, 49, 50, 51, 52,
53, 54, 55, 56, 57, 58, 59, 60, about 65, about 70, about 75, about 80, about
85, about 90, about
95, about 100, about 110, about 120, about 130, about 140, about 150, about
160, about 170,
about 180, about 190, about 200, about 210, about 220, about 230, about 240,
about 250, about
260, about 270, about 280, about 290, or about 300 nucleotides), or long
polynucleotides having
a length greater than about 300 nucleotides (e. g., polynucleotides of between
about 300 to about
400 nucleotides, between about 400 to about 500 nucleotides, between about 500
to about 600
nucleotides, between about 600 to about 700 nucleotides, between about 700 to
about 800
nucleotides, between about 800 to about 900 nucleotides, between about 900 to
about 1000
- 40 -
CA 03149497 2022-02-01
WO 2021/030271
PCT/US2020/045625
nucleotides, between about 300 to about 500 nucleotides, between about 300 to
about 600
nucleotides, between about 300 to about 700 nucleotides, between about 300 to
about 800
nucleotides, between about 300 to about 900 nucleotides, or about 1000
nucleotides in length, or
even greater than about 1000 nucleotides in length. Where a polynucleotide is
double-stranded,
its length can be similarly described in terms of base pairs.
[0189] As used herein, "in vitro transcription" or "IVT" refer to the
process whereby
transcription occurs in vitro in a non-cellular system to produce synthetic
RNA molecules
(synthetic mRNA) for use in various applications, including for therapeutic
delivery to a subject.
The synthetic RNA molecules (transcription product) generated can combined
with a delivery
vehicle. Synthetic transcription products include mRNAs, antisense RNA
molecules, shRNA,
circular RNA molecules, ribozymes, and the like. An IVT reaction may use a
purified linear
DNA template comprising a promoter sequence and the sequence of the open
reading frame of
interest, ribonucleotide triphosphates or modified ribonucleotide
triphosphates, a buffer system
that includes DTT and magnesium ions, and an appropriate phage RNA polymerase.
[0190] A "template" or 'double-stranded DNA template" refers to an isolated
nucleic acid
sequence that comprises the minimal component sequences required for in vitro
transcription of
an inserted open reading frame of interest.
[0191] As used herein, "fluid depots" may refer to a storage space for
holding a fluid, and
may include a vial, a bottle, a bag, a tube, etc. The fluid depot may include
a fluid line as an
integral portion (e.g., a passage or channel exiting the main body or chamber
within the fluid
depot).
[0192] As used herein fluid power includes both pneumatic and hydraulic.
For convenience,
the term pneumatic may be include hydraulic and these terms may be used
interchangeably.
[0193] As used herein a "therapeutic polynucleotide" refers to a
polynucleotide (e.g., a
therapeutic mRNA) that may be part of a therapeutic polynucleotide composition
for delivery to
a subject to treat, prevent, improve or otherwise modify the subject's health.
[0194] As used herein a "therapeutic polynucleotide composition" may
refer to a
composition including one or more polynucleotide (e.g., mRNA) encapsulated by
a delivery
vehicle that may be administered to a subject. An mRNA vaccine is just one
example of a
therapeutic polynucleotide composition.
[0195] As used herein, "free of bacterial DNA" or refers to the absence
of bacterial DNA. A
material that is substantially free of bacterial DNA may include less than
0.1%, 0.01%, less than
0.001%, etc. of bacterial DNA. As used herein "free of endotoxin" refers to
the absence of
endotoxin. A material that is "substantially free of endotoxin" refers to less
than 0.1%, less than
0.01%, less than 0.001%, etc. of endotoxin.
- 41 -
CA 03149497 2022-02-01
WO 2021/030271
PCT/US2020/045625
[0196] As used herein, "joining" refers to methods such as ligation,
synthesis, primer
extension, annealing, recombination, or hybridization use to couple one
component to another.
[0197] As used herein a microfluidic path device or microfluidic path
plate device may be
equivalently referred to as a chip, cartridge, biochip, microfluidic path
plate, etc. and may
include a plurality of fluidically interconnected chambers. These chambers may
be divided up
into fluid-contacting sides and pressure-receiving sides. The pressure-
receiving sides may be part
of a fluid power circuit, while the fluid-contacting sides may be isolated
from the outside
atmosphere and may be used to process materials in the microfluidic path
device. The
microfluidic plate path devices described herein may be generally flat (e.g.,
having a thickness of
less than about 4 cm, less than about 2 cm, less than about 1.5 cm, less than
about 1 cm, etc.) and
may include a plurality of pressure ports for interfacing with one or more
pressure lines to drive
and/or control the fluid power circuits in the microfluidic path plate device.
[0198] As used herein "on demand" is intended to define when a method or
service is
performed, and is used in contrast to stored, scheduled, ordered or prepared
in advance.
[0199] As used herein an optical sensor typically refers to a light-sensing
device and may
include one or more imaging devices. An optical sensor may include a single
lens, camera, stereo
cameras, multi-lens cameras, digital still cameras, thermographic camera, CCD,
fiber optic, etc.
[0200] As used herein "purifying" refers to physical and/or chemical
separation of a
component (e.g., particles) of other unwanted components (e.g., contaminating
substances,
fragments, etc.).
[0201] As used herein "sealed fluid communication" and "sealed and
closed fluidic path"
may both refer to the isolation of the material (e.g., a fluid containing a
material, such as but not
limited to a solution of template, therapeutic polynucleotide, and/or
therapeutic polynucleotide
composition) from the surrounding atmosphere.
[0202] As used herein, "template precursor material" refers to the material
necessary to form
the template (e.g., a DNA double-stranded template), and may include a
synthetic gene of
interest, and an in vitro transcription facilitator cassette provided as one
or more independent
elements.
[0203] As used herein, 2D purification refers to purification performed
within a substantially
flat microfluidic path devices (e.g., microfluidic path plate devices) as
described herein, and may
include using more than one type of an absorptive material to remove material
(e.g., double-
stranded RNA, unreacted nucleotides, unreacted capping reagents, buffer
components, etc.), or
the like.
[0204] Therapies such as mRNA therapeutics may be used for multiple
treatment modalities
including vaccination, immunotherapies, protein replacement therapies, tissue
re-
- 42 -
CA 03149497 2022-02-01
WO 2021/030271
PCT/US2020/045625
modelling/regeneration and treatment of genetic disease by gene editing. In
addition to their high
potency, mRNA therapeutics also have important advantages related to their
rapid development
cycle, standardized manufacturing, transient expression and low risk of
genomic integration.
[0205] In some variations, the mRNA therapeutics described herein may
include as an active
ingredient in the final drug product an mRNA that encodes an antigen or
protein of interest.
Robust translation of mRNA requires a functional 5' cap structure. A 5' cap
(or 7-
methylguanosine cap) consists of a terminal 7-methylguanosine residue that is
linked through a
5'-5'-triphosphate bond to the first transcribed nucleotide. Its presence is
critical for recognition
of the mRNA by the ribosome and protection from RNAses. The poly(A) tail
regulates mRNA
stability and translational initiation synergistically with the m7G cap by
binding the poly(A)
binding protein (PABP), which interacts with eukaryotic translation initiation
factor eIF4G, and
in turn forms a complex with eIF4E. The length of the poly(A) tail may
influence the efficiency
of the mRNA to protein translation process.
[0206] mRNA therapeutics can be broadly divided into at least 5
categories, used for: (i)
protein replacement, (ii) vaccines, (iii) Expression of effector proteins,
(iv) inducement of loss of
function through expression of dominant negative proteins and (v) Gene/genome
editing. The
methods and apparatuses described herein may provide mRNA therapeutics for any
of these
categories (or more than one).
[0207] The methods and apparatuses described herein may formulate the
mRNA therapeutic
to provide packaging and protection of mRNA cargos during circulation, avoid
immune
recognition, localize drug product in desired tissues, and facilitate cellular
uptake and release,
while avoiding toxicity or immunogenicity concerns which could limit repeated
dosing.
[0208] In general, a method of manufacturing an mRNA therapeutic
(including, but not
limited to a patient-specific T-cell lymphoma vaccine drug product) may
involve any or all of the
steps that are schematically represented in FIG. 1A, and include
identification of the a target
protein and design of the mRNA sequence 101, preparation a double stranded DNA
template as
for the target sequence 103. This sequence may be used to generate the mRNA
for the in vitro
transcription (IVT) reaction 105, to synthesize mRNA. This therapeutic mRNA
may then be
purified to remove process impurities and filtration to generate the drug
substance 107. The
therapeutic mRNA may then be formulated with the delivery vehicle 109
(including in some
variation with adjuvant and delivery vehicle components to form amphipathic
nanoparticle). The
formulation may then be processed and purified to generate drug product 111
that may be used
for delivery to the patient. As described above, in some variations some of
these steps may be
performed remotely (e.g., 101-107) and some locally (e.g., 109, 111); in some
variations they
may all (e.g., 103, 105, 107, 109, 111) be performed locally.
- 43 -
CA 03149497 2022-02-01
WO 2021/030271
PCT/US2020/045625
[0209] As a specific example of one variation, FIG. 1B shows an
exemplary process for
manufacturing a patient-specific T-cell lymphoma vaccine drug product. In FIG.
1B, the process
may include identification of a clonally expanded TCR sequence (idiotype)
expressed by the
lymphoma cells 121. The process may also include designing the mRNA vaccine
sequence 123,
and preparing a double stranded DNA template for the IVT reaction. The
template may be used
for the IVT reaction to synthesize mRNA 127, and this therapeutic mRNA may be
purified to
remove process impurities and filtration to prepare the therapeutic mRNA as
the drug substance
129. The therapeutic mRNA may then be formulated with adjuvant and delivery
vehicle
components to form amphipathic nanoparticles 131. Post-formulation processing
133 may then
be performed to generate drug product, such as a therapeutic mRNA vaccine 135.
[0210] Any of these manufacturing steps may be optimized to be performed
using an
automated microfluidic path device control system as described herein. For
example, a DNA
template production may take place in one or more microfluidic path devices;
in the example
shown in FIG. 1B, a template microfluidic path device (e.g., template biochip)
may be used. In
this same example, the steps of in-vitro transcription of the mRNA and the
purification of that
material to generate the drug substance may be performed on an IVT
microfluidic path device
(e.g., an IVT biochip), and drug product formulation steps may be done on a
formulation
microfluidic path device (e.g., formulations biochip). These microfluidic path
devices may
contain the input ports, metering valves, reaction chambers, and purification
structures required
to perform each step in the manufacturing process.
Apparatus
[0211] The methods described herein may generally be performed using an
apparatus that
may be used with and/or may include one or more microfluidic path devices
(e.g., biochips), and
a system (e.g., a microfluidic control system) that is configured to control
operations in the
microfluidic path device. These apparatuses may be referred to herein as
microfluidic
apparatuses, microfluidic control apparatuses, microfluidic path device
control system,
microfluidic control systems, or microfluidic systems. A microfluidic path
devices (also referred
to as a microfluidic path plate device) may be placed within the microfluidic
control system and
may operate in a closed path manner that prevents exposure of the component
parts of some, or
more preferably nearly all or all of the manufacturing components within the
system to the
atmosphere. In particular, the portions of the apparatus that contact the
fluid(s) within the system
are prevented from exposure to atmosphere. FIG. 2A shows one example of a
microfluidic path
device control system that includes: a microfluidic path device management
system 203
(including hardware for holding the microfluidic path device, applying
positive/negative pressure
- 44 -
CA 03149497 2022-02-01
WO 2021/030271
PCT/US2020/045625
to operate microfluidic operations in the microfluidic path device,
heating/cooling all or regions
of the microfluidic path device, detecting one or more features from the
microfluidic path device
and/or recording operations performed on the one or more microfluidic path
device), a controller
(not shown), and a refrigerated container 205 (e.g., an ISO class 5 cabinet).
This system may be
used or may include one or more microfluidic path devices 201.
[0212] A microfluidic apparatuses may be microfluidic apparatuses for
forming a therapeutic
polynucleotide (e.g., an mRNA therapeutic). The apparatus may include: a
seating mount for
removably holding a microfluidic path plate device, a plurality of pressure
lines; a plurality of
fluid vials, wherein each fluid vial either comprises a fluidic line or is
configured to couple with
the fluidic line, wherein each fluidic line and at least a subset of the
pressure lines are configured
to be biased against the microfluidic path plate device held in the seating
mount to form a closed
fluid path; and a controller configured to control the application of pressure
through the pressure
lines to drive fluidic movement in the microfluidic path plate device when the
microfluidic path
plate device is held in the seating mount, wherein the controller is
configured to direct the
synthesis of a synthetic template, direct an in vitro transcription (IVT)
reaction using the
template to form a therapeutic polynucleotide, and direct purification of the
therapeutic
polynucleotide in one or more microfluidic path plate devices held in the
seating mount.
[0213] A microfluidic apparatus (e.g., a microfluidic apparatus for
forming a therapeutic
polynucleotide, such as a therapeutic mRNA) may include: a seating mount for
removably
holding a microfluidic path plate device; a plurality of pressure lines; a
plurality of fluid vials,
wherein each fluid vial either comprises a fluidic line or is configured to
couple with the fluidic
line, wherein each fluidic line and at least a subset of the pressure lines
are configured to be
biased against the microfluidic path plate device held in the seating mount to
form a closed fluid
path; and a controller configured to control the application of pressure
through the pressure lines
to drive fluidic movement in the microfluidic path plate device when the
microfluidic path plate
device is held in the seating mount, wherein the controller is configured to
determine the
contents of the fluid vials, transfer sub-microliter amounts of material from
the fluid vials to one
or more reactors in the microfluidic path plate device held in the seating
mount, direct the
synthesis of a synthetic template, direct an in vitro transcription (IVT)
reaction using the
template to form a therapeutic polynucleotide, and direct purification of the
therapeutic
polynucleotide in one or more microfluidic path devices held in the seating
mount.
[0214] The controller may be configured to perform any of the method
described herein, an
in particular may be configured to receive inputs (e.g., optical input,
pressure input,
temperature/thermal input, etc.) and process the input to control movement of
fluid in the
microfluidic path device, temperature (including thermocycling) of various
regions of the
- 45 -
CA 03149497 2022-02-01
WO 2021/030271
PCT/US2020/045625
microfluidic path device, rinsing/combining, opening/closing of valve of the
microfluidic device,
detection of the microfluidic device, etc. The controller may include one or
more
microprocessors, communication circuitry, memory, etc. The controller may
comprise firmware,
hardware and/or software.
[0215] Any of these apparatuses may include a one or more (e.g., a
plurality) of optical
sensors arranged around the seating mount and reagent storage frame to monitor
fluid levels
within the reagent storage frame and fluidic movement in the microfluidic path
device when the
microfluidic path device is seated in the seating mount. Alternatively or
additionally, the optical
sensor(s) may be present on the bottom of the apparatus (e.g., beneath the
seating mount) and
.. may be directed upwards to detect fluid amounts, movement, etc.).
[0216] The methods and apparatuses described generally include one or
more fluid power
circuits to move material (liquid material) between the fluid chambers
(depots, fluid-contacting
sides, reactors, etc.) and channels of the microfluidic path device or within
the microfluidic path
device, and in some cases between the microfluidic path device and the fluid
depots (vails,
bottles, containers, etc.) within the apparatus. A fluid power circuit may be
a hydraulic or
pneumatic circuit that may include the microfluidic device, and in particular
one or more
pressure channels and pressure-receiving sides of the chambers in a
microfluidic device. The
fluid power circuits may also be referred to as microfluidic power circuits. A
single microfluidic
chip may include multiple fluid power circuits; the fluid power circuits may
also include one or
more pressure lines and the interface between the pressure lines of the
microfluidic control
apparatus and the one or more microfluidic chips within the microfluidic path
device. One or
more fluid power circuits may share components (valves, pressure lines, vacuum
caps, etc.) with
other, overlapping fluid power circuits. Furthermore, for the same of
convenience, it should be
understood that where the term "pneumatic" is used, a general fluid power
circuit (e.g., hydraulic
and/or pneumatic) may be used instead or additionally. The fluid material
being driven by the
fluid power line may be any appropriate fluid (e.g., gas or liquid, such as
air, water, oil, etc.).
[0217] Also described herein are microfluidic path devices for
processing therapeutic
polynucleotides in a closed path (e.g., closed-path microfluidic path
devices). As mentioned,
these microfluidic path devices may be referred to herein as microfluidic
chips, microfluidic path
plate, process chip, biochip, process plate, etc. In general, the microfluidic
path device may be
microfluidic path plate devices, which may be substantially flat plate-like
structures; these
structures may be relatively thin (e.g., less than a few mm thick, e.g.,
between 0.5-20 mm thick,
between 0.5-15 mm thick, between 0.5-10 mm thick, etc.). The microfluidic path
devices
described herein may generally be at least partially transparent, and in
particular, may be
transparent on the top of the microfluidic path device, so that one or more
optical sensors
- 46 -
CA 03149497 2022-02-01
WO 2021/030271
PCT/US2020/045625
(cameras, CCD, fiber optics, etc.) may be used to sense, detect, monitor,
record, etc. action,
including fluid movement and/or movement of the elastic layer, with the
microfluidic path
device as it is used by the microfluidic apparatuses described herein.
[0218] FIG. 2B is a schematic illustration of one variation of a
microfluidic path device
.. control system that may be used as described herein. In this example, the
apparatus includes a
housing 233 enclosing a seating mount 215 which can hold one or more
microfluidic path
devices 211, which may be single use devices. The housing may be a chamber,
enclosure, or the
like, which may include a lid or opening; when closed it may be sealed. The
housing may
enclose a thermal regulator and/or may be configured to be enclosed in a
thermally-regulated
environment (such as a refrigeration unit, etc.). The housing may form an
aseptic barrier. In
some variations the housing may form a humidified or humidity-controlled
environment.
[0219] The seating mount 215 may be configured to secure the
microfluidic path device
using one or more pins or other components configured to hold the microfluidic
path device in a
fixed and predefined orientation.
[0220] In some variations, a thermal control 213 may be located adjacent to
the seating
mount 215, to modulate temperature to the one or more microfluidic path
devices 211. The
thermal control may include a thermoelectric component (e.g. Peltier device)
and/or one or more
heat sinks for controlling the temperature of all or a portion of the
microfluidic path device. In
some variations, more than one thermal control may be included, for separately
regulating the
temperature of one or more regions of the microfluidic path device. The
thermal control may
include one or more thermal sensors (e.g., thermocouples, etc.) that may be
used for feedback
control of the microfluidic path device and/or thermal control.
[0221] In FIG. 2B, a fluidic interface assembly 209 couples the liquid
reagents and/or
pressure (e.g., gas) with a microfluidic path device 211 held in the seating
mount 215, and may
assist in delivery of fluidic materials as well as positive /negative gaseous
pressure, from the
pressure source 217, to the interior of the microfluidic path device 211. The
fluid interface
assembly may optionally assist in securing the microfluidic path device(s), as
described in
greater detail below. The fluid interface assembly may be removable coupled to
the apparatus
(and may be removed or a portion may be removed) for sterilization between
uses.
[0222] A reagent storage frame 207 may be configured to contain a plurality
of fluid sample
holders, each of which may hold a fluid vial configured to hold a reagent
(e.g., nucleotides,
solvent, water, etc.) for delivery to the microfluidic device 211 or,
alternatively, a fluid vial may
be configured to receive a product from the interior of the microfluidic path
device 211. The
reagent storage frame may be referred to as a reagent rack. In some
variations, the reagent rack
includes a plurality of pressure lines and/or a manifold configured to divide
one or more pressure
- 47 -
CA 03149497 2022-02-01
WO 2021/030271
PCT/US2020/045625
sources 217 into a plurality of pressure lines that may be applied to the
microfluidic path device
an may be independently or collectively (in sub-combinations) controlled.
Alternatively, the
fluid depots (vials, etc.) may be configured to directly secure and seal
against the microfluidic
path device(s).
[0223] The fluid interface assembly may include a plurality of fluid lines
and/or pressure
lines and may include a biased (e.g., spring-loaded) holder or tip that
individually and
independently drives each fluid and/or pressure line to the microfluidic path
device when it is
held in the seating mount 215 (or, as mentioned, alternatively the device may
directly be spring-
mounted). The tubing, e.g., the fluid lines and/or the pressure lines, may be
part of the fluid
interface assembly and or may connect to the fluid interface assembly. In some
variations the
fluid lines comprise a flexible tubing that connects between the reagent
storage frame, via a
connector that couples the vial to the tubing in a locking engagement (e.g.,
ferrule) and the
microfluidic path device. The ends of the fluid paths, in some variations the
ends of the fluid
lines/pressure lines, may be configured to seal against the microfluidic path
device, e.g., at a
sealing port formed in the microfluidic path device, as described herein. For
example, the ends of
the fluid lines may cut or formed to be flat (perpendicular in side view). The
vials may be
pressurized (e.g., > 1 atm pressure, such as 2 atm, 3 atm, 5 atm, etc.) to via
the connector which
may also connect to the pressure source. For example, the fluid vials may be
pressurized to
between 1-20 psig (e.g., 5 psig/20 psia, 10 spig, etc.). Negative or positive
pressure may be
applied; for example, a vacuum (e.g., -7 psig or 7 psia) may be applied to
draw fluids back into
the vials (e.g., the depots) at the end of the process. In general the fluid
vials may be driven at
lower pressure than the pneumatic valves, which may prevent or reduce leakage.
In some
variations the difference in pressure between the fluid and pneumatic valves
may be between
about 5 psi (e.g., about 7 psi, 10 psi, 12 psi, 15 psi, 20 psi, etc.).
[0224] Each vial may be coded (e.g., by an identifier that may be read by
one or more
sensors, as described below). The controller may monitor the fluid level and
therefore the
amount of each material in the fluid interface assembly.
[0225] The apparatus may also include a magnetic field applicator 219,
which may be
configured to create a magnetic field at a region of the microfluidic path
device 211. One or
more sensors 205, which may be optical sensors, may be part of the apparatus,
and may sense
one or more of a barcode, a fluid level within a fluid vial held within the
reagent storage frame,
and fluidic movement within the microfluidic path device 211 when the device
is mounted
within the mounting seat 215.
[0226] The sensors may make measurements of the process on the device,
e.g., by measuring
an optical indicator. In some variations visual/optical markers may be used to
estimate yield. For
- 48 -
CA 03149497 2022-02-01
WO 2021/030271
PCT/US2020/045625
example, fluorescence may be used to detect process yield or residual material
by tagging with
fluorophores. Alternatively or in addition, dynamic light scattering may be
used to measure
particle size distributions within a portion of the microfluidic path device
(e.g., such as a mixing
portion). In some variations, the sensor measurements may be done using one or
two optical
fibers to convey light (e.g., laser light) in and detect an optical signal
coming out. An instrument
package may be mounted remotely from the device. Such non-contact sensing may
be preferred.
[0227] In any of the methods and apparatuses described herein, the
sensors (e.g., video
sensors) may record all activity on the microfluidic path device (e.g., chip
or cartridge). For
example, an entire run for synthesizing and/or processing a material (such as
a therapeutic RNA)
may be recorded by one or more video sensors, including a video sensor that
may visualize the
microfluidic path device, e.g., from above. Processing on the microfluidics
path device may be
visually tracked and this record may be retained for later quality control
and/or processing. Thus,
the video record of the processing may be saved, stored and/or transmitted for
subsequent review
and/or analysis.
[0228] The internal portion of the apparatus, e.g., within the housing 233,
may be further
configured to be sterilizable. In particular, portions of the apparatus may be
removed and
individually sterilized. Sterilization may be performed, e.g., by UV
irradiation, or any other
method of sterilization that may be required to limit contamination or to meet
regulatory
requirements. The apparatus including the housing may be housed within a High
Efficiency
.. Particulate Air (HEPA) filtered environment. The apparatus including the
housing may be
housed within a temperature controlled enclosure. In addition, the apparatus
itself may include
one or more regions that are temperature controlled. In any of the apparatuses
described herein,
the apparatus may include (e.g., within the housing) a temperature controlled
region for storing
reagents and/or for storing mRNAs (e.g., therapeutic mRNAs), e.g., at a
storage temperature
.. (e.g., a temperature between -10 degrees C and 20 degrees C, such as 10
degrees C, 4 degrees C,
-10 degrees C, etc.). Any of these apparatuses may include a library of
manufactured mRNAs
that may be compounded individually or in combination with one or more
additional mRNAs
and a delivery vehicle.
[0229] As mentioned above, the microfluidic path device controller
system may be
.. controlled by controller 221, including to apply pressure through the
microfluidic path device
211 to at least drive fluidic movement. The controller may be completely or
partially outside of
the housing. The controller may be configured to include user inputs/outputs.
For example, the
user interface 223 of the system may permit easy operation and direction of
the apparatus and
microfluidic path device(s).
- 49 -
CA 03149497 2022-02-01
WO 2021/030271
PCT/US2020/045625
[0230] Any of the apparatuses described herein may include all or some
of the components
shown in FIG. 2B; not all components may be necessary. In FIG. 2B, only some
of the
connections between components are shown; additional (or alternative)
connections may be
used.
[0231] A microfluidic path device control system may support all the
production activities
inside the microfluidic path device such as supply of reagents, fluid control,
temperature control,
mixing, purification and process monitoring. Manufacturing activities on the
microfluidic path
device control system may be accessed and controlled through application
software.
[0232] The microfluidic path devices may be configured to include one or
more reactors for
the manufacturing steps which are performed to precisely prepare a therapeutic
(e.g., a
therapeutic mRNA) material. The same microfluidic path device may operate on
one or more
microfluidic path devices, either in series and/or in parallel, and without
interrupting the
continuous-path nature of the microfluidic path device control system. For
example, when
manufacturing a therapeutic using multiple processing steps performed in
multiple reactors using
multiple microfluidic path devices, the fluid product(s), including partial
products from one
microfluidic path device may be transferred to one or more additional
microfluidic path device in
a closed-path manner by the apparatus, including by moving fluid containing
the microfluidic
path device product(s) into a storage depot portion of the microfluidic path
device control device.
[0233] Each microfluidic path device may be configured to include one or
more reactors for
processing during the manufacturing processes. For example, FIGS. 3A-3C
illustrate three
examples of microfluidic path devices. These examples illustrate three
distinct types of
microfluidic path device: a template microfluidic path device (FIG. 3A), an in
vitro transcription
(IVT) microfluidic path device (FIG. 3B) and a formulation microfluidic path
device (FIG. 3C).
Each of these microfluidic path device examples may be configured to include
features to
perform a set of unit operations in a controlled and highly reproducible
manner.
[0234] In some variations, a microfluidic path device may be configured
as multilayered
structure composed of two more rigid layers with a flexible membrane
sandwiched between the
two ridged layers. FIG. 4 illustrates a sectional view (transverse to the
plane of the microfluidic
path device) through one example of a microfluidic path device having multiple
layers that form
the reactors for processing the therapeutic as described herein. The reactors
may include seals,
channels, valves, and chambers, including pumping chambers formed from the
multiple layers.
For example, a microfluidic path device may be formed of two or more rigid or
semi-rigid plates
403, 405 and at least one elastic layer 407. The elastic layer 407 may be a
sheet of elastic
material that is liquid-impermeable. The elastic layer maybe somewhat gas
permeable, or may be
treated to be more or less gas permeable, including in various regions.
Although a single
- 50 -
CA 03149497 2022-02-01
WO 2021/030271
PCT/US2020/045625
continuous sheet of elastic material may be used, in some variations multiple
elastic materials
sheets may be used, or the 'sheet' may be formed of sections of multiple
sheets. The layers and
the elastic sheet may be laminated together. In general, chambers for holding,
valving and/or
pumping fluid may be formed in the plates on either side of the elastic layer
so that the elastic
layer bisects the chambers into a liquid containing side and a pressure (e.g.,
gas) applying side.
The overall volume of chamber(s) may be constant, and may be formed into both
the first (e.g.,
upper) plate and the second (e.g., lower) plate, but this volume may be
divided into the pressure
side and the liquid side. By applying positive or negative pressure into the
pressure side, the
elastic sheet may be deformed to make reduce (down to zero, closing the
chamber off) the
volume of the liquid containing side or to increase the volume of the liquid
containing side (to a
predetermined maximum). The pressure applying side of the chamber may be
connected, e.g.,
via a pressure port 443 in the upper plate 403 connecting to a pressure
channel 447, for applying
negative or positive pressure to the pressure-receiving side 419 of one or
more chambers. The
liquid containing side 417 opposite the pressure-applying side of each chamber
may be
connected via a fluid channel 421 to a fluid port 423. Both the fluid port and
the pressure port
may be formed by an opening into the upper plate 403 and the elastic layer
407, allowing a
sealed connection that is isolated from the atmosphere even when there are
multiple different
input lines as the pressure line is pushed into the elastic layer 407 that is
supported on the
underside of the port by the opposite rigid or semi-rigid layer(s), 405, 409.
[0235] In FIG. 4, the microfluidic path device 400 includes a first (e.g.,
upper) plate 403
having a first (e.g., top or upper) surface 411 and a second (bottom or lower)
surface 429 and a
thickness between the two. The first surface 411 may form an exposed outer
surface. The
microfluidic path device also includes a second plate 405 having a first
(e.g., upper or top)
surface 431 and a second (e.g., lower or bottom) surface 433 and a thickness
therebetween. An
elastic layer 407 is sandwiched between the second surface 429 of the first
plate 403 and the first
surface 431 of the second plate 405. A third plate 409 is coupled to the
second plate on the
second surface 433 of the second plate, either directly or indirectly. The
third plate 409 also has a
first (e.g., upper or top) surface and a second (lower or bottom) surface and
a thickness
therebetween. The second surface of the third plate may form a bottom surface
of the
microfluidic path device. Any of the plates may be formed of multiple layers,
which may be
laminated or otherwise connected together. For example, in FIG. 4, the third
plate 409 includes
an optional second elastic layer 413 which may help couple the third plate to
the second plate;
the second elastic layer 413 in this example forms the first surface 435 of
the third plate 409. The
layers and plates shown in FIG. 4 may not be to scale (e.g., the elastic layer
407 may be thinner
relative to the plates).
- 51 -
CA 03149497 2022-02-01
WO 2021/030271
PCT/US2020/045625
[0236] The microfluidic path device 400 shown in FIG. 4 may also include
a plurality of
chambers 415, 416, 418, 420 each having a fixed volume. These chambers are
formed by cut-out
regions (e.g., rounded/curved cuts) into the second (bottom) surface 429 of
the first plate 403 and
the first (upper) surface 431 of the second plate 405; the elastic layer 407
bifurcates these
chambers 415 so that each includes a liquid containing side 417 and a pressure
(e.g., gas
containing) side 419. The microfluidic path device 400 may also include
multiple liquid (e.g.,
fluid) channels. In FIG. 4, a single fluid channel 421 is shown extending from
a fluid port 423
passing through the thickness of the first plate 403, to a fluid channel
opening 425 through the
elastic layer 407 and through much of the thickness of the second plate 405
down to the bottom
surface 433 of the second plate where a length of the liquid channel 421
running parallel to the
bottom surface of the third plate is formed in the bottom surface 433 of the
second plate, and
bounded by the upper surface of the third plate 409.
[0237] In regard to the fluid port 423, the diameter of the opening into
the first plate 403
forming the fluid port 423, which extends through the thickness of the first
plate, may be larger
than the diameter of the fluid channel opening 425 which extends through the
elastic layer 407
and into the liquid (e.g., fluid) channel 421. The fluid channel opening 425
may be centered
relative to the bottom of the fluid port opening, and may be offset from the
walls of the fluid port
opening by at least the expected wall thickness of the fluid line or fluid
line coupling interface
that will connect to the fluid port.
[0238] The fluid channel 421 connects to the liquid containing side 417 of
a first chamber
415. This first chamber may be configured as a valve, which has a relatively
low retaining
volume (fixed volume), but can be fully opened or closed by the movement of
the elastic layer
407.
[0239] The microfluidic path device 400 also includes a plurality of
pressure channels that
may be independently controlled to apply positive and/or negative pressure. In
FIG. 4, a single
pressure port 443 is shown, connected to the fourth chamber 420, although each
of the chambers
415, 416, 418 may be connected to a separate pressure port and pressure
channel for
independently operating and controlling the movement of the portion of the
elastic layer 407
bifurcating these chambers, to valve, and/or pump each chamber independently.
In some
variations the pressure ports may be shared between multiple chambers. In FIG.
4 the pressure
(e.g., gas) port 443 is similar to the fluid (e.g., liquid) port 425, and
includes an opening
completely through the first plate 403, down to the exposed elastic layer 407,
to an opening
through the elastic layer forming a pressure (e.g., gas) channel opening 445.
The pressure
channel opening 445 is continuous with a pressure (e.g., gas) channel 447 that
extends from the
pressure port 443, passing through much of the thickness of the first plate
403, and in a cut-out
- 52 -
CA 03149497 2022-02-01
WO 2021/030271
PCT/US2020/045625
channel along the bottom of the second plate (or alternatively into a cut-out
region in the top of
the third plate) and back up through the second plate and the elastic layer
407, to a region of the
pressure channel within the first plate that connects to the pressure (e.g.,
gas) containing portion
419 of the fourth chamber 420. As described for the similar fluid (e.g.,
liquid) port, the diameter
of the pressure port 443 passing through the thickness of the first plate 403
may be larger than
the diameter of the pressure channel opening 445 through the elastic layer
407, and may be
centered or offset by greater than the wall thickness of a pressure line or
pressure line coupling
interface that will connect to the pressure port.
[0240] In the section through a microfluidic path device 400 shown in
FIG. 4, there are
multiple connections to other fluid (e.g., liquid) lines, fluid ports,
pressure lines and pressure
ports that are not shown, as they may be out of the plane shown. For example,
in FIG. 4 the
liquid containing side or portion 417 of the fourth chamber may be connected
to additional
valves (chambers) and/or channels, including, e.g., an exit channel extending
from the liquid
containing side 417. An additional chamber (e.g. configured as a valve), no
shown may be
formed as described above. In some variations, an exit channel may deliver
fluid from the one or
more chamber through another fluid port (not shown) to a fluid receiving
depot, e.g., a vial, tube,
etc. This receiving depot may be held in the reagent storage frame.
[0241] In general, this configuration of the microfluidic path device
and the microfluidic
apparatus is configured so that multiple, complex steps may be executed by the
apparatus on the
microfluidics path device in a fully enclosed (sealed and protected from
atmosphere) manner,
without requiring manual intervention. Fluid may be metered using the fixed-
volume chambers
and moved, mixed, filtered, etc. by applying pneumatic pressure to deflect
regions of the elastic
layer.
[0242] In some variations, the chambers within the microfluidic path
device may be
.. configured as mixing chambers, for mixing fluid within the microfluidic
path device. In some
variations the chamber(s) may be configured as dialysis chambers, which may
include a dialysis
material and one or more countercurrent channels for dialyzing material within
the fluid. In some
variations one or more chambers may be configured as a concentrator for
concentrating the
therapeutic material(s).
[0243] Although the various microfluidic path devices may have different
arrangements of
channels, ports and chambers, they may also share a similar basic architecture
and a number of
functional elements that can be used in different configurations to carry out
different protocols.
Functional elements include input ports, metering valves, pumps, reaction
chambers, mixing
structures and purification structures, as described above.
- 53 -
CA 03149497 2022-02-01
WO 2021/030271
PCT/US2020/045625
[0244] Any of these microfluidic path apparatuses may include one or
more bubble removal
chambers, or any of the chambers of the fluid-contacting side of the chamber
may be configured
as a bubble removal chamber, in which bubbles within the fluid of the fluid-
containing side may
be removed. A bubble removal chamber may be referred to as a vacuum cap, and
may generally
be configured to apply negative pressure on the opposite side of the membrane
while fluid is held
within the fluid-contacting side of the chamber. The membrane may be at least
partially gas-
permeable, as mentioned. FIG. 19 shows an example of a bubble removal chamber.
All, or more
preferably a portion 1988 (e.g., just a cap region), of the membrane dividing
the chamber may be
in contact with the vacuum through a vacuum line 1987, e.g., in the upper
surface or upper plate
of the device, as shown in FIG. 19C. In operation, the vacuum cap 1938, may
remove or reduce a
bubble within the line by holding fluid within the fluid-contacting side of
the chamber and
applying a negative pressure on the upper (pressure receiving) side of the
chamber. The
membrane dividing the chamber into the fluid-contacting side and the pressure-
receiving side
may be gas permeable, so that the negative pressure may remove gas from the
liquid (fluidic)
side by drawing gas (e.g., air, nitrogen, etc.) through the membrane overlying
the fluid path. For
example, the membrane (or the region of the membrane in the vacuum cap may be,
e.g.,
PolyDiMethylSilicone (PDMS) elastomer film that is sufficiently gas permeable
to allow remove
gas from the liquid side of the membrane. Fluid chambers having a fixed volume
(e.g., formed
between the first plate and the second plate) as described herein may include
or be coupled to
one or more bubble removal chambers (vacuum caps) and/or may be configured as
bubble
removal chambers. In some variations the portion of the elastic layer disposed
between the first
and the second surfaces forming the chamber, which divides the fluid-
contacting side, e.g., in the
second surface (and/or second plate) and a pressure-receiving side in the
first surface (and/or first
plate) may be only minimally (or not at all) deflected. For example, the
upper, pressure-receiving
.. side, may be minimally spaced, and/or nearly flush with the relaxed
membrane (e.g., flat), while
the fluid-contacting side is concave and extends into the second surface
(second plate). A
controller may hold fluid within the vacuum cap region, e.g., by blocking
valves on either or
both sides (entrance and exit) of the vacuum cap, e.g., by applying positive
pressure to the
pressure-receiving side of the valve, and may apply negative pressure to the
pressure-receiving
side of the vacuum cap. The absolute amount of negative pressure applied
(e.g., the magnitude of
the negative pressure) may be less than that applied to deflect the membrane
(e.g., less than the
absolute value of the positive pressure applied to close the valve, and/or
pump). Alternatively, in
some variations the membrane may be configured to be deflected (e.g.,
deflected up), against the
first surface and/or plate, e.g., to draw fluid into the enlarged fluid-
contacting side of the
chamber. The membrane may be held by the applied negative pressure against the
first, upper
- 54 -
CA 03149497 2022-02-01
WO 2021/030271
PCT/US2020/045625
surface, allowing gas bubbles (e.g., air bubbles) to be removed. The
controller may hold fluid in
the vacuum chamber for a period sufficient to remove all or some gas (e.g., 1
second or more, 5
seconds or more, 10 seconds or more, 20 seconds or more, 30 seconds or more, 1
minute or
more, 1.5 minutes or more, 2 minutes or more, 5 minutes or more, between 1
second and 5
.. minutes, between 2 seconds and 5 minutes, between 5 seconds and 5 minutes,
etc.). In FIG. 9C,
the pressure may be applied through the pressure line 987 in communication
with the pressure-
receiving sides of the chamber formed between the first and second surface
(e.g., first and second
plate) of the device. The vacuum cap 938 may be valved by one or more valves
992. Fluid may
exit the fluid-contacting side from a fluid line 989 at an opposite side of
the vacuum cap.
[0245] The fluid-contacting side of the chamber of the pressure cap (as
with the valves and
reactors described herein) may be in fluid communication with a fluid port
that fluidly connect
with the fluid-contacting side of each of the chambers via one or more fluid
channels, which may
be in the second surface and/or plate. The pressure-receiving side of the
vacuum cap may be in
fluid communication with a pressure port extending through the first
surface/plate (e.g., and into
.. the surface/plate) to fluidly connect with the pressure-receiving port or
side via a pressure
channel extending through the second plate and along the first plate, as
described herein.
[0246] Any of the microfluidic path devices described herein may be
microfluidic path plate
devices, in which the device is substantially thin, as described above. Thus
processing in/on the
plate may be performed in substantially two dimensions (2D), including
purification of any
.. polynucleotides (e.g., mRNA). Purification of the polynucleotides in 2D is
particularly
advantageous compared to prior art techniques, which may require the use of
columns and may
involve steps that are difficult or impossible to perform in a closed path
environment and/or in
small volumes as described herein.
[0247] In addition, as illustrated in FIG. 4, the fluid-contacting sides
(and/or the pressure-
.. receiving side) of each chamber may be configured to so that the elastic
layer seats flush and
without gaps to the fluid-contacting side in the second surface when a
positive pressure in the
pressure-receiving side drives the elastic layer against the fluid-contacting
side. In some
variations the fluid contacting sides and/or the pressure-receiving sides may
be concave. The
concavity may have a somewhat shallow, oval cross-section to permit the
elastic layer to readily
.. seat flush against the wall of the fluid contacting side (and/or pressure-
receiving side). The
elastic layer may push (e.g., seat) against the wall of the chamber so that
there is no dead
retention portion of the chamber (e.g., of the fluid-contacting side).
[0248] The microfluidic path devices may interface with the microfluidic
path device control
system through a set of spring-loaded connections for both the reagents, as
well as pneumatic
lines used for managing fluid movement and valve control. The reagent and gas
lines may be
- 55 -
CA 03149497 2022-02-01
WO 2021/030271
PCT/US2020/045625
sealed by pressure against an elastomeric layer embedded in the microfluidic
path device that
creates a completely sealed path from reagent vials into the microfluidic path
device and from
the microfluidic path device to the export vials. The sealed path may be
maintained through all
of the reactions inside the microfluidic path device(s), effectively
precluding any contact with the
atmosphere and minimizing the risk of contamination.
[0249] The microfluidic path device control systems described herein may
provide an,
aseptic controlled environment, and may include an interface for loading
reagents and retrieving
outputs. In any of the apparatuses (e.g., systems) described herein, the
apparatus may include an
enclosure that provide a controlled environment; this enclosure may also be
placed within a
controlled environment. For example, the enclosed apparatus may be a class 5
environment that
may be placed within a class 7 environment.
[0250] The microfluidic path device control systems of the microfluidic
path device(s) and
may provide a single-step connection to all the actuators. These control
systems may also scan
all the reagent and microfluidic path device identifiers (e.g., barcodes), and
may monitor fluid
.. levels. In general, these microfluidic path device control systems may
automate all or some of
the microfluidic path device functions, and may generate a visual recording of
all process steps
that may be monitored (such as for optical quality control analysis, e.g., of
intermediate process
outputs), stored, transmitted, or later reviewed.
[0251] As mentioned above, a microfluidic path device control system may
include a
microfluidic path device management system that includes the hardware, such as
a nest
(microfluidic path device holder) that may be engineered such that
microfluidic path devices are
correctly aligned can only be inserted in a single orientation. This may be
managed, e.g., through
two pins and/or a notch in the nest that is matched by the shape of the
microfluidic path device
(Error! Reference source not found.). The microfluidic path device management
system
(control system) also includes vial racks to hold the reagent and export
vials, a downward
looking camera that records all liquid and valve movements, and product
export. Side cameras
on rails to capture barcodes and detect fluid levels, and a robotic arm with
magnets for bead
manipulation. The microfluidic path device is held in place with a vacuum
chuck which ensures
good contact with a Peltier device for temperature management. Once the
microfluidic path
device is in place, mating with all the connectors is achieved in a single
step by lowering the top
part of the microfluidic path device management system through a dowel pin
guided system.
[0252] As mentioned, the microfluidic path device control system may
include a control
panel, which may be an interface for all electronic devices (CPU, Ethernet RIO
device controller,
etc.) as well as the valves and manifolds for pneumatic control, and pressure
regulators. Any of
.. these systems may also include a refrigerated cabinet or chamber (e.g., an
ISO class 5 safety
- 56 -
CA 03149497 2022-02-01
WO 2021/030271
PCT/US2020/045625
cabinet) that behaves like a biosafety hood providing a microbiologically safe
enclosure through
HEPA air filtering and air flow management. In addition, this may ensure that
all reagents are
kept at the correct temperature through the manufacturing process. The cabinet
may also be
equipped with UV lamps for sterilization of the microfluidic path device and
all the internal
.. microfluidic path device management system components. The microfluidic
path device control
system may reside inside an environment (e.g., a 6 ft x 6 ft ISO class 5 mini
environment) that is
itself in an ISO class 7 room. Operator and system interactions, including
loading reagent vials
and microfluidic path device(s) may all be performed following aseptic best
practices.
Delivery Vehicle
[0253] The methods and apparatuses described herein are compatible with a
broad array
mRNA delivery vehicles. For example, the delivery vehicle may be compatible
with
electroporation and gene gun, viral delivery through adenovirus (AV) or adeno-
associated virus
(AAV), exosomes and liposomes, encapsulation by cationic polymers and
formulation with lipid
nanoparticles (LNPs).
Manufacture of Therapeutics
[0254] Described herein are methods, and apparatuses (e.g., devices, and
systems) for
making therapeutics. These methods and apparatuses may be used to manufacture
patient-
specific therapeutics, in a very rapid time period. In particular, these
methods and apparatuses
may be used to manufacture therapeutics based on polynucleotides, such as
mRNA, as described
above. As part of this process, the methods and apparatuses may perform some
or all of the steps
described above, including producing the IVT DNA template, performing the IVT
reaction to
produce a therapeutic mRNA, purifying the therapeutic mRNA, formulating the
mRNA with a
delivery vehicle to form the therapeutic composition and post-formulation
processing of the final
drug product.
Producing the IVT template
[0255] The methods for making DNA templates and in particular for making
synthetic DNA
templates described herein may be especially useful for making better, more
scalable, faster and
safer vaccines and therapeutics. The use of synthetic template for mRNA
synthesis by IVT is
beneficial in numerous ways, including preventing potential microbial
contamination. Solutions
containing the synthetic DNA templates are generally free from contaminating
cells, free from
cell extracts, and free from endotoxins from cells. These solutions may be
especially well suited
to be part of a vaccine for injecting into a patient with virtually no risk of
toxicity due to
contaminating cells, cell extracts, or endotoxins.
- 57 -
CA 03149497 2022-02-01
WO 2021/030271
PCT/US2020/045625
[0256] In some variations, the in vitro transcription facilitator
cassette (IFC) as described
herein is an in vitro transcription capable double-stranded DNA. FIG. 6 shows
an example in
vitro transcription facilitator cassette useful for making a double stranded
DNA template. The in
vitro transcription facilitator cassette includes functional elements
configured to facilitate
effective in vitro transcription (e.g., from an inserted gene of interest),
such as a promoter, a
portion encoding a 5' untranslated region, (5'UTR), a portion encoding a 3'
untranslated region
(3'UTR), and a portion encoding for a polyA tail. The in vitro transcription
facilitator cassette
also includes one or more linkers useful for cloning a gene of interest into
the in vitro
transcription facilitator cassette for expression of the gene of interest and
restriction sites to
ensure template linearization.
[0257] An in vitro transcription facilitator cassette can be
manufactured synthetically or non-
synthetically but in general will be manufactured synthetically. In some
variations, methods of
manufacturing synthetic in vitro transcription facilitator cassette include
using a commercially
available DNA synthesizer such as those available from Twist Bioscience (San
Francisco, CA)
or ThermoFisher Scientific (Waltham, MA). Further, the in vitro transcription
facilitator cassette
can be assembled from separate pieces of DNA, or it may be synthesized as one
piece. In some
embodiments, the in vitro transcription facilitator cassette is linear and may
include compatible
ends that can be ligated together. In some embodiments, the in vitro
transcription facilitator
cassette is circular. In some embodiments, the circular in vitro transcription
facilitator cassette
includes a site (e.g., a restriction endonuclease site) between the portion
encoding a polyA region
and the promoter configured for generating a linear DNA containing, in order,
a promoter, a 5'
UTR, linker region, a 3'UTR, and a portion encoding a polyA region upon
application of the
appropriate restriction endonuclease. In general, the in vitro transcription
facilitator cassette does
not encode an antibiotic resistance gene. For example, a synthetically
synthesized in vitro
transcription facilitator cassette does not need an antibiotic resistance gene
as it is not grown in a
biological (e.g., bacterial) cell and does not require antibiotic selection.
In general, the in vitro
transcription facilitator cassette does not have an origin of replication (on)
or related control
elements for facilitating DNA replication. For example, a synthetically
synthesized in vitro
transcription facilitator cassette does not need an on as it is not grown in a
biological (e.g.,
bacterial) cell and does not need an on for replication. The total length of
the in vitro
transcription facilitator cassette can be smaller than many plasmids. The in
vitro transcription
facilitator cassette can be less than 2kb in length, less than 1.5 kb in
length, less than 1.0 kb in
length, less than 900 bps in length, less than 800 bps in length, less than
700 bps in length, or less
than 600 bps in length.
- 58 -
CA 03149497 2022-02-01
WO 2021/030271
PCT/US2020/045625
[0258] As indicated above, in vitro transcription facilitator cassette
includes a promoter. The
enzyme RNA polymerase binds to the promoter and initiates transcription of RNA
from a gene
of interest (e.g., after a double stranded DNA template has been assembled
from the cassette and
the gene of interest). Examples of promoters useful for transcription in the
cassette include
natural or modified T7 promoters, natural or modified T3 promoter, or natural
or modified SP6
promoters.
[0259] The in vitro transcription facilitator cassette also includes a
portion encoding an
exchangeable 5' untranslated region (5' UTR) and a portion encoding an
exchangeable 3'
untranslated region (3' UTR). These regions, which do not themselves get
translated into protein
or peptide, help regulate translation of an mRNA into a protein or peptide.
The in vitro
transcription facilitator cassette also includes a portion encoding a polyA
tail. A polyA tail in an
mRNA is a long chain of tens or hundreds of repeated adenine residues. A polyA
tail on an
mRNA is believed to serve several functions such as increasing the stability
of the mRNA in the
cytoplasm of a cell and aiding in translation of the mRNA into protein. Unlike
the rest of the
sequence of an mRNA which is encoded directly by the DNA in a template in
mRNAs, the
polyA tail is not normally directly encoded by the DNA (e.g., in nature).
Rather, naturally
occurring DNAs contains a shorthand signal, called a polyadenylation signal
(e.g., AATAAA),
that along with other DNA sequences, signals the transcription machinery in a
cell to add a
polyA tail to an mRNA that is being synthesized. In other words, the length of
the polyA tail in
naturally occurring mRNAs is determined by the cell that makes mRNA. As seen
in FIG. 6, the
in vitro transcription facilitator cassette as described herein includes a
region of DNA that
directly encodes for the polyA tail (e.g., the entire tail). The length of the
polyA tail is
determined by the length (e.g., the number of adenines or polyAs or the number
of thymidines or
polyTs) in the region of DNA that directly encodes for the polyA tail. The
region of DNA that
.. direct encodes for the polyA tail can be at least 100 bp long, at least 200
bp long, at least 300 bp
long, at least 400 bp long, or at least 500 bp long and can be anything in
between these sizes
(such as 350 base pairs long). A polyA tail can be added to an mRNA made using
the cassette as
a template using the same process as used to generate the rest of the mRNA.
One advantage of
this is that the process for generating the entire mRNA, including the polyA
tail, is greatly
simplified. Living cells and complex extracts from cells containing cell DNA,
cell RNA, cell
membrane proteins, and other components are not needed in order to generate
mRNA. Instead,
well-defined transcription mixtures can be used to generate the entire mRNA,
including the
polyA tail, from a double-stranded DNA template as described herein, making a
transcription
mixture generally free from toxic side products that may otherwise be found in
transcription
mixtures that are made using cells or cell extracts. The well-defined mixture
may be safely
- 59 -
CA 03149497 2022-02-01
WO 2021/030271
PCT/US2020/045625
delivered to a patient with only minimal clean-up required. When the double-
stranded DNA
template is also generated from a well-defined mixture substantially free from
toxic side
products, the transcription product made from the double-stranded DNA template
is suitable for
direct injection into a patient with only minimal clean-up necessary.
Described herein is a
double-stranded DNA template that is generated from a well-defined mixture
substantially free
from toxic side products.
[0260] The in vitro transcription facilitator cassette also includes
one or more linker regions.
The linker region is between the 5' UTR and the 3' UTR. The linker region
includes at least one
cleavable site and generally two cleavable sites. If two or more cleavable
sites are present they
may be have the same sequence or different sequences. The one or more
cleavable restriction
sites are useful for inserting a gene of interest (GOT) into the in vitro
transcription facilitator
cassette to generate a synthetic linear or circular ligated product. The gene
of interest is generally
inserted between the 5'UTR and 3'UTR in the in vitro transcription facilitator
cassette though in
some cases 5'UTR or 3'UTR sequences could be included with the gene of
interest and inserted
into the in vitro transcription facilitator cassette along with the gene of
interest. The cleavable
site(s) may be a restriction endonuclease site, such as a Type II (type JIG,
type ITS) restriction
endonuclease, such as BsaI, BbsI, AarI, HhaI, HindIII, NotI, BbvCI, EcoRI,
BglII, FokI, AlwI,
AcuI, or BcgI available from New England Biolabs (NEB; Ipswich, MA); Promega
Corporation
(Madison, WI); or ThermoFisher Scientific (Waltham, MA).
[0261] The gene of interest (GOT) as described herein is a short piece of
DNA that generally
encodes for a functional product molecule (RNA or protein). The gene of
interest may encode a
particular protein, a part of a protein, or a particular function. In some
cases it may contain
instructions for generating an RNA that does not encode for a particular
protein or part of a
protein (e.g., it may encode a functional RNA that does not get translated).
[0262] A gene of interest useful for inserting into an in vitro
transcription facilitator cassette
can be manufactured synthetically or non-synthetically, but in general will be
manufactured
synthetically. Methods of manufacturing synthetic genes of interest include by
using a
commercially available DNA synthesizer and method such as those available from
Twist
Bioscience (San Francisco, CA) or ThermoFisher Scientific (Waltham, MA).
Further, although
the genes of interest can be assembled from separate pieces of DNA, in general
it is synthesized
as one piece. A gene of interest may be manufactured as a linear piece of DNA
or a circular
piece. A circular gene of interest may be digested with a restriction enzyme
to form a linearized
gene of interest. The manufactured gene of interest may be purified (e.g., by
column,
electrophoretic separation, etc.).
- 60 -
CA 03149497 2022-02-01
WO 2021/030271
PCT/US2020/045625
[0263] A gene of interest in general will be cleaved prior to combining
it with an in vitro
transcription facilitator cassette. In particular, a gene of interest may be
cleaved with the same
restriction endonuclease(s) as used to cleave the in vitro transcription
facilitator cassette, but may
also be generated through enzymatic amplification, In general, the gene of
interest does not
encode an antibiotic resistance gene. For example, a synthetically synthesized
gene of interest
does not need an antibiotic resistance gene as it is not grown in a biological
(e.g., bacterial) cell
and does not require antibiotic selection. In general, the gene of interest
does not have an origin
of replication (on) or related control elements for facilitating DNA
replication. For example, a
synthetically synthesized gene of interest does not need an on as it is not
grown in a biological
(e.g., bacterial) cell and does not need an on for replication. In some
embodiments, total length
of the gene of interest can be smaller than many plasmids. The gene of
interest can be less than
2kb in length, less than 1.5 kb in length, less than 1.0 kb in length, less
than 900 bps in length,
less than 800 bps in length, less than 700 bps in length, or less than 600 bps
in length, less than
500 bps in length, less than 400 bps in length, or less than 300 bps in
length, less than 200 bps in
length, less than 100 bps in length.
[0264] In some examples, the gene of interest is a T-cell receptor (TCR)
or a portion of a T-
cell receptor, such as for treating a CTCL or other disease or condition
mediated by a T-cell
receptor (TCR) or a portion of a T-cell receptor. For example, in T-cell
development, cells must
rearrange the T-cell receptor (TCR) genes to create and express a novel TCR
molecule. Because
TCR rearrangement occurs early in T-cell development and prior to the
development of mature
T-cell lymphomas such as CTCL, every malignant CTCL cell expresses an
identical, clonal
TCR, composed of unique TCR alpha and TCR beta subunits. This TCR is unique to
the
lymphoma cells, making it otherwise foreign to the immune system and therefore
an excellent
target for therapy.
[0265] The gene of interest may be part or all of a complementary
determining region (CDR)
region. CDRs are the highly variable portions of the TCR sequences and mediate
binding of the
T cell to an antigen-major histocompatibility complex (MHC). FIG. 8 shows one
region of a T-
cell receptor useful for making a double-stranded DNA for use in a vaccine or
therapeutic. In
particular, the CDR3 region which spans the junctions between the V(D)J and C
regions have the
highest variability and represent a truly unique protein fragment that should
only be found in the
lymphoma cells. Thus the CDR3 region extended by 10 amino acids both at the C
and N termini
constitutes the vaccine peptide fragment. In some methods, the unique sequence
of a gene, such
as T-cell receptor (TCR) or a portion of a T-cell receptor, is determined from
an individual and
the gene of interest is manufactured to be the same as the T-cell receptor
(TCR) or a portion of a
T-cell receptor from the individual. Although in some cases, the sequence may
be controllably
- 61 -
CA 03149497 2022-02-01
WO 2021/030271
PCT/US2020/045625
modified in a specific, known way, such as for codon optimization or optimized
RNA stability or
expression, the sequence of the gene of interest is nonetheless based on the
sequence obtained
from the individual. In some embodiments, the sequence of the gene of interest
comprises a T-
cell receptor having a DNA sequence identical to a DNA sequence from a patient
or controllably
.. modified in a known way relative to the DNA sequence from the patient.
[0266] Described herein are methods of making a double stranded DNA
template, and in
particular methods of making a synthetic double stranded DNA template. The
double stranded
DNA template may be especially useful for performing in vitro transcription to
generate mRNA
such as for use in a vaccine or other therapeutic for injection or another
mode of delivery to a
patient.
[0267] Existing DNA templates for performing in vitro transcription and
mixtures for
performing in vitro transcription commonly include crude or semi-purified
cellular extracts (e.g.,
bacterial, other microbial, or other extracts) and may be complex and
undefined. Such extracts
may include bacterial, other microbial, or other DNA, endotoxin, and/or other
undesirable
components. When used for generating DNA templates or performing in vitro
transcription as
part of a process for vaccine or therapeutic use, undesirable components can
increase the risk of
serious side effects. For example, endotoxin is a large molecule of
lipopolysaccharide in the
exterior cell wall of Gram-negative bacteria, a commonly used source for
generating cellular
extracts for use in in vitro transcription reactions. Endotoxin in the
bloodstream, such as by
injection, can cause a variety of problems in humans and other animals, such
as inflammation
and sepsis and poses a significant health risk. The methods described herein
may be especially
useful for making a double-stranded DNA template free of biological
contaminants (bacterial,
other microbial or other contaminants), free of bacterial (or other microbial
or unwanted) DNA,
and/or free of endotoxin. The methods described herein may include using
defined or synthetic
components for making a gene of interest, making an in vitro transcription
facilitator cassette,
and/or making a double-stranded DNA template (or making any intermediaries
used for making
these materials). The defined or synthetic components may be made from defined
or synthetic
ingredients such as DNA synthesizers, purified nucleotides and purified
enzymes. The defined or
synthetic components may be essentially free of bacterial, other microbial, or
other DNA,
endotoxin, and/or other undesirable components. By avoiding the use of
biologically based
components, biological contaminants such as DNA and endotoxin do not
contaminate the DNA
template (or other components) in the first place. Double-stranded DNA
templates and
downstream materials are safer without the need for difficult or troublesome
purification steps.
This and other methods herein may include steps of joining a synthetic gene of
interest with a
synthetic in vitro transcription facilitator cassette to create a synthetic
linear or circular ligated
- 62 -
CA 03149497 2022-02-01
WO 2021/030271
PCT/US2020/045625
product; removing unreacted synthetic gene of interest and unreacted synthetic
in vitro
transcription facilitator cassette; amplifying the circular ligated product to
generate a linear,
circular or branched amplified DNA; and linearizing the amplified DNA ligated
product to
generate double stranded DNA template.
[0268] As indicated above, joining a gene of interest with an in vitro
transcription facilitator
cassette to create a synthetic linear or circular ligated product may include
inserting the gene of
interest into an in vitro transcription facilitator cassette. FIG. 7 shows a
double-stranded DNA
template generated as described herein. The gene of interest and in vitro
transcription facilitator
cassette may have the same restriction endonuclease site(s) as described
elsewhere herein and the
method may include digesting the gene of interest and the in vitro
transcription facilitator
cassette with the restriction endonuclease for the restriction endonuclease
site, creating
compatible ends, and ligating the gene of interest into the cassette. The
method may include
combining a gene of interest, an in vitro transcription facilitator cassette,
a restriction
endonuclease buffer, a source of energy, one or more restriction endonuclease
enzyme(s), a
ligase buffer, and a ligase and incubating the mixture for an appropriate
amount of time. The
buffer(s) may be suitable for or optimized for the particular restriction
endonuclease and/or
ligase and may be one buffer or may be two (or more) buffers. Endonuclease
and/or ligase
buffers may be commercially available buffers (e.g., NEB, Promega) and/or may
include Tris,
potassium, magnesium, sodium chloride, and dithiothreitol, such as Tris-
acetate (e.g., 6mM ¨ 90
mM), potassium acetate (50 mM - 100 mM), magnesium acetate (5mM - 10mM),
bovine serum
albumin (BSA; 50 ug/ml -200 ug/ml) dithiothreitol (1mM) at a pH from about 7.4
to about 9Ø
The ligase may be a commercially available (e.g., NEB, Promega, Thermo Fisher
Scientific) or
other ligase such as T3 DNA ligase, T4 DNA ligase, or T7 DNA ligase. Digesting
may take
place from 10 minutes to 4 hours, or any amount of time in between (e.g., 30
min, 1 hour, 2
hours, etc.) The ligating step may take place from 10 minutes to 4 hours, or
any amount of time
in between (e.g., 30 min, 1 hour, 2 hours, etc.). The digesting and ligating
steps may be
performed simultaneously or sequentially. A source of energy may be adenosine
5' ¨
triphosphate (ATP) (e.g., from 0.1 mM to 5 mM). Additional quantities of any
of the components
such as restriction endonuclease and ligase may be added over time and
incubation may
continue. In some embodiments, only materials certified to be animal origin
free (AOF) will be
used for therapeutic manufacturing to reduce the risk of transmitting
infectious agents. Some of
these methods in which the in vitro transcription facilitator cassette is not
circular includes the
step of ligating the ends of the in vitro transcription facilitator cassette
and generating a circular
in vitro transcription facilitator cassette. Alternatively, other methods for
ligating the gene of
interest and the in vitro transcription facilitator cassette such as chew back
methods can be used.
- 63 -
CA 03149497 2022-02-01
WO 2021/030271
PCT/US2020/045625
Alternatively or additionally ligation between the in vitro transcription
facilitator cassette and the
gene of interest can be performed using primer extension to generate linear
molecules prior to
exponential amplification methods.
[0269] This or other methods described herein may include the step of
removing unreacted
synthetic gene of interest and unreacted synthetic in vitro transcription
facilitator cassette away
from the synthetic linear or circular ligated product or purifying the double-
stranded DNA away
from the unreacted synthetic gene of interest and unreacted synthetic in vitro
transcription
facilitator. Removing unreacted synthetic gene of interest and unreacted
synthetic in vitro
transcription facilitator cassette away from the synthetic circulated ligated
product may be done
.. using an enzyme such as an exonuclease (such as exonuclease V) in an
appropriate exonuclease
buffer (NEB; Promega, Thermo Fisher). The method may include digesting
synthetic gene of
interest and unreacted synthetic in vitro transcription facilitator. The
method may include passing
the digested mixture through a resin or column, such as an ion exchange resin
or size exclusion
resin, and holding either the unreacted synthetic gene of interest and
unreacted synthetic in vitro
transcription facilitator cassette in the column or holding the double-
stranded DNA template in
the column and allowing the double-stranded DNA template or the unreacted
synthetic gene of
interest and unreacted synthetic in vitro transcription facilitator cassette
to pass through the resin
or column. Some embodiments may also include holding digested nucleotides
within the resin or
column or allowing digested nucleotides to pass through the resin or column.
Some embodiments
include washing and/or eluting the resin or column. Some embodiments may also
include
holding digested nucleotides within the resin or column. Some embodiments
include binding
unreacted synthetic gene of interest and unreacted synthetic in vitro
transcription facilitator
cassette to beads or binding double-stranded DNA to the beads, holding the
beads with a magnet
and removing either the double-stranded DNA or unreacted synthetic gene of
interest and
unreacted synthetic in vitro transcription facilitator cassette from the
double-stranded DNA.
Resins, columns, and magnetic beads are available from places such as Bangs
Laboratories, Inc.,
(Fishers, IN), Beckman Coulter (Brea, CA), Millipore (Burlington MA), Thermo
Fisher, VWR
(Radnor, PA). Some embodiments may include the use of methylation sensitive
restriction
enzymes.
[0270] This and other methods described herein may include amplifying the
linear or circular
ligated product to generate amplified DNA. Some methods include amplifying the
linear or
circular ligated product to generate a linear amplified DNA. Some methods
include amplifying
the linear or circular ligated product to generate a linear, branched or
circular amplified DNA.
The amplified product may be amplified using helicase-dependent amplification
(HAD), loop-
mediated isothermal amplification (LAMP), multiple displacement amplification
(MDA), nucleic
- 64 -
CA 03149497 2022-02-01
WO 2021/030271
PCT/US2020/045625
acid sequence based amplification (NASBA), polymerase chain reaction (PCR),
rolling circle
amplification (RCA), self-sustained sequence replication (3 SR), or strand
displacement
amplification (SDA). The appropriate buffer, deoxyribonucleotide triphosphates
(dNTPs),
enzyme (DNA polymerase), and primers for the reaction are added as needed.
Temperature and
timing of the amplification is controlled. The method may include the steps of
heating the linear
or circular ligated product (e.g., at or above 70 C to 100 C) to denature the
DNA and then
cooling the DNA. The method may include the step of adding a denaturation
buffer configured
for denaturing the DNA to the linear or circular ligated product to denature
the DNA and then
adding a neutralization buffer to the denatured DNA mixture to neutralize the
denaturation buffer
and leave denatured DNA. The method may include the step of adding an enzyme
such as a
DNA polymerase enzyme for amplifying or extending the denatured DNA (e.g., Bst
DNA
polymerase, (1)29 DNA (Phi29) polymerase, Taq DNA polymerase) and amplifying
or extending
the DNA with the enzyme to generate amplified DNA (e.g., branched, circular,
or linear
amplified DNA).
[0271] Some methods include the step of purifying the amplified or extended
DNA away
from the buffer, enzyme, nucleotides, and other unwanted components. The
method may include
passing amplified or extended DNA using through beads, resin or a column, such
as an ion
exchange resin, magnetic beads, or size exclusion resin, and either holding
the amplified or
extended DNA or allowing the amplified or extended DNA to pass through the
beads, resin or
column and holding the unwanted enzyme and other components in the beads,
resin or column.
Some embodiments include washing and/or eluting and/or drying and/or
rehydrating the resin or
column. Some embodiments include repeating one or more of these steps. Some
embodiments
include a two or more (a plurality) of depots of beads, resin, or columns and
repeating one or
more of the washing/eluting/drying/and/or rehydrating steps. Some embodiments
include binding
DNA to beads, holding the beads with a magnet and removing (washing) unwanted
components
and contaminants away from the DNA and beads. Resins, columns, and magnetic
beads suitable
for use are available from Bangs Laboratories, Inc., (Fishers, IN), Beckman
Coulter (Brea, CA),
Millipore (Burlington MA), Thermo Fisher, and VWR (Radnor, PA).
[0272] In some embodiments, amplified DNA is not linear; it may be
branched or circular.
Some methods include the step of linearizing DNA and generating linearized
template DNA.
Some methods may include the step of adding a restriction endonuclease (in an
appropriate
buffer) to purified amplified or extended DNA, incubating the DNA with the
restriction
endonuclease, and linearizing the DNA. The restriction enzyme is chosen to cut
outside of the
5'UTR, gene of interest, 3'UTR, and the portion encoding the polyA region. In
some
embodiments, the restriction enzyme cuts between the 3'UTR of one extended or
amplified DNA
- 65 -
CA 03149497 2022-02-01
WO 2021/030271
PCT/US2020/045625
and the 5'UTR of an adjoining (and downstream) extended or amplified DNA. The
restriction
enzyme can be any restriction enzyme, such as a type Hs restriction enzyme as
indicated above
with regards to restriction enzyme digestion for joining a synthetic gene of
interest with a
synthetic in vitro transcription facilitator cassette to create a synthetic
linear or circular ligated
product. In some examples, the restriction enzyme is at least one of BsaI,
BbsI, AarI, HhaI,
HindIII, NotI, BbvCI, EcoRI, BglII, FokI, AlwI, AcuI, or BcgI available from
New England
Biolabs (NEB; Ipswich, MA); Promega Corporation (Madison, WI); or ThermoFisher
Scientific
(Waltham, MA). In some embodiments, the restriction endonuclease is/are the
same restriction
endonuclease(s) as used for inserting the synthetic gene of interest into the
in vitro transcription
facilitator cassette. In some embodiments, the restriction endonuclease is/are
different from the
restriction endonuclease(s) used for inserting the synthetic gene of interest
into the in vitro
transcription facilitator cassette. Also described herein is microfluidic path
device reactor for
making double-stranded DNA as described herein.
[0273] FIG. 9 shows an example of one variation of an architecture of a
microfluidic biochip
reactor for generating double-stranded DNA. This and other methods described
herein may
include generating double-stranded DNA from the gene of interest and the in
vitro transcription
facilitator cassette in a sterile, closed biochip in which all components are
sterilely maintained
during generation. The sterile, closed biochip is closed to the atmosphere.
FIG. 9 shows the
microfluidic biochip reactor with 4 interconnecting reactors (e.g., modules or
chambers) through
which DNA precursors at different stages along the pathway to becoming a
double-stranded
DNA template move. For example, in FIG. 9 a ligation reactor (ligation
reaction chamber 901), a
pre-mixing chamber 903, an amplification reactor (amplification reaction
chamber 905) and a
digestion reactor (digestion reaction chamber) 907 may be included (connectors
and valves are
not shown in this example. Different steps of the methods described herein are
carried out in
different modules or chambers. The gene of interest and the in vitro
transcription facilitator
cassette are mixed together in the pre-mixing chamber. The gene of interest
and the in vitro
transcription facilitator cassette are joined together to create a ligated
product in the ligation
reaction chamber. The ligated product is amplified to generate amplified DNA
in the
amplification chamber. The amplified DNA is further processed, such as being
digested in the
digestion reaction chamber to remove unwanted DNA or to separate different
copies of the
amplified gene of interest.
IVT Reaction
[0274] The next step in the process may be the IVT reaction that
produces the mRNA. This
process may be conducted inside the same or a different microfluidic path
device (e.g., in some
variations in an IVT microfluidic path device) which may be housed in the
microfluidic path
- 66 -
CA 03149497 2022-02-01
WO 2021/030271
PCT/US2020/045625
device control system as previously described. The high-level mRNA
manufacturing process
illustrating the main steps and sub-compartments within the IVT microfluidic
path device are
described in FIG. 11.
[0275] The IVT reaction may involve combining the DNA template with T7
polymerase
enzyme, nucleotides and capping reagents and incubating the reaction under
controlled
conditions to produce capped mRNA molecules. The IVT reactions may take place
inside a
reaction chamber of a microfluidic path device (e.g., an IVT microfluidic path
device) and
process parameters such as temperature, mixing and reagent additions (both at
the beginning and
throughout the reaction) may be controlled to optimize levels. The process may
be driven by the
controller, as described above. The buffers and solutions may be delivered via
an array of
microvalves and volume may be controlled using a pre-set programs that may be
specific to the
protocol optimized for each mRNA drug substance.
[0276] Following the IVT reaction, a DNAse treatment may be performed to
degrade the
template DNA. This step may be performed inside the IVT reaction chamber (part
of the IVT
reactor), and parameters such as dilution rate, enzyme/buffer concentration,
temperature and
mixing may be controlled to optimized levels. This procedure may be executed
autonomously
and recorded by a monitoring camera.
IVT Purification
[0277] The DNAse treated mRNA may be purified to remove impurities and
side products.
In particular, degraded template, any unreacted nucleotides, enzymes (T7
polymerase and
DNAse) and dsRNA affect the quality and immunogenicity of the drug substance.
For
purification, a 2-step solid-phase reversible immobilization procedure, using
supports with
different surface chemistries may be used. The first step may involve using a
cellulose
membrane to selectively capture dsRNA under precisely controlled binding
conditions and
eluting the non-bound fraction into a second purification chamber. The second
purification step
may use 1-2 [tm carboxyl-coated paramagnetic beads that selectively capture
mRNA greater than
500 bp in length. A number of washes may then be performed to remove unbound
material that
includes nucleotides, enzymes and degraded template. The pure mRNA can then be
eluted in
USP grade water. In- line microfluidics based purification enables a fully
integrated workflow,
without exposing materials to the atmosphere, avoids the use of toxic mobile-
phases used with
traditional HPLC-based methods and significantly reduces manual intervention.
[0278] As mentioned above, in general, these methods and apparatuses are
aseptic methods
and apparatuses that permit the manufacture of therapeutic mRNA, or any or all
of the
components for manufacturing therapeutic mRNAs without exposure to outside
atmosphere,
and/or to possible sources of RNAse and/or contaminating components that may
otherwise be
- 67 -
CA 03149497 2022-02-01
WO 2021/030271
PCT/US2020/045625
necessary. For example, as described herein these methods may be performed
without the
addition of bacterial sources of polynucleotides (e.g., in the template DNA),
and/or without the
addition of components, such as plasticizers, that may be present when
purifying via HPLC or
other traditional techniques. Described herein are apparatuses and methods for
purifying within
the microfluidic path device (e.g., using pure cellulose).
[0279] The purified mRNA may be quantified using A260 nm UV absorption,
or
fluorescence using an mRNA specific fluorescent dye. Additional mRNA QC steps
may be
performed to confirm purity and identity. The entire mRNA manufacturing
process may be
conducted inside the microfluidic path device control system and reagent
addition and export
may be performed via the closed-path microfluidic path device control system
described above,
e.g., using aseptic techniques. Finally, a filtration, e.g., through a 0.22
[tm filter may be
performed. The final product may be considered low bioburden drug substance
and released for
drug product formulation if it meets the acceptance criteria for: yield (e.g.,
by UV
vis/Fluorometry, > 6.5 ug mRNA per ul of starting IVT), identity (e.g., by
sequencing, 100%
consensus homology to target), integrity (e.g., sequencing, < 1% mutation
rate), purity (e.g., CE,
>95% of product in single band), capping efficiency (HPLC, >95% capped mRNA),
residual
dsRNA (e.g., FRET/Immunoblot, <0.02% (1 ng)), bacterial components (e.g., HCP
ELISA (for
DNA & protein), <X), bacterial components (e.g., HC-DNA, <X), endotoxin (e.g.,
LAL test, <
0.2 EU/ml), bioburden (e.g., microbial limits testing (MLT)), etc.
Formulation of mRNA into ANPs
[0280] The purified mRNA may be combined with delivery components to
form a
nanoparticle formulation. This process is depicted in FIG. 12. For example, an
aqueous solution
of the mRNA cargo (therapeutic mRNA, also referred to herein as drug
substance) may be
combined with an ethanolic solution of delivery vehicle in a microfluidic
mixing structure within
a formulation microfluidic path device. The material may then undergo two post-
formulation
processing steps involving first an on-chip dialysis process to exchange
buffer components in the
formulated product, followed by a concentration step to reduce the volume of
the drug product to
match specifications. The implementation of these processes onto a
microfluidic path device-
based manufacturing device may result in a high degree of control over the
formulation process
without the need for human intervention and with minimal possibility for human
error.
[0281] In general, the component parts of the manufacturing methods
described herein,
including, e.g., synthesizing the template, performing the IVT to generate the
mRNA, purifying
the mRNA, combining the mRNA with a delivery vehicle to form a therapeutic
composition,
dialyzing the therapeutic composition, and/or concentrating the therapeutic
composition may be
performed on a single microfluidic path device and/or multiple microfluidic
path devices, as
- 68 -
CA 03149497 2022-02-01
WO 2021/030271
PCT/US2020/045625
shown in FIGS. 3A-3C, described above. Thus, the fluidic path may be
continuous or partially
continuous (e.g., continuous over the component portion of the manufacturing
process, such as
one or more of: template formation, IVT, purifying the mRNA, combining the
mRNA with a
delivery vehicle to form a therapeutic composition, dialyzing the therapeutic
composition, and/or
concentrating the therapeutic composition). In all cases, the same controller
apparatus may be
used, or different controller apparatuses may be used. The product of each of
these component
portions may be stored in a fluid vial (e.g., depot) in the controller
apparatus and transferred to a
new or subsequent microfluidic path device. Thus, in any of these methods and
apparatuses, the
product may be protected from exposure to the atmosphere.
[0282] As mentioned above in some variations a peptoid-based lipid
formulations may be
used as the drug vehicle, which may incorporate both cationic groups and lipid
moieties onto an
N-substituted peptide (i.e. peptoid) backbone. The delivery vehicle components
may be
monodisperse, fully-characterizable chemical entities which can be sourced
through conventional
means.
[0283] A controlled and consistent formulation process may be crucial to
maintaining small,
uniform particle sizes in mRNA ANP formulations. Delivery vehicle components
are rapidly
mixed with mRNA in a controlled ratio by the methods and apparatuses described
herein.
Exposure of DV components to aqueous solution and interaction between cationic
(+) lipids and
anionic (-) mRNA may trigger particle formation. This process can be carried
out (to control
particle size and uniformity) by using the microfluidic path devices described
herein. The mRNA
may be dissolved in an acidic buffer (pH 3-5) which may help ensure full
protonation of basic
functional groups (such as amines) on the delivery vehicle which are
responsible for its cationic
charge. The delivery vehicle may be dissolved in an aqueous-miscible organic
solvent (typically
ethanol) which facilitates the formation of nano-sized particles upon exposure
to the aqueous
cargo solution. Immediately after mixing, the solution pH may be stabilized by
a neutral buffer.
The resulting formulation can be stored at 4 C for weeks with no apparent
loss of function.
Alternatively, the formulation process can be performed just-in-time and at
the point-of-care.
[0284] A formulation microfluidic path device as described herein may be
designed to
accomplish these formulation tasks. FIG. 13 illustrates a schematic of a
general architecture of
such a microfluidic path device that may be used. The first portion of the
formulation
microfluidic path device may include pre-dilution of both the mRNA and the DV
components
into separate staging chambers. The input materials may be advanced from
sterile, barcoded vials
into these pre-mixing chambers. The mRNA material(s) may be pre-diluted in
acidic formulation
buffer, and the delivery vehicle components are diluted in ethanol. At this
stage, the
concentrations of both materials may be adjusted to match required
specifications for target
- 69 -
CA 03149497 2022-02-01
WO 2021/030271
PCT/US2020/045625
DV/mRNA ratio, and the volume ratio that matches, e.g., a 3:1 aqueous:ethanol
ratio that has
previously shown to achieve good mixing behavior.
[0285] A microfluidic path device including a mixing structure may
control, with precision,
the mixing rate of the material. Faster or slower mixing may be provided, and
controlled (e.g., by
a controller). For example, a microfluidic path device including a mixing
structure may provide
for a significantly increased DV/mRNA mixing rate. At the start of the mixing
process, equal
pressure may be applied to both mixing chambers which forces fluid through the
microfluidic
structure at, e.g., 0.5 mL/min. The geometry of this structure may be
determined by the rapid
mixing time of roughly 3 ms. Under these conditions, amphipathic nanoparticles
(ANPs) may be
formed as water-insoluble lipid domains on the peptoid molecule are exposed to
the aqueous
mRNA solution.
[0286] Immediately following mixing, ANPs may be diluted with an in-line
addition of 1:1
neutral PBS. This neutralizes the acidic formulation buffer and may prepare
the formulation for
dialysis and concentration. All of these processes may be controlled through
the microfluidic
path device control system to maintain highly-reproducible particle sizes and
formulation
properties.
[0287] The microfluidic device allows for the formulation of a
personalized therapeutic at
the point of care. In some examples, the therapeutic is a T-cell receptor
(TCR) or a portion of a
T-cell receptor, such as for treating a CTCL or other disease or condition
mediated by a T-cell
receptor (TCR) or a portion of a T-cell receptor. Personalized therapeutics
may base the
therapeutic composition on a specific patient's genetics (e.g., genotype),
including generating a
specific mRNA composition based on the patient's own sequence). The methods
and apparatuses
described herein may also or alternatively permit individualized therapeutics.
Individualized
therapeutics may be based on the patient's phenotype, e.g., based on the
category a patient falls
into, such as risk factor categories. Individualized therapeutics may
therefore adapt specific
therapeutics to a patient based on the patient's category. For example, a
microfluidic formulation
device may allow for multiple mRNAs to be mixed, for example, to generate from
a sub-set of
mRNAs from a larger library a therapeutic composition that is individualized
to a patient based
on the components and rations (amounts) of each component which may be
determined from
phenotype data on the patient. Any of these compositions may be compounded at
the point-of-
care to generate an optimized treatment for an individual.
Post-formulation processing to generate drug product
[0288] Once ANPs are formed during the formulation process, several post-
processing
operations may be completed on the formulation microfluidic path device. These
may include
- 70 -
CA 03149497 2022-02-01
WO 2021/030271
PCT/US2020/045625
dialysis for buffer exchange and ethanol removal, followed by evaporative
concentration to
reduce volume for dosing. See, e.g., FIG. 14.
[0289] The resulting nanoparticles may be analyzed on the microfluidic
path device (e.g., by
the microfluidic path device control system) for size distribution using,
e.g., Dynamic Light
Scattering (DLS) and % mRNA encapsulation using fluorescence. Analysis may be
completed
on a small aliquot of the final formulated material that is diverted from the
main fluid path into
an optically-transparent sampling chamber. Within this chamber, a fiber-optic
light source may
be used for the light scattering measurement to determine particle size and
dispersity. Next, a
fluorescent mRNA-specific probe is used to determine RNA concentration before
and after
particle disruption by addition of a detergent. This assay may elucidate the
mRNA concentration
for dosing information and the percentage of mRNA encapsulated in the ANPs
versus free in
solution. For example, analytical methods that may be used to test the
formulated mRNA drug
Product may include: Optical clarity (e.g., by visual inspection, no visible,
aggregates, clear
solution), characterizing lipid composition (e.g., by HPLC), size (e.g., DLS,
80 - 300 nm), %
.. Encapsulation (e.g., by fluorometry, > 95% encapsulation), dispersity
(e.g., DLS, PDI <0.25),
endotoxin (e.g., LAL test, <0.2 EU/ml), sterility (e.g., culture (USP), <X
cfu), pH (e.g., USP ,
pH 7.4 +/-0.2), potency (e.g., bioassay/ELISA, X EC50).
Examples
[0290] As mentioned above, the methods and apparatuses described herein
may be used to
manufacture mRNA therapies, including, for example, treatments for Cutaneous T-
Cell
Lymphoma (CTCL). Mature T-cell express a unique TCR which is formed by a
combination of
two proteins, the alpha and beta chains in a43 T-cells or the delta and gamma
chains in sfry T-cells.
Each TCR chain is formed by a unique recombination event by which any one of
many possible
exons encoding the V, (D) and J regions of the genes are brought together by a
process called
V(D)J recombination. These V(D)J recombination events are quasi-random and can
produce a
large number of combinations resulting in a large diversity of TCRs. In
addition, during the
V(D)J recombination process, random additions or deletions of nucleotides can
occur at exon
junctions, resulting in the generation of additional TCR diversity which
together generate an
individual's TCR repertoire. Healthy individuals sequenced deeply by next-
generation
technologies have been estimated to harbor in the order of 1-5 x 106 different
TCRs in peripheral
blood at any given time point, and in the absence of infection no single TCR
usually accounts for
more than 5% of the total population. T-cell lymphomas arise from the clonal
expansion of a
single malignant T-cell leading to tumor development either in lymphoid
tissues (spleen or
lymph nodes) or other tissues such as skin, liver or gastro-intestinal track.
- 71 -
CA 03149497 2022-02-01
WO 2021/030271
PCT/US2020/045625
[0291] Alternative methods have been developed to sequence an
individual's TCR repertoire
which also serves to diagnose and identify the clonally expanded TCR in T-cell
lymphoma
patients. One commonly used method is to sequence TCRP or 7 genomic re-
arrangements using
carefully developed panels of PCR primers, where amplification bias is
controlled. Thus, a
multiplex PCR can be performed for target enrichment followed by next-
generation sequencing.
Such methods, for example the Immunoseq assay from Adaptive biotechnologies
have been
validated and are used in the clinic as a diagnostic tool and for minimal
residual disease
quantification. An alternative approach is to deeply sequence cDNA directly
with no target
enrichment to identify significantly overrepresented TCR chains.
Identification of the
Lymphoma TCR, is usually referred to as the lymphoma idiotype or clonotype.
[0292] For the determination of the Idiotype, biopsies may be collected
and samples may be
sequenced to determine lymphoma idiotype identification. The digital data
concerning the
patient-specific idiotype may be used for patient-specific vaccine design.
Design of the mRNA vaccine
[0293] Production of an mRNA-based patient specific cancer vaccine may
start with the
design of a DNA sequence corresponding to a personalized target peptide
capable of generating a
specific and immunological effective epitope presentation by antigen
presenting cells (APCs). To
accomplish this, the first step may include extracting the Complementary-
Determining Regions
(CDRs) from the idiotype TCR chains (ar3 or 78). The CDR3 regions can be
extracted by
performing a sequence alignment to a canonical TCR. CDRs are the highly
variable portions of
the TCR sequences which mediate binding to the antigen-MHC complex. In
particular, the
CDR3 region which spans the junctions between the V(D)J and C regions have the
highest
variability and represent a truly unique protein fragment that should only be
found in the
lymphoma cells. Thus, for example, a CDR3 region extended by 10 amino acids
both at the C
and N termini constitutes the vaccine peptide fragment, as described above for
FIG. 8.
[0294] Since the TCR has two chains (a & r3) there are 2 CDR3s per
patient, although in a
minority of cases only one CDR3 will be identified. In one example, assuming
that a CDR3a
and CDR3r3 are available, the vaccine peptide may be designed with the
following structure:
CDR3a¨linker-CDR3r3 where the linker is the standard GSGGGSGGGSGGGS sequence
commonly used for the design of single-chain variable fragment (ScFv)
molecules.
[0295] Once the final vaccine peptide amino acid sequence is identified
the design process
may include codon optimization to derive a DNA sequence that can be: (i)
highly transcribed and
highly translated, leading to good protein expression, (ii) amenable to DNA
synthesis, (iii)
includes adaptor sequences required for the template generation step, and (iv)
excludes sequence
- 72 -
CA 03149497 2022-02-01
WO 2021/030271
PCT/US2020/045625
motifs such as restriction enzymes that would otherwise interfere with the
template generation
process. Codon optimization may be performed, e.g., to balance the sequence
GC, and remove
sequence repeats, internal promoter sequences, termination sequences, splice
sequences,
recombination sequences, and internal ribosomal entry sites (IRES). In
addition, the codon usage
may be adapted to that observed in highly expressed human genes. A schematic
view of one
example of a codon optimization process that may be used is shown in FIG. 10.
[0296] Once the sequence design process is completed, the optimized
sequence may be
synthesized as a linear DNA molecule. A template for IVT may be prepared as
described above.
For example, prior to mRNA synthesis via IVT, an IVT-capable double-stranded
DNA template
may be generated. The DNA template may comprise (i) a protein coding sequence
(or CDS),
defined as the set of codons corresponding to the target patient specific
peptide to be produced,
(ii) non-coding sequences that include the 5' Untranslated region (5'UTR) and
3'UTR, (iii) a
polyA sequence that protects mRNA from exonuclease activity and (iv) a
promoter sequence that
recruits the RNA polymerase enzyme that transcribes the DNA template into
mRNA, as
described in FIG. 6, above.
[0297] Thus, a patient-specific peptide encoding sequence that is a
synthetic linear DNA
(e.g., from a DNA synthesis vendor) may be paired with the generic functional
elements required
for IVT, as a template generation process.
[0298] The microfluidic path device-based methods and described herein
may include
template generation and may be much faster and more efficient than currently
practiced bacterial
culture-based methods which may take ¨ 4 days or longer, may result in
variable length polyA
tails (due to bacterial recombination processes) and may have a risk of carry-
over of bacterial
proteins, bacterial DNA and endotoxins. In contrast, the methods and
apparatuses described
herein can be performed in a single day (-12 hours), and may result in
consistent poly A tails
(greater than 300 bp), and may not involve any contact with host nucleic acids
or host cell
proteins. The final double-stranded DNA may be made from chemically produced
nucleotides
and can thus be considered of synthetic origin.
[0299] As described above, these methods may include four steps: (i)
ligation of the sGOI
with the TIFC, and removal of non-ligated material by an exonuclease
treatment, (ii) circular
amplification of the ligated product via a technology called multiple
displacement amplification
(MDA), (iii) linearization of the amplified product using digestion with a
type IIs restriction
enzyme, (iv) on-chip purification procedure to remove impurities. As a final
step, the purified
template may be filtered through a 0.22 [tm filter. To ensure the quality of
the resulting material
prior to use in the IVT reaction a number of analytical tests may be
performed, including tests for
yield (e.g., >50 ug at 1 ug/ul, 260/280 nm ratio >1.8), identity (e.g., 100%
consensus homology
- 73 -
CA 03149497 2022-02-01
WO 2021/030271
PCT/US2020/045625
to target), integrity (e.g., <1% mutation rate), purity (e.g., >95% of product
in a single band by
CE), and endotoxin (e.g., <0.2 EU/ml).
[0300] Thus, the drug products may include an mRNA encoding patient-
specific TCR
peptides together with CpG as an adjuvant mixed in 1:1 ratio. The nucleic acid
mix may be
encapsulated into 200 nm ANPs that serve to protect the mRNA from degradation
by RNases
and also act as facilitators for its cellular uptake and cytoplasmic release.
Intact mRNA
bioavailability in the cytoplasm where the translation process takes place may
be required for the
active ingredient's mechanism of action. The ANPs are composed of the nucleic
acid
components, the cationic amine-functionalized peptoid NTX-DV-0024 and 2 wt%
PEG-lipid, at
.. an overall ratio of mRNA:DV of 5:1 w/w. The size distribution of the ANPs
may be unimodal
with a Z-average particle size of approximately 200 nm. ANPs may be suspended
in phosphate
buffered saline (0.144 mg/mL potassium phosphate monobasic, 9.0 mg/mL sodium
chloride, and
0.795 mg/mL sodium phosphate dibasic) at a target pH of 7.4. All formulation
excipients may
generally be recognized as safe. The final product may be sterile and
physiologically isotonic
.. with an osmolality of 295 20 mOsm/kg.
[0301] Although mRNA itself has an attractive safety profile, levels of
sub-visible particles,
host cell proteins (HCP), host cell DNA, process-related impurities,
bioburden, bacterial
endotoxin levels, sterility, and leachables and extractables, for example, are
predominantly
safety-related and must be minimized and controlled according to established
safety profiles and
industry standards. In addition, eliminating or minimizing the presence of
residual template
DNA, double stranded RNA, and enzymes used to manufacture IVT mRNA may ensure
a safe
and efficacious product.
[0302] As mentioned, the methods and apparatuses described herein may
include
quantitative analysis of particulate matter, e.g., by one or more procedures,
such as a light
obscuration particle count test, and/or a microscopic particle count test. It
may be necessary to
test some preparations by the light obscuration particle count test followed
by the microscopic
particle count test to reach a final conclusion on conformance to
requirements. Since
nanoparticle preparations are intrinsically opaque due to light scattering by
droplets and/or
particle assemblies present in the injection, filtration and subsequent
microscopic analysis of the
filter may be used for particulate matter analysis. A light microscope
adjusted to 100 10
magnifications may be used which allows visualization of particles as small as
approximately 1
p.m and the nominal pore size of the filter used in the method can be up to
1.0 p.m, drug product
nanoparticles in the 100 nm to 250 nm range will not interfere with
particulate matter detection.
- 74 -
CA 03149497 2022-02-01
WO 2021/030271
PCT/US2020/045625
[0303] The methods for template generation described herein do not
involve the use of
bacteria or any other live microorganisms but relies on the use of enzymatic
reaction and
chemically manufactured nucleotides, thus the template and mRNA products are
fully synthetic.
[0304] With respect to residual host cell DNA in the finished drug
product, the methods and
apparatuses described herein may have less than 10 ng/dose and 200 base pairs
in the final
product dose. In addition to minimizing the presence of process-related
impurities, product-
related impurities may be controlled through the manufacturing process,
formulation
development and optimization, and the identification of proper storage
conditions described
herein. Although the IVT mRNA product are intended to be manufactured and
administered as
.. soon as possible, the stability profile may meet defined acceptance
criteria until administration at
a minimum. The duration for maintaining adequate stability for the
therapeutics described herein
may be at least 30 days under refrigerated conditions.
[0305] Once IVT mRNA has entered the cytoplasm, its pharmacology is
governed by the
same cellular mechanisms that regulate the stability and translation of native
mRNA. Thus, IVT
mRNA potency will largely be dependent on cytoplasmic bioavailability and
focus should be on
developing the product such that cellular uptake is maximized.
[0306] The storage containers (e.g., depots) described herein may
generally protect the
product from the external environment (including oxygen ingress and protection
from
photodegradation, if applicable), be sterilizable and ensure that sterility is
maintained throughout
the shelf-life, be compatible with the product formulation, and contribute
minimal little to no
leachable chemicals to the product during storage. For example, the depots may
include Type I
borosilicate glass vials with halobutyl rubber stoppers confer proper product
protection and
ensure that sterility, safety, and efficacy are maintained throughout the
product's shelf-life.
[0307] A preliminary screening maximizing mRNA expression, minimizing
impacts on
cellular viability, and achieving favorable biodistribution profiles was
performed. For these
experiments, a bioluminescence assay based on firefly luciferase (Fluc)
expression was selected.
This assay allows for the quantitative measurement of gene expression
resulting from mRNA
uptake by each delivery vehicle candidate in a high-throughput fashion. For
initial evaluation,
thirty-six amino-lipidated peptoids were synthesized for initial evaluation by
solid phase peptoid
synthesis and isolated by lyophilization and or precipitation. These candidate
materials contained
structural variations in both their cationic and lipid domains. These thirty-
six materials were
combined with Fluc mRNA at different ratios along with 2% (w/w) of a lipid-
anchored PEG
(1,2-dimyristoyl-rac-glycero-3-methoxypolyethylene glycol-2000). Several cell
lines were
treated with the resulting formulations including HeLa, HepG2, and JAWSII
dendritic cells,
leading to the down-selection of 6 lead candidates.
- 75 -
CA 03149497 2022-02-01
WO 2021/030271
PCT/US2020/045625
[0308] In vivo mRNA expression and biodistribution of delivery vehicle
candidates were
quantified by Fluc expression in Balb/c mice following intravenous (IV),
subcutaneous (SC), and
intramuscular (IM) injections. Based on expression (in vitro and in vivo) and
biodistribution (in-
vivo), NTX-DV-0024 was selected as a candidate. mRNA coding for Ovalbumin was
synthesized and evaluated as a model vaccine. Ovalbumin is extremely well-
studied in the
context of vaccination, and reagents are commercially available to track
epitope presentation and
T-cell responses which make it an ideal candidate for proof-of-concept
studies. Initial evaluation
of OVA mRNA produced as described herein was conducted on an in vitro model
using JAWSII
murine (C57BL/6) dendritic cells. Briefly, JAWSII cells were transfected with
OVA mRNA
candidates using commercial transfection reagents (ex. Lipofectamine2000Tm)
for 24 hours, after
which time cells were stained using a fluorescent antibody for MHC-I bound to
the SIINFEKL
epitope. The mean fluorescence intensity (MFI) of the stained population
represents a measure of
overall antigen presentation. This is described schematically in FIG. 15.
[0309] Using this assay, mRNA produced as described herein was evaluated
against
.. commercially-purchased material. In this case the produced mRNA resulted in
42% higher levels
of SIINFEKL presentation on MHC-I compared to the commercial control. The
reproducibility
of the on-device mRNA synthesis was also demonstrated, with 5 batches of OVA
mRNA (NTX-
RNA-0184) resulting in similar levels of SIINFEKL+ JAWSII cells.
[0310] mRNA candidates were similarly evaluated as vaccine candidates in
a murine in vivo
experiment. C57BL/6 mice were injected (IV) with commercial or produced mRNA
(produced
by the microfluidics path devices described herein) and a delivery vehicle.
Seven days post-
injection, peripheral blood was isolated and stained using a fluorescent MHC-I
tetramer specific
for T-cells recognizing the OVA epitope. The fraction of OVA-specific CD8+ T-
cells was then
quantified by flow cytometry. In this experiment, as before, produced mRNA
resulted in 50%
increase in the fraction of OVA-specific T-cells in peripheral blood relative
to the commercial
control, indicating the strength of these molecules as vaccination candidates.
[0311] The first demonstration the in vivo efficacy of an mRNA-based
vaccine (produced as
described herein) was in murine, OVA-expressing, EG.7, syngeneic T-cell
lymphoma model.
This model is a physiologically relevant animal model for the indication
lymphoma and relevant
to the immunotherapeutic mechanism of action of NTX-0565. Syngeneic mouse
models are
grafts of immortalized mouse cancer cell lines in murine hosts from the same
inbred background
strain (homograft). The syngeneic host murine background enables immunotherapy-
based drugs
to recruit a functional anti-tumor immune response from the host, which is
necessary for
investigating immunotherapies. Syngeneic models feature fully competent murine
immunity,
diversity of immune cell infiltration into the tumor, comprehensive mouse
tumor, immune cells
- 76 -
CA 03149497 2022-02-01
WO 2021/030271
PCT/US2020/045625
and stroma interface, and ease of tumor synchronization for pharmacology
studies including
genetic and protein expression histories.
[0312] The murine E.G7-OVA Lymphoma tumor model was used. The E.G7-OVA
tumor
cell line is an EL-4 lymphoma derivative line engineered to carry 1 genomic
copy of OVA
antigen expressed consistently and robustly. This method enables a highly
specific immune
reaction to exogenous OVA-based antigens, making these tumor cells ideal for
studying cancer
vaccines. Tumor growth inhibition has been demonstrated in the literature
using DNA, cell-
based, and siRNA vaccines. For a first efficacy study, the vaccine component
was an mRNA
encoding the OVA antigen, and study design was modeled after previous
literature on this
animal model with an mRNA-based vaccine. A randomized concurrent negative
control was run
parallel using test article delivery vehicle ¨ phosphate buffered saline.
Animals were age and
sex-matched and group assignment were randomized to ensure average
distribution of tumor size
and body weight. Test articles were blinded so that the in vivo study director
was removed from
bias. Sample analysis was blinded again to remove analyst bias. Inclusion and
exclusion criteria
for acceptance into the study were predefined in the proposal prior to
initiation. Endpoints,
observation frequency and schedule were predefined in the study proposal prior
to study
initiation. Euthanasia criteria and animal care interventions were predefined.
[0313] This initial study demonstrated that the mRNA vaccine described
herein had
statistically highly significant therapeutic efficacy (FIG. 16A-D). When the
OVA mRNA
vaccine was delivered intravenously to group 2, the group began showing
statistically extreme
significance on day 14 post tumor implantation (***, p<0.0005, relative to
Neg. Control via
Multiple Dunnett's Comparison Test on day 14). On day 21, tumor volumes were
797 mm3 in
group 2 versus 2000 mm3 in group 1 control (**, p<0.005 as measured by
Multiple Dunnett's
Comparisons Test on day 21). This translated into a tumor growth inhibition of
61.42% when
animals received the mRNA vaccination manufactured as described herein (IV).
Tumor growth
inhibition (TGI%) was calculated on day 21 post implantation when the negative
control group
(Group 1) reached the predetermined endpoint tumor volume (2,000 mm3). Tumor
growth
inhibition (%) was defined by the following formula: TGI (%) = (TVcontrol
group - TVtreated
group)/TVcontrol x 100 and is relative to the negative control on day 21 post
tumor implantation,
when all control animals had reached terminal tumor volume. This tumor growth
inhibition
translated into a highly statistically significant increase in survival for
the mRNA-vaccinated
group with Group 2: mRNA-vaccinated animals having a time to endpoint of 25
days versus
Group 1: Vehicle-treated animals having a median time to endpoint of 23 days
(** p <0.01 as
measured by Log Rank Test Against Control). No observable toxicity at the
given doses was
observed based on weight and laboratory test results. In FIG. 16A-16C a
manufactured mRNA-
- 77 -
CA 03149497 2022-02-01
WO 2021/030271
PCT/US2020/045625
based vaccine shows in vivo efficacy in a murine lymphoma E.G7 syngeneic
model. Tumor
growth was inhibited by 61.4% as seen in the individual animal curves (FIG.
16A, 16B) and in
the average tumor volume for each group (FIG. 16C) (*p<0.01). This tumor
growth inhibition
translated into a statistically significant increase in survival for the mRNA-
vaccinated group
(FIG. 16D) (**, p<0.01).
[0314] In vivo testing of stored drug product formulations using
reporter gene expression to
supplement the physical measurements above was also performed over a one week
time period.
In this experiment, formulations of firefly luciferase mRNA and NTX-DV-0028
were prepared
1) 7 days prior to injection, 2) 3 days prior to injection, and 3) 1 hour
prior to injection. Post-
.. formulation, products were stored at 4 C until administration. All three
materials were then
administered to Balb/c mice at a dose of 0.25 mg/kg via a tail vein injection.
8 hours post-
injection, whole-body bioluminescence was measured, and the resulting images
are shown in
FIG. 17A, and quantified in FIG. 17B (showing quantified photon flux of whole-
body luciferase
expression following injection with stored mRNA formulations). Over the course
of this 1-week
storage experiment, there was no substantial loss in measured bioluminescence.
Both the 3-day
and 7-day stored materials are within error of the material formulated
immediately prior to
injection. This functional stability data supports the particle size stability
data above to strongly
indicate that the mRNA formulations described herein are stable to storage at
4 C for at least 1
week.
[0315] In general, an mRNA drug substance formulated with a delivery
vehicle molecule
into an ANP as described herein may have an approximately 200 nm size,
precluding the use of a
0.2 micron sterile filter at the conclusion of the final formulation step to
prevent loss. Therefore,
multiple methodical filtration steps may be incorporated throughout the
manufacturing process to
alleviate sterility risks while avoiding disruption of the final ANP drug
product. FIG. 18
schematically illustrates various times at which filtration may be applied.
Prior to the IVT
reaction, both the purified template and the individual IVT reagents
(including dNTPs, enzyme,
etc.) may be filtered through 0.22 um filters (FIG. 18 A, B). After mRNA
production is
completed in the IVT microfluidic path device, all input materials will be
filtered prior to the
final formulation process (in which ANPs are formed). These include drug
substance (mRNA,
.. e.g., FIG. 18, C), adjuvant (CpG), amphipathic peptoid delivery vehicle
components and buffers
(FIG. e.g., FIG. 18, D), DMG-PEG2000 delivery vehicle component (e.g., FIG.
18, D), and
dialysis buffer (e.g., FIG. 18, E). In addition to 0.22 micron filtration of
the input materials, the
final amphipathic nanoparticle drug product may be filtered through a 0.45
micron filter to
remove any particulate or aggregated material (FIG. 18, F). This larger
filtration step may help
.. prevent disruption of ANPs and maintain efficacy of the final drug product.
- 78 -
CA 03149497 2022-02-01
WO 2021/030271
PCT/US2020/045625
[0316] To supplement the discreet filtration steps described above, the
microfluidic path
device control systems described herein may be designed to operate with a
sealed, sterile fluid
path which will ensure the safety and sterility of the final drug product,
e.g., as descried herein,
using one or more sealed microfluidic path devices that conduct the required
operations for drug
product manufacturing including template preparation, in vitro transcription
(IVT), formulation
with delivery vehicle into amphipathic nanoparticles (ANPs), and buffer
exchange and
concentration steps. These microfluidic path devices may reside within a
temperature-controlled
class 5 laminar hood which is further housed, e.g., in 6 x 6 class 7 clean
room. The mRNA
reactor(s) may be an automated piece of equipment that is protected from human
and external
environment. The reagent and product fluid path may be delivered to core of
the reactor from
pressurized, sterile containers using a single use sterile nuclease free tube.
The final product
formulation and drug product may be manufactured within the multilayer
microfluidic path
device(s) as described above in a fully closed system.
PERMEABLE INSERTS
[0317] Any of the microfluidic path devices described herein may include
one or more
permeable inserts for processing the solution of therapeutic material (or the
solution in which the
therapeutic material is being formed). The permeable insert may be inserted
into the fluid-
contacting side of a chamber in the microfluidic path device. And may be
configured so that
fluid entering or passing through the fluid-contacting side of the chamber
must pass through, and
therefore be modified by, the permeable insert. Any appropriate permeable
insert may be used.
For example, the permeable insert may include a material that is configured to
remove an
undesirable material; in some examples the permeable insert include a
cellulose material that is
configured to remove double stranded RNA (dsRNA) from a therapeutic solution
of single
stranded RNA (ssRNA).
[0318] FIGS. 19A shows one example of a microfluidic path device 1900
including a
permeable insert 1969 within the fluid-contacting side of a chamber 1957. In
FIG. 19A a
microfluidic path device 1900 may include at least one pair of chambers 1953,
1957, 1957', each
of which may include a fluid-contacting side 1917, a pressure (e.g., gas) side
1919, fluidic
connections, pressure connections and fluidic/pressure lines that may be
formed in the thickness
of the microfluidic path device. In some variations the chambers are paired,
and each chamber of
the pair of chambers may be connected to each other by a fluidic connector
1955. The fluidic
connector 1955 may be used in coordination with positive and/or negative
pressure applied to the
pressure side of the chamber(s) to drive liquid in the liquid side between the
two chambers to
mix this liquid within each of the chambers. The chamber may be bifurcated by
an elastic
- 79 -
CA 03149497 2022-02-01
WO 2021/030271
PCT/US2020/045625
material (e.g., an elastic layer or membrane) and deflecting an elastic
material within the fixed
volume of a chamber may drive any liquid within the liquid in/out of the fluid-
contacting side of
the chamber (e.g., between the two chambers).
[0319] The microfluidic path device 1900 may include more than one pair
of chambers, any
.. of which may include a permeable insert. Each pair of chambers may be used
for different
processes. For example a first pair of chambers 1953 may be used for synthesis
of the RNA. A
second pair of chambers 1957, 1957' may be used for purification of the
synthesized
polynucleotides. Fluid from a first pair of chambers 1953 may be driven to a
second pair of
chambers upon application of pressure to the pressure-receiving side 1919 of
the respective
chambers and opening a valve 1959 between the first pair of chambers 1953 and
the second pair
of chambers 1957. The valve chamber 1959 may be formed by the elastic layer
1907 within a
connector channel between the two pairs of chambers.
[0320] The microfluidic path device 1900 as shown in FIGS. 19A and 19B
may have a
plurality of pressure ports 1943 and fluid ports 1923. The plurality of
pressure ports and fluid
.. ports may be disposed adjacent to a periphery of the microfluidic path
device, and are configured
to be connected to the fluid interface assembly 109 as described above.
[0321] Ports (e.g., sealing valves) may be formed from the elastic
layer, along the length of a
connecting channel 1939 (either pressure channel or fluid channel), such as is
shown in FIG.
19A, for valve 1961, which may control timing of delivery of a reagent driven
from fluidic port
.. 1923, but when placed in series with one or more similarly constructed
valves, may also permit
metering to the chambers of the device. For example, in FIG. 19A, three valve
chambers are
shown (described in greater detail below); the first of these three valves may
act as a peristaltic
pump, while the middle valve may be a metering chamber that meters small
(e.g., having a
metering volume of about 10 nL, 20 nL, 25 nL, 50 nL, 75 nL, 100 nL, etc.). The
size of the
channels, and particularly the size of the chambers connected to the channels)
can meter out the
volume dispensed along fluidic connecting channel 1939, 1921 and delivered
into the chamber
1953 that is connected to the fluidic connecting channel 1939, 1921. In some
variations, a
metered volume may be as little as 50 nL. Metered volumes of about 100 nL, 1
microliter, 5
microliters or more may be imported. A variety of valve sizes may be pre-
selected for
.. incorporation with in the microfluidic path device 1900, and reagents may
be connected to
appropriate metering sizes by user choice.
[0322] Additionally, more than one valve body 1961 may be included in a
row along fluidic
connecting channel 1939. A series of valves 1961 may act as a peristaltic pump
to move fluid,
including (but not limited to) viscus fluids. The ability to function as a
peristaltic pump for fluids
- 80 -
CA 03149497 2022-02-01
WO 2021/030271
PCT/US2020/045625
generally, may have particular advantage for moving fluid that may be viscous
or contain
suspended particles such as purification or capture beads.
[0323] As mentioned, a microfluidic path device 1900 may also include a
delivery or export
reservoir or depot 1963. In FIG. 19A, a pre-selected volume may be formed
similarly to the
chamber construction described above, or may contain only a metering side, as
desired. In either
case, valves may be used to meter desired volumes into the reservoir 1963.
Valve 1965 can
control delivery of fluid from reservoir 1963. If larger volumes are desired,
the delivery may be
repeated. Alternatively, if reservoir 1963 was pre-selected to be an export
reservoir, valve 1965
may open, and deliver fluid from chamber 1957, while retaining valve 1967
shut, which permits
only the measured volume of fluid to be exported to reservoir 1963. This fluid
may then be
exported to a fluid vial on the reagent storage frame for further processing
or testing. In some
variations, a chamber, reservoir or depot (e.g., 1963) may be configured as a
metering section of,
e.g., a 1 i.it pump formed by three valve structures (1967, 1965, 1967). A
chamber may be
configured for export of waste, for example, from a mixing chamber 1957.
[0324] The microfluidic path device 1900 can be a sealed path construction.
While fluid
vials, fluidic lines and the microfluidic path device are connected, operation
of the apparatus may
be performed without any exchange of materials in or out of the system, and in
particularly
in/out of the fluid path of the microfluidic path device for processing,
including synthesizing a
polynucleotide (RNA) and preparing it for biological delivery (as a
therapeutic, such as drug,
vaccine, etc.). Thus the entire system may operate as a closed path and/or
individual microfluidic
path devices may operate in the system as a closed path (protected from the
atmosphere).
[0325] In general, these microfluidic path devices can include
incorporating one or more
permeable inserts 1969 within the fluid side 1917 of a chamber or channel. The
permeable insert
may be configured to absorb selected moieties (e.g., selected material) from
the fluidic mixture
.. in a chamber or channel. The absorbed material may be an unwanted material
that is purified out
of the solution, or it may be a desired material that is removed from the
solution to be later eluted
and further processed. In one variation, the permeable material of the insert
may include a
cellulose material, which can selectively absorb double-stranded mRNA from a
mixture. The
cellulose material may be inserted in only one chamber of a pair of chambers,
such that upon
mixing or passing the fluid through the permeable insert in the first chamber,
dsRNA may be
effectively removed from the fluidic mixture, which can then be transferred to
another pair of
chambers further downstream for further processing or export.
[0326] Some variations of the microfluidic device 1900 may further
include a concentrator
within a chamber, which may be disposed within the thickness of the second
plate and may be in
fluid communication with an exit channel such as 1949. The polynucleotides may
be
- 81 -
CA 03149497 2022-02-01
WO 2021/030271
PCT/US2020/045625
concentrated by driving off excess fluidic medium, and the concentrated
polynucleotide mixture
exported out of the microfluidic path device 1900 for further handling or use.
In some variations,
the concentrator may be a dialysis chamber. For example, a dialysis membrane
may be present
within or between the plates of a microfluidic path device.
[0327] The microfluidic path device 1900 may be formed of materials that
are at least
substantially translucent to visible and/or ultraviolet light. By
substantially translucent is meant
that at least 90% of light is transmitted through the material compared to a
translucent material.
In some variations, the microfluidic path device 1900 may be formed of
materials that are
substantially transparent to visible and/or ultraviolet light. By
substantially translucent is meant
that at least 90% of light is transmitted through the material compared to a
completely
transparent material.
[0328] The microfluidic path device may be formed of two or more plates
that are layered
atop each other with the chambers and/or channels formed between the plates;
an elastic material
may be sandwiched between the first and second plates. The first plate and/or
the second plate
may be formed from a rigid material. The plates may be formed of the same
material, or a
different material(s). For example, the rigid material may be a polymer or
glass. The polymer or
glass may be biocompatible, e.g., does not leach any monomers or soluble small
molecules that
are toxic to living cells. Any suitable biocompatible polymer may be used,
including medical
grade polycarbonate-urethane, silicone polycarbonate urethane, polyether
urethane, amongst
.. others. In some variations, the polymer may be a cycloolefin copolymer.
[0329] FIG. 19B shows a section through a portion of a microfluidic path
device, showing a
permeable insert 1969 within the fluid-contacting side 1917 of a chamber 1920
that is bifurcated
by an elastic material 1907 into a fluid-contacting side and a pressure-
receiving side 1919. Thus,
a microfluidic path device may be configured as multilayered structure
composed of two more
rigid layers 1903, 1905 with a flexible membrane 1907 sandwiched between the
two ridged
layers. FIG. 19B shows a portion of a sectional view (transverse to the plane
of the microfluidic
path device) through one example of a microfluidic path device having multiple
layers that form
reactors for processing a therapeutic as described herein. The reactors may
include seals,
channels, valves, and chambers, including pumping chambers formed from the
multiple layers.
For example, a microfluidic path device may be formed of two or more rigid or
semi-rigid plates
1903, 1905 and at least one elastic layer 1907. The elastic layer 1907 may be
a sheet of elastic
material that is liquid-impermeable. The elastic layer maybe somewhat gas
permeable, or may be
treated to be more or less gas permeable, including in various regions.
Although a single
continuous sheet of elastic material may be used, in some variations multiple
elastic materials
sheets may be used, or the 'sheet' may be formed of sections of multiple
sheets. The layers and
- 82 -
CA 03149497 2022-02-01
WO 2021/030271
PCT/US2020/045625
the elastic sheet may be laminated together. In general, chambers for holding,
valving and/or
pumping fluid may be formed in the plates on either side of the elastic layer
so that the elastic
layer bisects the chambers into a liquid containing side and a pressure (e.g.,
gas) applying side.
The overall volume of chamber(s) may be constant, and may be formed into both
the first (e.g.,
upper) plate and the second (e.g., lower) plate, but this volume may be
divided into the pressure
side and the liquid side. By applying positive or negative pressure into the
pressure side, the
elastic sheet may be deformed to make reduce (down to zero, closing the
chamber off) the
volume of the liquid containing side or to increase the volume of the liquid
containing side (to a
predetermined maximum). The pressure applying side of the chamber may be
connected, e.g.,
via a pressure port 1943 in the upper plate 1903 connecting to a pressure
channel 1947, for
applying negative or positive pressure to the pressure-receiving side 1919 of
one or more
chambers. The liquid containing side 1917 opposite the pressure-applying side
of each chamber
may be connected via a fluid channel 1921 to a fluid port 1923. Both the fluid
port and the
pressure port may be formed by an opening into the upper plate 1903 and the
elastic layer 1907,
allowing a sealed connection that is isolated from the atmosphere even when
there are multiple
different input lines as the pressure line is pushed into the elastic layer
1907 that is supported on
the underside of the port by the opposite rigid or semi-rigid layer(s), 1905,
1909.
[0330] In FIG. 19B, the microfluidic path device 1900 includes a first
(e.g., upper) plate
1903 having a first (e.g., top or upper) surface 1911 and a second (bottom or
lower) surface 1929
and a thickness between the two. The first surface 1911 may form an exposed
outer surface. The
microfluidic path device also includes a second plate 1905 having a first
(e.g., upper or top)
surface 1931 and a second (e.g., lower or bottom) surface 1933 and a thickness
therebetween. An
elastic layer 1907 is sandwiched between the second surface 1929 of the first
plate 1903 and the
first surface 1931 of the second plate 1905. In this example, a third plate
1909 is coupled to the
second plate on the second surface 1933 of the second plate, either directly
or indirectly. The
third plate 1909 also has a first (e.g., upper or top) surface and a second
(lower or bottom)
surface and a thickness therebetween. The second surface of the third plate
may form a bottom
surface of the microfluidic path device. Any of the plates may be formed of
multiple layers,
which may be laminated or otherwise connected together. For example, in FIG.
19B, the third
plate 1909 includes an optional second elastic layer 1913 which may help
couple the third plate
to the second plate; the second elastic layer 1913 in this example forms the
first surface 1935 of
the third plate 1909. The layers and plates shown in FIG. 19B may not be to
scale (e.g., the
elastic layer 1907 may be thinner relative to the plates).
[0331] The microfluidic path device 1900 shown in FIG. 19B may also
include a plurality of
chambers 1915, 1916, 1918, 1920 each having a fixed volume. These chambers are
formed by
- 83 -
CA 03149497 2022-02-01
WO 2021/030271
PCT/US2020/045625
cut-out regions (e.g., rounded/curved cuts) into the second (bottom) surface
1929 of the first
plate 1903 and the first (upper) surface 1931 of the second plate 1905; the
elastic layer 1907
bifurcates these chambers 1915 so that each includes a liquid containing side
1917 and a
pressure-receiving (e.g., gas containing) side 1919. The microfluidic path
device 1900 may also
.. include multiple liquid (e.g., fluid) channels. In FIG. 19B, a single fluid
channel 1921 is shown
extending from a fluid port 1923 passing through the thickness of the first
plate 1903, to a fluid
channel opening 1925 through the elastic layer 1907 and through much of the
thickness of the
second plate 1905 down to the bottom surface 1933 of the second plate where a
length of the
liquid channel 1921 running parallel to the bottom surface of the third plate
is formed in the
bottom surface 1933 of the second plate, and bounded by the upper surface of
the third plate
1909.
[0332] In regard to the fluid port 1923, the diameter of the opening
into the first plate 1903
forming the fluid port 1923, which extends through the thickness of the first
plate, may be larger
than the diameter of the fluid channel opening 1925 which extends through the
elastic layer 1907
and into the liquid (e.g., fluid) channel 1921. The fluid channel opening 1925
may be centered
relative to the bottom of the fluid port opening, and may be offset from the
walls of the fluid port
opening by at least the expected wall thickness of the fluid line or fluid
line coupling interface
that will connect to the fluid port.
[0333] The fluid channel 1921 connects to the liquid containing side
1917 of a first chamber
1915. This first chamber may be configured as a valve, which has a relatively
low retaining
volume (fixed volume), but can be fully opened or closed by the movement of
the elastic layer
1907.
[0334] The microfluidic path device 1900 also includes a plurality of
pressure channels that
may be independently controlled to apply positive and/or negative pressure. In
FIG. 19B, a
single pressure port 1943 is shown, connected to the fourth chamber 1920,
although each of the
chambers 1915, 1916, 1918 may be connected to a separate pressure port and
pressure channel
for independently operating and controlling the movement of the portion of the
elastic layer 1907
bifurcating these chambers, to valve, and/or pump each chamber independently.
In some
variations the pressure ports may be shared between multiple chambers. In FIG.
19B the pressure
(e.g., gas) port 1943 is similar to the fluid (e.g., liquid) port 1925, and
includes an opening
completely through the first plate 1903, down to the exposed elastic layer
1907, to an opening
through the elastic layer forming a pressure (e.g., gas) channel opening 1945.
The pressure
channel opening 1945 is continuous with a pressure (e.g., gas) channel 1947
that extends from
the pressure port 1943, passing through much of the thickness of the first
plate 1903, and in a
cut-out channel along the bottom of the second plate (or alternatively into a
cut-out region in the
- 84 -
CA 03149497 2022-02-01
WO 2021/030271
PCT/US2020/045625
top of the third plate) and back up through the second plate and the elastic
layer 1907, to a region
of the pressure channel within the first plate that connects to the pressure
(e.g., gas) containing
portion 1919 of the fourth chamber 1920. As described for the similar fluid
(e.g., liquid) port, the
diameter of the pressure port 1943 passing through the thickness of the first
plate 1903 may be
larger than the diameter of the pressure channel opening 1945 through the
elastic layer 1907, and
may be centered or offset by greater than the wall thickness of a pressure
line or pressure line
coupling interface that will connect to the pressure port.
[0335] In the section through a microfluidic path device 1900 shown in
FIG. 19B, there are
multiple connections to other fluid (e.g., liquid) lines, fluid ports,
pressure lines and pressure
ports that are not shown, as they may be out of the plane shown. For example,
in FIG. 19B the
liquid containing side or portion 1917 of the fourth chamber may be connected
to additional
valves (chambers) and/or channels, including, e.g., an exit channel extending
from the liquid
containing side 1917. An additional chamber (e.g. configured as a valve), no
shown may be
formed as described above. In some variations, an exit channel may deliver
fluid from the one or
more chamber through another fluid port (not shown) to a fluid receiving
depot, e.g., a vial, tube,
etc. This receiving depot may be held in the reagent storage frame.
[0336] As mentioned above, the permeable insert 1969 may be inserted
into the fluid-
contacting side of the separation chamber and may be configured to be
compressed by the elastic
material separating the fluid-contacting chamber from the pressure-receiving
side of the
chamber. In this example, the positive or negative pressure applied to the
receiving side (e.g., via
a pressure port that is addressed to this chamber) may deflect the elastic
material to change the
volume of the fluid-contacting side. Fluid may be driven into the chamber 1920
with the
permeable insert 1969, and the fluid may be passed through the insert to
modify the solution. In
variations in which the permeable insert is compressible it may be compressed
to remove and
eject the fluid from the chamber; in some variations the permeable insert may
then be expanded
(or allowed to expand) back to the expanded configuration and fluid may then
be passed through
it again, or further processing may be performed.
[0337] The permeable inserts described herein may generally be used to
modify a solution
including the therapeutic material (or in which the therapeutic material is
being formed). FIG.
20A schematically illustrates one example of a method of processing a
therapeutic material in a
fluid (e.g., an RNA sample) using any of the apparatuses described herein. For
example, the
method may include first attaching the microfluidic path device (or more than
one microfluidic
path device) to a microfluidic path device control system 2001. This step may
include coupling a
microfluidic path device to a pressure source. In some variations, this step
(or an additional step)
may include coupling the microfluidics path device to a source of the
therapeutic material, such
- 85 -
CA 03149497 2022-02-01
WO 2021/030271
PCT/US2020/045625
as RNA. Optionally, in some variations the method may include synthesizing, in
the
microfluidics path device, the therapeutic material, such as generating the
therapeutic RNA by in
vitro transcription 2003.
[0338] The method may further include transporting the sample with the
therapeutic material
(e.g., RNA) to a fluid-contacting portion of a processing chamber containing a
permeable insert
2005. For example, this may include applying pressure to transport the sample
to the fluid-
contacting side of a separation chamber of the microfluidic path device. In
some variations,
pressure may be applied by deflecting an elastic material (e.g., an elastic
membrane) in within
the microfluidics path device to drive the fluid including the therapeutic (or
putative therapeutic
.. material) into the fluid-contacting side of the chamber. As part of this
step, the fluid (including
the therapeutic/putative therapeutic) sample may be passed into the permeable
insert within the
fluid-contacting side of the separation chamber, to modify the sample 2007.
For example,
material from the therapeutic/putative therapeutic may be added or removed by
interacting with
the permeable insert.
[0339] Finally, pressure may be applied to transport the sample out of the
fluid-contacting
side of the separation chamber, e.g., by deflecting an elastic material, such
as an elastic
membrane, separating the fluid-contacting side of the chamber from the
pressure-receiving side
of the chamber 2009.
[0340] FIG. 20B illustrates a specific example of a method of processing
a therapeutic
material in a fluid (e.g., an RNA sample) using any of the apparatuses
described herein. For
example, in FIG. 20B, the method may be a method of removing double-stranded
RNA (dsRNA)
from an RNA sample containing both dsRNA and single-stranded RNA (ssRNA). In
this
variations, the method may include: coupling a microfluidic path device to a
pressure source
2011. As mentioned, in some variations this may include coupling the
microfluidic path device
to a source of the therapeutic RNA, and/or performing in vitro transcription
of the therapeutic
RNA in the microfluidic path device, as described above 2013. The method may
then include
applying pressure to transport the RNA sample to a fluid-contacting side of a
separation chamber
of the microfluidic path device 2015. The RNA sample may then be passed
through/into a solid
and permeable insert, which comprises collagen, within the fluid-contacting
side of the
separation chamber 2017, wherein the cellulose binds the dsRNA, so that dsRNA
is retained by
the insert. Pressure may then be applied to transport the RNA sample out of
the fluid-contacting
side of the separation chamber, leaving the ssRNA in the therapeutic solution
2019. The steps
may be repeated as necessary to remove all or substantially all of the dsRNA.
[0341] As mentioned above, further processing (combining with a delivery
vehicle, dialysis,
.. concentration, etc.) may then be performed.
- 86 -
CA 03149497 2022-02-01
WO 2021/030271
PCT/US2020/045625
[0342] The apparatuses described herein may include and/or may be used
with one or more
isolation chambers. For example, in some variations the apparatuses described
herein may be
part of a therapeutic polynucleotide manufacturing 'factory' that may produce
therapeutic
polynucleotides, e.g., for delivery to a subject. The therapeutic
polynucleotide may be, e.g., a
therapeutic mRNA. FIGS. 21A-21B illustrate one example of an apparatus that
may be used by
itself as a factory apparatus or that may be used as part of a parallel
manufacturing unit. In FIG.
21A the apparatus(s) 2101, 2101' may include or may be held in a class 5
isolation cabinet 2103;
the isolation cabinet may itself be held within a class 7 isolation space. In
FIG. 21A the cabinet
includes two microfluidic control apparatuses 2101, 2101'. The apparatuses may
be part of an
assembly factory providing copy-exact GMP units that may automatically
manufacture
therapeutic polynucleotides, such as therapeutic mRNA rapidly for patient use.
These
apparatuses may be hightly reconfigurable and allow for rapid deployment and
low cost
production. In some variations they may be deployed on-demand manufacturing
"factory" units.
In some variations these apparatuses may be set up as part of a mobile unit
that may be deployed
.. to a remote site temporarily or for a longer time period.
[0343] When a feature or element is herein referred to as being "on"
another feature or
element, it can be directly on the other feature or element or intervening
features and/or elements
may also be present. In contrast, when a feature or element is referred to as
being "directly on"
another feature or element, there are no intervening features or elements
present. It will also be
understood that, when a feature or element is referred to as being
"connected", "attached" or
"coupled" to another feature or element, it can be directly connected,
attached or coupled to the
other feature or element or intervening features or elements may be present.
In contrast, when a
feature or element is referred to as being "directly connected", "directly
attached" or "directly
coupled" to another feature or element, there are no intervening features or
elements present.
Although described or shown with respect to one embodiment, the features and
elements so
described or shown can apply to other embodiments. It will also be appreciated
by those of skill
in the art that references to a structure or feature that is disposed
"adjacent" another feature may
have portions that overlap or underlie the adjacent feature.
[0344] Terminology used herein is for the purpose of describing
particular embodiments
only and is not intended to be limiting of the invention. For example, as used
herein, the singular
forms "a", "an" and "the" are intended to include the plural forms as well,
unless the context
clearly indicates otherwise. It will be further understood that the terms
"comprises" and/or
"comprising," when used in this specification, specify the presence of stated
features, steps,
operations, elements, and/or components, but do not preclude the presence or
addition of one or
more other features, steps, operations, elements, components, and/or groups
thereof. As used
- 87 -
CA 03149497 2022-02-01
WO 2021/030271
PCT/US2020/045625
herein, the term "and/or" includes any and all combinations of one or more of
the associated
listed items and may be abbreviated as "/".
[0345] Spatially relative terms, such as "under", "below", "lower",
"over", "upper" and the
like, may be used herein for ease of description to describe one element or
feature's relationship
to another element(s) or feature(s) as illustrated in the figures. It will be
understood that the
spatially relative terms are intended to encompass different orientations of
the device in use or
operation in addition to the orientation depicted in the figures. For example,
if a device in the
figures is inverted, elements described as "under" or "beneath" other elements
or features would
then be oriented "over" the other elements or features. Thus, the exemplary
term "under" can
encompass both an orientation of over and under. The device may be otherwise
oriented (rotated
90 degrees or at other orientations) and the spatially relative descriptors
used herein interpreted
accordingly. Similarly, the terms "upwardly", "downwardly", "vertical",
"horizontal" and the like
are used herein for the purpose of explanation only unless specifically
indicated otherwise.
[0346] Although the terms "first" and "second" may be used herein to
describe various
features/elements (including steps), these features/elements should not be
limited by these terms,
unless the context indicates otherwise. These terms may be used to distinguish
one
feature/element from another feature/element. Thus, a first feature/element
discussed below
could be termed a second feature/element, and similarly, a second
feature/element discussed
below could be termed a first feature/element without departing from the
teachings of the present
invention.
[0347] Throughout this specification and the claims which follow, unless
the context requires
otherwise, the word "comprise", and variations such as "comprises" and
"comprising" means
various components can be co-jointly employed in the methods and articles
(e.g., compositions
and apparatuses including device and methods). For example, the term
"comprising" will be
understood to imply the inclusion of any stated elements or steps but not the
exclusion of any
other elements or steps.
[0348] In general, any of the apparatuses and methods described herein
should be understood
to be inclusive, but all or a sub-set of the components and/or steps may
alternatively be
exclusive, and may be expressed as "consisting of' or alternatively
"consisting essentially of' the
various components, steps, sub-components or sub-steps.
[0349] As used herein in the specification and claims, including as used
in the examples and
unless otherwise expressly specified, all numbers may be read as if prefaced
by the word "about"
or "approximately," even if the term does not expressly appear. The phrase
"about" or
"approximately" may be used when describing magnitude and/or position to
indicate that the
value and/or position described is within a reasonable expected range of
values and/or positions.
- 88 -
CA 03149497 2022-02-01
WO 2021/030271
PCT/US2020/045625
For example, a numeric value may have a value that is +/- 0.1% of the stated
value (or range of
values), +/- 1% of the stated value (or range of values), +/- 2% of the stated
value (or range of
values), +/- 5% of the stated value (or range of values), +/- 10% of the
stated value (or range of
values), etc. Any numerical values given herein should also be understood to
include about or
approximately that value, unless the context indicates otherwise. For example,
if the value "10"
is disclosed, then "about 10" is also disclosed. Any numerical range recited
herein is intended to
include all sub-ranges subsumed therein. It is also understood that when a
value is disclosed that
"less than or equal to" the value, "greater than or equal to the value" and
possible ranges between
values are also disclosed, as appropriately understood by the skilled artisan.
For example, if the
value "X" is disclosed the "less than or equal to X" as well as "greater than
or equal to X" (e.g.,
where X is a numerical value) is also disclosed. It is also understood that
the throughout the
application, data is provided in a number of different formats, and that this
data, represents
endpoints and starting points, and ranges for any combination of the data
points. For example, if
a particular data point "10" and a particular data point "15" are disclosed,
it is understood that
greater than, greater than or equal to, less than, less than or equal to, and
equal to 10 and 15 are
considered disclosed as well as between 10 and 15. It is also understood that
each unit between
two particular units are also disclosed. For example, if 10 and 15 are
disclosed, then 11, 12, 13,
and 14 are also disclosed.
[0350] Although various illustrative embodiments are described above,
any of a number of
changes may be made to various embodiments without departing from the scope of
the invention
as described by the claims. For example, the order in which various described
method steps are
performed may often be changed in alternative embodiments, and in other
alternative
embodiments one or more method steps may be skipped altogether. Optional
features of various
device and system embodiments may be included in some embodiments and not in
others.
Therefore, the foregoing description is provided primarily for exemplary
purposes and should
not be interpreted to limit the scope of the invention as it is set forth in
the claims.
[0351] The examples and illustrations included herein show, by way of
illustration and not of
limitation, specific embodiments in which the subject matter may be practiced.
As mentioned,
other embodiments may be utilized and derived there from, such that structural
and logical
substitutions and changes may be made without departing from the scope of this
disclosure. Such
embodiments of the inventive subject matter may be referred to herein
individually or
collectively by the term "invention" merely for convenience and without
intending to voluntarily
limit the scope of this application to any single invention or inventive
concept, if more than one
is, in fact, disclosed. Thus, although specific embodiments have been
illustrated and described
herein, any arrangement calculated to achieve the same purpose may be
substituted for the
- 89 -
CA 03149497 2022-02-01
WO 2021/030271
PCT/US2020/045625
specific embodiments shown. This disclosure is intended to cover any and all
adaptations or
variations of various embodiments. Combinations of the above embodiments, and
other
embodiments not specifically described herein, will be apparent to those of
skill in the art upon
reviewing the above description.
- 90 -
